Development of a matrix-in-cylinder system for sustained zero-order drug release by Mehuys, Els
 
 
            
            
             
GHENT UNIVERSITY 
FACULTY OF PHARMACEUTICAL SCIENCES 
 
 
 
DEVELOPMENT OF A MATRIX-IN-CYLINDER SYSTEM 
FOR SUSTAINED ZERO-ORDER DRUG RELEASE 
 
Els Mehuys 
Pharmacist 
 
Thesis submitted to obtain the degree of  
Doctor in Pharmaceutical Sciences 
 
 
2004 
 
 
Promoters: 
Prof. Dr. J.P. Remon 
Prof. Dr. C. Vervaet 
Laboratory of Pharmaceutical Technology 
Dankwoord 
Dankwoord 
Bij het voltooien van dit doctoraatsonderzoek zou ik iedereen die een bijdrage 
leverde tot het tot stand komen van dit werk van harte willen bedanken. 
Ik wens hierbij  enkele mensen in het bijzonder te danken: 
In de eerste plaats Prof. Dr. J.P. Remon omdat hij mij de kans gaf te doctoreren, 
voor de enthousiaste en stimulerende wijze waarop hij dit onderzoek begeleidde, 
de leerrijke discussies en de vele opportuniteiten die hij mij bood. 
Prof. Dr. C. Vervaet voor de vele uren kritisch nalezen van dit proefschrift en de 
verhelderende discussies met betrekking tot dit werk. 
Het Instituut voor de Aanmoediging van Innovatie door Wetenschap en 
Technologie (IWT) – Vlaanderen voor de toekenning van een specialisatiebeurs. 
Ik wil volgende personen bedanken voor de goede samenwerking: Olivier Janssens 
(Faculteit Wetenschappen) voor de XRD opnames, Dr. Peter Adriaensens (LUC) 
voor de NMR opnames, Dr. Ingrid Gielen en Prof. Dr. Henri Van Bree (Faculteit 
Diergeneeskunde) voor de RX-en, Dr. Annelies Korst en Prof. Dr. Luc Van Bortel 
(Faculteit Geneeskunde) voor de humane in vivo studie en Prof. Dr. Christopher 
Porter en Prof. Dr. William Charman (Monash University, Australië) voor het 
lymfe-experiment. 
Alle collega’s, ex-collega’s en medewerkers  van het Laboratorium voor 
Farmaceutische Technologie voor de leuke werksfeer, hun hulp en 
bereidwilligheid. In het bijzonder Ellen voor de ontspannende middagpauzes en de 
fijne tijd samen op het lab en Els voor de hulp bij de statistische verwerking van de 
gegevens. 
Alle thesisstudenten voor hun inzet en praktische assistentie. 
Dhr. Daniël Tensy voor de deskundige uitvoering van de dierexperimenten, de vele 
staalnames ook ’s avonds en tijdens het weekend en zijn interesse in het onderzoek 
en de sport. 
Katharine en Bruno voor het inscannen van de figuren, oplossen van 
computerproblemen en uitvoeren van administratieve taken. 
Arne Vanhollebeke voor de Franse vertaling van de samenvatting en Wouter 
Haelewyn voor het nemen van de digitale foto’s. 
Zeker en vast ook mijn bureaugenote en beste vriendin Nathalie voor haar vele 
aanmoedigingen vooral als het onderzoek eens wat minder vlotte, haar steun en 
Dankwoord 
advies zowel op professioneel als persoonlijk vlak, de vriendschap en natuurlijk 
ook voor de leuke sfeer (en mopjes) in ons bureau. 
Mijn ouders, familie en vrienden voor de emotionele betrokkenheid. 
Tenslotte wil ik mijn vriend Gunther bedanken voor zijn hulp bij het verbeteren 
van de thesis en vooral voor de steun tijdens het schrijven van dit werk. 
        
       Els Mehuys 
       Gent, 29 oktober 2004. 
 
Table of contents I
TABLE OF CONTENTS 
 
1 INTRODUCTION AND OBJECTIVES ........................................ 1 
1.1 Introduction .......................................................................................................... 1 
1.2 Objectives ............................................................................................................. 8 
1.3 References .......................................................................................................... 10 
 
 
2 HOLLOW FIBERS AS DRUG DELIVERY DEVICES ............ 14 
2.1 Introduction ........................................................................................................ 14 
2.2 Production of hollow fibers ................................................................................ 14 
2.3 Pharmaceutical applications of hollow fibers..................................................... 19 
2.3.1 Hollow fibers for oral controlled drug delivery .............................................................19 
2.3.2 Hollow fibers for sustained drug delivery to periodontal pockets .................................21 
2.3.3 Hollow fibers as implants for subdermal drug delivery.................................................22 
2.4 References .......................................................................................................... 25 
 
 
 
3 FORMULATION STUDY FOR THE PRODUCTION OF  
 A MATRIX-IN-CYLINDER SYSTEM ........................................ 31 
3.1 Introduction ........................................................................................................ 31 
3.2 Materials ............................................................................................................. 32 
3.2.1 Ethylcellulose.................................................................................................................32 
3.2.2 Triglycerides ..................................................................................................................33 
3.2.3 Polyglycolised glycerides ..............................................................................................35 
3.3 Methods .............................................................................................................. 36 
3.3.1 Hot-melt extrusion of hollow ethylcellulose pipes ........................................................36 
3.3.2 Production of matrix-in-cylinders..................................................................................37 
3.3.3 In vitro evaluation..........................................................................................................38 
3.4 Results and Discussion....................................................................................... 40 
3.4.1 Hot-melt extrusion of hollow ethylcellulose pipes ........................................................40 
3.4.2 Selection of core material ..............................................................................................41 
3.5 Conclusion.......................................................................................................... 46 
3.6 References .......................................................................................................... 47 
Table of contents II
4 DEVELOPMENT AND EVALUATION OF A MATRX-IN-  
CYLINDER SYSTEM WITH A HPMC-GELUCIRE® 44/14 
 CORE .............................................................................................. 49 
4.1 Introduction ........................................................................................................ 49 
4.2 Materials ............................................................................................................. 50 
4.2.1 Hydroxypropyl methylcellulose (HPMC)......................................................................50 
4.3 Methods .............................................................................................................. 52 
4.3.1 Production of hollow ethylcellulose pipes .....................................................................52 
4.3.2 Production of matrix-in-cylinders with a HPMC-Gelucire® 44/14 core ........................52 
4.3.3 Production of HPMC-Gelucire® 44/14 extrudates .........................................................52 
4.3.4 In vitro evaluation..........................................................................................................53 
4.4 Results and Discussion....................................................................................... 54 
4.4.1 Influence of viscosity grade and substitution type of HPMC ........................................54 
4.4.2 Modification of core formulation...................................................................................59 
4.4.3 Modification of dimensions ...........................................................................................60 
4.4.4 Impact of the hollow pipe ..............................................................................................62 
4.4.5 Influence of drug solubility and drug loading................................................................63 
4.4.6 Stability study ................................................................................................................65 
4.4.7 Physicochemical characterisation of the HPMC-Gelucire® 44/14 mixture....................70 
4.5 Conclusion.......................................................................................................... 73 
4.6 References .......................................................................................................... 74 
 
 
5 IN VITRO AND IN VIVO EVALUATION OF THE  
 MATRIX-IN-CYLINDER SYSTEM ............................................ 77 
5.1 Introduction ........................................................................................................ 77 
5.2 Materials ............................................................................................................. 78 
5.2.1 Propranolol.....................................................................................................................79 
5.3 Methods .............................................................................................................. 80 
5.3.1 Production of the matrix-in-cylinder system..................................................................80 
5.3.2 In vitro evaluation..........................................................................................................80 
5.3.3 In vivo study...................................................................................................................82 
5.3.4 Propranolol assay...........................................................................................................83 
5.3.5 Validation of the HPLC method ....................................................................................84 
5.3.6 Data analysis ..................................................................................................................90 
5.3.7 Determination of gastrointestinal transit time................................................................90 
5.4 Results and Discussion....................................................................................... 91 
Table of contents III
5.4.1 In vitro dissolution tests .................................................................................................91 
5.4.2 In vivo study...................................................................................................................99 
5.5 Conclusion........................................................................................................ 104 
5.6 References ........................................................................................................ 105 
 
 
6 HUMAN BIOAVAILABILITY OF PROPRANOLOL  
 FROM THE MATRIX- IN-CYLINDER SYSTEM .................. 108 
6.1 Introduction ...................................................................................................... 108 
6.2 Materials ........................................................................................................... 109 
6.3 Methods ............................................................................................................ 109 
6.3.1 Production of the matrix-in-cylinder system................................................................109 
6.3.2 In vivo study.................................................................................................................109 
6.3.3 Propranolol assay.........................................................................................................111 
6.3.4 Validation of the HPLC method ..................................................................................112 
6.3.5 Data analysis ................................................................................................................116 
6.4 Results and Discussion..................................................................................... 117 
6.4.1 In vivo evaluation.........................................................................................................117 
6.4.2 Food effect on propranolol absorption.........................................................................119 
6.4.3 Formulation effect on propranolol absorption .............................................................120 
6.4.4 Inhibition of presystemic metabolism of propranolol ..................................................131 
6.4.5 Bypass of presystemic metabolism of propranolol ......................................................132 
6.5 Conclusion........................................................................................................ 142 
6.6 References ........................................................................................................ 143 
 
 
7 GENERAL CONCLUSION ........................................................ 148 
 
 
SUMMARY ............................................................................................. 149 
 
 
SAMENVATTING.................................................................................. 153 
 
 
RÉSUMÉ.................................................................................................. 158 
 
Introduction and objectives 1
1 INTRODUCTION AND OBJECTIVES 
1.1 INTRODUCTION 
Sustained release formulations are usually intended to optimize a therapeutic regimen by 
providing slow and continuous drug delivery over the entire dosing interval in combination 
with reduced side effects, whilst also providing greater patient compliance and convenience 
(Chien, 1982).  
The classical way to design an oral sustained release dosage form is by coating tablets, pellets 
or capsules with insoluble, pH-independent polymers (reservoir type). However, coating is a 
time-consuming and expensive process with possible problems related to reproducibility of 
drug release and dose dumping. Another common sustained drug delivery system is the 
matrix type (where the drug is uniformly dissolved or dispersed throughout the rate-
controlling polymer) because of its effectiveness, low cost and ease of manufacturing (Chien, 
1982). Especially hydrophilic polymer-based (e.g. cellulose derivates) sustained release 
dosage forms are very popular. However, drug release from a hydrophilic matrix is generally 
characterised by a time-dependent profile. Initially, the drug present at the surface of the 
matrix is released quickly, yielding a burst effect, then with time, as the diffusion pathlength 
increases the release rate is progressively reduced (Figure 1.1a). A burst effect is often 
undesirable since it is unpredictable and may have negative therapeutic consequences such as 
toxicity due to drug concentrations increasing beyond the acceptable limit, especially on 
repeated administration. Moreover, any drug released during the burst stage may be 
metabolized and excreted without being effectively utilized, reducing the effective lifetime of 
the device and requiring more frequent dosing (Huang and Brazel, 2001). Over the years 
Introduction and objectives 2
considerable efforts have been made in the development of new drug delivery concepts in 
order to achieve zero-order release (Figure 1.1b), since constant rate delivery is the primary 
goal of sustained release systems, especially for drugs with a narrow therapeutic index.  
 
     (a)           (b) 
 
 
Figure 1.1: Time-dependent (first-order) (a) and time-independent (zero-order) drug release 
profile (b). 
 
Many authors have described various approaches to limit the burst effect from matrix systems 
in order to obtain zero-order drug release. A number of variables able to affect the release 
pattern of polymeric matrix devices were evaluated: physico-chemical properties (solubility, 
viscosity) of the drug and polymers, drug/polymer weight ratio, administration form and 
manufacturing processes (Salomon et al., 1979; Alderman, 1984; Ford et al., 1987; Gander et 
al., 1987). However, it appeared rather difficult to achieve a constant drug release rate by 
changing these variables.  
Scott and Hollenbeck (1991) investigated the concept of non-uniform drug distribution, in 
which drug is more concentrated in the deeper layers of a matrix, in order to prevent the burst 
effect. They prepared non-eroding diffusional matrix pellets, containing a non-uniformly 
distributed drug, using a fluid bed suspension layering technique (Scott and Hollenbeck, 
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1991). These dosage forms exhibited an almost linear drug release profile with some 
discontinuities due to the fact that four discrete layers were used to approximate a continuous 
drug gradient in the matrix. Although this technique showed promise at preventing burst 
release, difficulties during manufacturing to achieve non-uniform drug loading made this 
concept impractical in most situations. 
Some researchers introduced a fairly simple approach to reduce the burst effect by extracting 
the drug formulations for a short period of time in vitro before using them in an in vivo 
application (Lee, 1984; Ficek and Peppas, 1993; Mallapragada et al., 1997). This method was 
effective at reducing burst release because the drug is removed from the outer layers of 
controlled release devices, but one important issue was still the cost of extraction and the 
reduction in the effective use of (often expensive) drugs.    
Another approach implied the synchronisation of the movement of the swelling and erosion 
fronts in the tablets whereby the thickness of the gel layer (i.e. the distance between fronts) 
remained constant and (near) zero-order drug release was achieved (Colombo et al., 1987; 
Conte et al., 1988; Harland et al., 1988; Rao Rango et al., 1988, 1990; Devi et al., 1989). 
Front synchronisation can be obtained by mixing different polymers in an optimum ratio, 
however the movement of the fronts is also a function of drug solubility and the 
hydrodynamic conditions of the dissolution test. Due to the varying hydrodynamic conditions 
along the gastrointestinal tract, it is doubtful that in vivo drug release will be at zero-order 
kinetics using these dosage forms.  
Varying the matrix geometry is also a possible means of altering release kinetics from matrix 
systems. This led to the development of matrix systems having spherical, cylindrical, 
biconvex or donut shapes; hemispheres with a cavity; partially coated cores with a hole in the 
middle; oval bi-dose divisible tablets, etc. (Cobby et al., 1974a,b; Hsiesh et al., 1983; Zin El-
Din et al., 1989; Shah and Britten, 1990; Benkorah and McMullen, 1994; Kim, 1994; Chopra, 
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2003). Although some of these devices were able to linearize drug release, in most cases their 
design seemed not suitable for large-scale manufacturing.  
Another popular method used to prevent burst release relied on the restriction of the matrix 
surface area in contact with the dissolution medium, leading to a decreased matrix hydration 
and swelling rate and consequently a slower drug release rate. Furthermore, this approach also 
limited the surface available for drug release. These effects resulted in a linearization of the 
drug release profile from hydrophilic matrix systems (Conte et al., 1993). The reduction of the 
matrix surface area exposed to the dissolution medium can be obtained in different ways. 
Conte et al. (1993) and Conte and Maggi (1996, 1998, 2000) designed a multilayered 
hydrophilic matrix system (Geomatrix®) as a means to obtain zero-order drug delivery, 
coating one or both sides of a matrix tablet with a swellable or erodible barrier (Figure 1.2).  
 
 
Figure 1.2: Hydration behaviour of a plain hydrophilic matrix and of a Geomatrix® three-layer 
tablet employing swellable or erodible barriers (Conte and Maggi, 2000). 
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The Smartrix® system is a multilayered tablet very similar to the Geomatrix® system. It is 
based on the principle that the geometric design of the drug-containing core, in combination 
with slowly eroding cover layers, provides quasi-linear drug release (Figure 1.3) (Zerbe and 
Krumme, 2003).  
 
  
Figure 1.3: Drug release profile from a three-layered Smartrix® tablet (full line) and from a core 
matrix alone (dotted line) (Zerbe and Krumme, 2003).  
 
Colombo et al. (1990) described the modulation of the drug release by physically restricting 
matrix swelling through partial coating of the matrix with an impermeable cellulose acetate 
propionate film. Danckwerts (1994) developed a core-in-cup tablet consisting of an inert cup 
of ethylcellulose and carnauba wax into which a drug-containing matrix layer was 
compressed, thus leading to a matrix with only one side in contact with the surrounding 
medium (Figure 1.4).  
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Figure 1.4: Schematic drawing of a core-in-cup tablet. 
 
Wong et al. (1996, 1997) patented RingCap®, an oral controlled-release drug delivery system 
consisting of a capsule-shaped matrix tablet to which bands of insoluble material are applied 
circumferentially to the surface of the tablet. These bands modified drug release by 
controlling the surface area, which changed over time as the area around the bands became 
hydrated and eroded creating new surface area (Figure 1.5).  
 
   
 
Figure 1.5: Schematic erosion of a RingCap® tablet (Dickason and Grandolfi, 2003). 
 
 
CORE 
  CUP
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Krögel and Bodmeier (1999) invented a system composed of a hydrophilic matrix tablet 
placed in an impermeable polypropylene cylinder, reducing drug release to the open ends of 
the cylinder (Figure 1.6). 
 
      
 
Figure 1.6: Hydrophilic matrix tablet placed in an impermeable polypropylene cylinder (Krögel 
and Bodmeier, 1999). 
 
These reports demonstrated that the idea of partial ‘coating’ of a matrix is a successful 
approach to obtain a constant and slow drug release. However, they have in common that their 
production process is complicated and time-consuming (with possible problems such as poor 
adhesion between the different layers of the tablets). 
 
Although favourable for a limited number of applications, under most circumstances in 
sustained drug delivery, burst release is considered as a negative effect. The importance of 
avoiding burst release from matrix systems can be seen in the number of publications focused 
on this topic.  However, of the suggestions made to prevent burst release and to achieve zero-
order drug release, many involve additional time-consuming and expensive production steps 
making them inefficient in an economic setting. 
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Research work performed at the Laboratory of Pharmaceutical Technology (Ghent 
University) showed that embedding hot-melt extruded starch matrices within a hollow starch 
cylinder allowed to produce an oral dosage form without a burst effect and with a near zero-
order sustained drug release profile, while the single matrices (without surrounding pipe) 
showed a rather high burst effect and a markedly quicker drug release rate. However, these 
experimental formulations performed less well in vivo than the commercially available 
product, probably due a progressive breakdown of the starch pipes by the mechanical friction 
forces in the gastrointestinal tract (Henrist et al., 2001). This research project was set up to 
further explore the possibilities of this drug delivery concept (a drug-containing core 
embedded within a hollow cylinder). 
1.2 OBJECTIVES 
The objective of this study was to develop a partially ‘coated’ matrix in order to obtain zero-
order sustained drug release, taking into account that this dosage form must be manufactured 
by means of a simple, flexible and economically feasible manufacturing method. Therefore, 
the properties of a “matrix-in-cylinder system” (based on a drug-containing matrix inserted 
into an impermeable hollow cylinder) were evaluated (Figure 1.7). It was anticipated that a 
drug matrix encased in a water-insoluble, non-biodegradable tube open at both ends will 
expose the same area to the dissolution medium at all times, thus resulting in a zero-order 
drug release profile.  
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(a) 
 
 
 
(b) 
      
 
 
 
Figure 1.7: Schematic drawing (a) and picture (b) of the matrix-in-cylinder system. 
 
 
 
 
 
 
Drug-containing matrix 
 
 
 
 
Impermeable hollow cylinder 
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2 HOLLOW FIBERS AS DRUG 
DELIVERY DEVICES  
2.1 INTRODUCTION 
The matrix-in-cylinder system under evaluation consists of a drug-containing matrix 
surrounded by a hollow insoluble cylinder in order to obtain slow and constant drug release. 
This chapter gives an overview of other pharmaceutical dosage forms using the principle of 
hollow cylinders as a method to control drug release.  
Only a limited number of studies appeared in literature exploring the use of hollow cylinders 
(also called ‘hollow fibers’) as delivery systems for pharmaceuticals. Some publications can 
be found reporting on the use of hollow fibers as oral controlled drug delivery system, as drug 
delivery platform to the periodontal pockets and as implant for subdermal drug release. 
However, hollow fibers are interesting drug delivery devices since drug release can be 
controlled through their open ends as well as through the membrane sheet, and hollow fibers 
offer great flexibility in design since they can be manufactured by simple production methods. 
2.2 PRODUCTION OF HOLLOW FIBERS 
Three different methods have been reported for the production of hollow fibers for 
pharmaceutical applications: hot-melt extrusion, injection moulding and spinning.   
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¾ Hot-melt extrusion 
Hot-melt extrusion comprises the forcing of molten material through an opening (extrusion 
die) by means of pressure. As material passes through the die, the material acquires the shape 
of the die opening and the extruded product is referred to as the extrudate (Morton-Jones, 
1989; Rauwendaal, 1994). An extruder is typically composed of a feeding hopper, a barrel 
containing one or more screws, a die, a screw driving unit, a cooling unit and a control panel 
(Figure 2.1). When the extruder is fed with molten polymer, it is called melt fed extrusion. 
Solid state extrusion occurs when the material is fed to the extruder in the solid state. The 
material will melt as it is conveyed by the extruder screw from the feed port to the die, and is 
called plasticating extrusion.            
 
                                          
 
Figure 2.1: Schematic diagram of a twin screw extruder with a) control panel, b) driving unit, c) 
feeding hopper, d) barrel and e) die (Miyagawa et al., 1996).  
 
Hot-melt extrusion finds its roots in the polymer and food industry (Van Zuilichem, 1992). Its 
initial pharmaceutical applications were already described in the seventies, but the major 
breakthrough occurred only in the late eighties as a result of the collaborative research 
between Knoll and BASF (Goertz et al., 1987; Klimesch et al., 1987, 1989a,b,c; Mueller et 
al., 1992). This work initiated several research teams to explore the possibilities of hot-melt 
extrusion to develop pharmaceutical dosage forms such as granules (Miyagawa et al., 1996; 
McGinity and Koleng, 1997; Koleng and McGinity, 1997, 1998, 1999), sustained release 
a 
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pellets (Mank et al., 1989, 1990; Follonier et al., 1994, 1995; Young et al., 2002), matrix 
tablets (Prapaitrakul et al., 1991; Mueller et al., 1992; Sprockel et al., 1997; Zhang and 
McGinity, 1999, 2000; Kidokoro et al., 2001; Liu et al., 2001), sustained release mini-
matrices (De Brabander et al., 2003), transdermal drug delivery systems (Aitken-Nichol et al., 
1996; Repka et al., 1999), double matrix systems (Henrist et al., 2001), solid solutions and 
dispersions (Breitenbach et al., 1998; Hülsmann et al., 2000; Leuner and Dressman, 2000; 
Forster et al., 2001a,b,c;) and implants (Bhardwaj and Blanchard, 1997, 1998; Lemmouchi et 
al., 1998).  
The main advantage over conventional pharmaceutical production methods is the simplicity 
and continuity of the extrusion process (mixing, melting, homogenizing and shaping are 
carried out in a single machine) which results in a decrease of capital investment and 
increased automation of the production. Furthermore, this technique is characterized by a high 
throughput, limited material loss, an excellent homogeneity of the products, the absence of 
organic solvents in the production process, the ability to make solid solutions in order to 
improve the bioavailability of poorly soluble drugs and the possibility of minimizing the 
number of excipients (Mueller et al., 1992; Breitenbach et al., 1995).  
 
¾ Injection moulding  
Injection moulding, a technique related to hot-melt extrusion, refers to a process where the 
polymer is heated to a molten or viscous state and the molten polymer is injected in a cavity 
mould at high pressure (Figure 2.2). The material cools in the cavity and solidifies, taking the 
shape of the mould. The mould is then opened and the article is removed (Breitenbach, 2002).  
Injection moulding is a commonly used process in the polymer and food industry, because it 
gives a good surface finish and can be used for very complex mouldings. This technique has 
been used for pharmaceutical applications such as tablets, sustained release formulations and 
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drug solid dispersions or solutions (El-Egakey et al., 1971; Wacker et al., 1971; Hüttenrauch, 
1974; Hüttenrauch and Schmeiss, 1976; Cuff and Raouf, 1998). Injection moulding was also 
considered suitable for the production of starch based capsules (Eith et al., 1987). 
 
 
Figure 2.2: Schematic diagram of an injection moulding system (Cuff and Raouf, 1998). 
 
¾ Spinning  
Spinning can be defined as the formation of fibers by forcing polymers, using an extruder 
and/or gear pump, through fine holes in a spinneret (Figure 2.3). A spinneret is a type of die, 
usually a metal plate with many small holes. The spinning of fibers from polymers can be 
achieved by various routes. The three common methods of spinning are melt spinning, dry 
spinning and wet spinning. Melt spinning involves the heating of a polymer above its melting 
point and extruding it through a spinneret. Once extruded, the melt is cooled which allows the 
polymer to solidify into a filament. In the dry spinning process, a solution of the polymer is 
extruded through an orifice (with desired shape) and is fed into a heated column, which 
allows evaporation of the solvent and subsequent formation of a filament. In the wet spinning 
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process, a solution of the polymer is extruded through a spinneret and quenched in a 
coagulant for the polymer, resulting in the formation of a fiber (Rosato, 1998).  
The spinning technique originates from the textile and polymer industry and is for example 
used for the production of nylon fibers. Pharmaceutical applications of spinning are rather 
limited. Recently, some authors evaluated electrostatic spinning (a variation of the basic 
spinning technique without using the spinneret) as a method to incorporate poorly water-
soluble drugs into a polymeric matrix forming amorphous systems (Ignatious and Baldoni, 
2001; Kenawy et al., 2002; Zong et al., 2002; Verreck et al., 2003a,b). 
  
Figure 2.3: Schematic drawing of a melt spinning system (Rosato, 1998). 
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2.3 PHARMACEUTICAL APPLICATIONS OF 
HOLLOW FIBERS 
2.3.1 Hollow fibers for oral controlled drug delivery 
Hussain et al. (1989a) developed an oral sustained release device consisting of 
phenylpropanolamine bound to ion-exchange resin, which was encapsulated in hollow fibers 
made of segmented polyurethane. The hollow polyurethane cylinders allowed exchanging 
ions to enter at both ends of the fibers and diffuse through the channels within the matrix core. 
Once phenylpropanolamine was released from the resin, it diffused through the channels 
within the polymer matrix and entered the dissolution medium through the open ends of the 
fiber segments. The fibers were manufactured by means of the wet spinning process and cut 
into different lengths (diameter = 0.071 cm, length = 0.32 - 1.28 cm). As the length decreased, 
the drug release rate from the fiber increased, indicating that diffusion of the drug through the 
polymer matrix core combined with release from the open ends of the cylinders are the most 
significant factors in the overall drug release process. Administration of this dosage form to 
dogs showed that the phenylpropanolamine plasma concentrations peaked within the first 
hours followed by constant drug levels, reflecting a continuous drug release from the fibers. 
The same research group also evaluated the in vivo behaviour of this hollow fiber device 
containing propranolol hydrochloride as a model drug. This resulted in a sustained profile of 
propranolol plasma concentrations similar to that observed with the marketed reference 
product Inderal® LA (Hussain et al., 1989b). 
  
Krögel and Bodmeier (1999) described a multifunctional drug delivery system based on 
hydroxypropyl methylcellulose (HPMC) matrix tablets placed within a hollow impermeable 
polypropylene cylinder (open at both ends). Depending on the configuration of the device, 
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sustained release, floating or pulsatile drug delivery systems were obtained (Figure 2.4). 
When the configuration consisted of a drug-containing hydrophilic matrix tablet placed in the 
middle of the cylinder, restricting the exposed surface area to the two circular faces of the 
tablet, extended drug release was obtained (case 1). A drug-containing matrix tablet placed at 
each end of the cylinder with in between an air-filled space formed a low density floating 
device (case 2). The pulsatile system consisted of an impermeable capsule (cylinder with an 
open end and a closed end), partially filled with drug and excipients, the open end sealed with 
a drug-free HPMC matrix tablet forming a plug (case 3).  
 
 
Figure 2.4: Configurations of the multifunctional drug delivery system developed by Krögel and 
Bodmeier (1999). 
 
Bar-Shalom (1988) developed and patented the Egalet® technology, consisting of an 
impermeable shell with lag plugs, enclosing a plug of active drug in the middle of the unit. 
Drug release can be modulated by the length and composition of the plugs. The shells were 
made of cetostearyl alcohol and ethylcellulose, while the matrix of the plugs comprised a 
mixture of polyethylene glycol monostearates and polyethylene oxides. These drug delivery 
devices were produced via injection moulding (Bar-Shalom, 1988).  
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2.3.2 Hollow fibers for sustained drug delivery to periodontal pockets 
Periodontal disease is an inflammatory response in which the structural supports of the teeth 
are destroyed. One of the clinical features of periodontal disease is the formation of a 
periodontal pocket, which is a pathologically deepened sulcus. In a normal sulcus, the gap 
between the gingiva and the tooth is usually between 1 and 3 mm deep. However, during 
periodontitis, the depth of the pocket usually exceeds 5 mm. Progressive pocket formation 
leads to the destruction of the supporting periodontal tissues, followed by high mobility and 
exfoliation of the tooth. One treatment of periodontal disease is the local delivery of 
antibiotics or anti-inflammatory agents to the periodontal pocket. However, to prolong the 
therapeutic levels of the drug at the inflammation site, a local sustained release device is 
required. Since the periodontal pocket allows easy access to insert a device, it is an area 
suitable for treatment with a local sustained release system. The goals to be achieved by using 
an intrapocket device are to release the therapeutic agent inside the pocket and to maintain 
sufficient levels of the drug for a stated period of time (Steinberg and Friedman, 1988). 
Therefore, hollow fiber devices were developed to introduce a drug inside a periodontal 
pocket. Hollow fibers for periodontal use are closed at both ends, hence the drug is released 
by diffusion through the walls of the fiber (this is in contrast with the matrix-in-cylinder 
system where drug release occurs through the open ends of the hollow fiber). 
Goodson et al. (1979) and Lindhe et al. (1979) described the use of small, permeable 
cellulose acetate hollow fibers filled with a 20% solution of tetracycline. The hollow fibers 
(outer diameter 250 µm) were placed in periodontal pockets. The clinical parameters were 
evaluated at certain time points after the onset of the treatment and compared with a control 
group receiving conventional treatment of periodontal disease. An improvement of the 
clinical parameters was observed in the hollow fiber group as well as the control group, 
however the reduction of the symptoms was more obvious in the latter. This could be ascribed 
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to the high tetracycline release rate from the hollow fibers, since 95 % of the drug was 
released 2 h after the hollow fibers were inserted into the pockets. The fast release rate from 
these devices indicated that the hollow fibers acted as a poor rate-limiting tool, resulting in a 
too rapid depletion of tetracycline.   
Another research study was conducted on cellulose-based hollow fibers (cut at different 
lengths) loaded with a 20% solution of chlorhexidine gluconate. An in vivo study, whereby 
the tube was kept in the periodontal pocket for 7 days, showed a remarkable clinical 
improvement (Addy et al., 1982). 
2.3.3 Hollow fibers as implants for subdermal drug delivery 
The first report describing the use of hollow fibers as implants for subdermal drug delivery 
appeared in 1987. Schindler (1987) developed a tubular implant of poly(ε-caprolactone) with 
a porous wall suitable for the release of decapeptides. The tube was prepared by extrusion of 
molten poly(ε-caprolactone) to which a certain amount of polyoxyethylene and 
polyoxypropylene was added. Following treatment of the extruded tube with appropriate 
solvents, the additives were extracted and a reservoir wall with an interconnected pore 
structure was formed.  
 
The pharmaceutical company Organon intensively investigated the hollow fiber concept for 
the controlled release of contraceptive hormones. Eenink and Feijen (1987) described the 
development and characterisation of an implant based on biodegradable poly(L-lactide) 
hollow fibers for the controlled release of levonorgestrel. The hollow fibers, manufactured via 
spinning, were filled with a 25 % dispersion of levonorgestrel in castor oil and the open ends 
of the fiber were heat-sealed, making that drug release is controlled by diffusion through the 
membrane sheet. An in vivo experiment (in rabbits) showed that this biodegradable hollow 
fiber device resulted in constant levonorgestrel plasma levels for a period up to 210 days. 
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Further research on the influence of the membrane structure on the release properties of the 
poly(L-lactide) fibers was performed by Van de Witte et al. (1993). The pore structure of the 
fibers was regulated by changing the spinning system and the spinning conditions. When 
fibers with dense toplayers were used, low drug release rates were observed, whereas fibers 
with an interconnected pore structure over the entire fiber wall showed very high release rates.  
These experiments showed that the hollow fiber concept seemed promising as a long acting 
contraceptive delivery system. Based on this knowledge Organon developed Implanon®, a 
subdermal implant for the controlled release of 3-ketodesogestrel. Implanon® is an 
ethylenevinylacetate rod containing 3-ketodesogestrel surrounded by rate-controlling 
ethylenevinylacetate membrane. The ethylenevinylacetate type used for the membrane has a 
lower permeability for 3-ketodesogestrel than the core type ethylenevinylacetate. The 
manufacture of Implanon® is based upon fibre spinning technology. The main process step is 
the hot-melt extrusion of a co-axial fibre (allowing continuous production of the fibre) which 
is subsequently cooled and cut into segments. The contraceptive efficiency of Implanon® lasts 
for 3 years, whereafter the implant has to be removed (Sam, 1992). Norplant®-2 is a similar 
contraceptive implant based on a set of two flexible cylindrical implants, consisting of a 
mixture of dimethylsiloxane-methylvinylsiloxane copolymer and levonorgestrel, and is 
produced via injection moulding. The drug-containing rods are surrounded by a thin silicone-
membrane and the open ends of the silicone membrane are closed with a 
polydimethylsiloxane adhesive (Sam, 1992).  
 
Recently, Kajihara et al. (2001) and Maeda et al. (2003a,b) designed a covered-rod-type 
implant using silicone, which is biocompatible and non-biodegradable. This formulation has a 
two-component structure, with a drug-containing silicone matrix as the inner component, and 
with its lateral side covered with a silicone outer layer. This device was produced via 
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extrusion. The covered-rod implant was studied in vitro and in vivo as a sustained release 
formulation for various drugs. Zero-order drug release was achieved for 1 month or longer 
and by addition of additives (to the inner core) such as polyethylene glycol and deoxycholate 
sodium different drug release patterns could be obtained  
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3 FORMULATION STUDY FOR THE 
PRODUCTION OF A MATRIX-IN-
CYLINDER SYSTEM  
3.1 INTRODUCTION 
The objective of this research project was to develop a monolithic matrix system for sustained 
zero-order drug release by encapsulating a matrix in a non-erodible hollow cylinder. Hot-melt 
extrusion, a simple and continuous production technique, was chosen as the manufacturing 
method for the hollow cylinders. Ethylcellulose was selected as the hollow fiber forming 
material due to its water-insoluble nature and its thermoplastic properties, making this 
molecule suitable for hot-melt extrusion. The first part of this chapter focused on the 
production of the hollow cylinders, evaluating the influence of formulation and process 
parameters on the quality of the extruded cylinders. 
Another objective was to identify a core material for the matrix-in-cylinder system, which 
released the drug in a sustained and zero-order manner. Therefore, the ethylcellulose cylinders 
were filled with lipophilic materials. Triglyceride-bases and saturated polyglycolised 
glycerides were evaluated as core material of the matrix-in-cylinder system. Glycerides are 
widely used pharmaceuticals as solvents, suppository bases and oil phase in emulsions. More 
recently, there has been interest in their use as controlled release systems, because of their 
hydrophobic nature, low cost and pharmaceutical acceptability (Craig, 1995).  
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3.2 MATERIALS 
Ethylcellulose (EC) (Ethocel® FP10) (ethoxyl content: 48-49.5 % (w/w); viscosity: 9-11 
mPa.s (5 % solution in toluene-EtOH, 80:20, 25°C)) was kindly donated by the Dow 
Chemical Company (Horgen, Switzerland). Triethyl citrate, triacetin, dibutyl sebacate and 
dibutyl phthalate were purchased from Sigma (St-Louis, USA).  
Theophylline monohydrate (Ludeco, Brussels, Belgium) was used as a model drug, since it is 
non-toxic, cheap, easily detectable via U.V. spectroscopy and often used in the domain of 
sustained drug delivery. Ovucire® and Gelucire® (44/14, 50/13, 50/02) were kindly donated by 
Gattefossé (St. Priest, France). Witepsol® was obtained from Sasol Benelux (Antwerp, 
Belgium). α-Lactose monohydrate (Pharmatose 200M) was purchased from De Melkindustrie 
(Veghel, The Netherlands). Tribasic calcium phosphate was supplied by Ludeco (Brussels, 
Belgium).  
3.2.1 Ethylcellulose 
Ethylcellulose, an ethyl ether of cellulose, is a long chain polymer of β-anhydroglucose units 
(Figure 3.1). Ethylcellulose ethers are a family of inert hydrophobic polymers (organosoluble 
thermoplastics) that have been widely used in pharmaceuticals since their commercial 
introduction in the mid-1930’s. These polymers are essentially tasteless, odourless, colourless, 
non-caloric and physiologically inert.  
After evaporation of the organic solvent they form water-insoluble films, whose permeability 
can be altered by the incorporation of hydroxypropyl methylcellulose. An aqueous polymer 
dispersion (or latex) of ethylcellulose produces films without the need for organic solvents. 
Ethylcellulose is useful in a variety of pharmaceutical applications: as rate controlling 
polymer in matrix tablets, as tablet binder and cushioning agent, as coating polymer, as 
granulation binder and as matrix for solid dispersions (Rowe et al., 2003). The processing of 
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ethylcellulose (having a glass transition temperature of 133°C) via hot-melt extrusion has 
been described by Follonier et al. (1994, 1995), De Brabander et al. (2003) and Crowley et al. 
(2004).   
 
   
Figure 3.1: Structure of ethylcellulose. 
 
3.2.2 Triglycerides 
Glycerides are fatty acid esters of the trihydroxy alcohol glycerol. The basic structure is given 
in Figure 3.2. 
   
Figure 3.2: Basic structure of triglycerides. 
 
The groups R1, R2 and R3 represent the hydrocarbon moieties of the constituent fatty acids 
which may be saturated (e.g. capric, lauric, myristic, palmitic and stearic acid) or unsaturated 
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(e.g. oleic, linoleic and palmitoleic acid). The terms tri-, di- and monoglyceride refer to the 
number of alcohol groups esterified with a fatty acid. Triglycerides may be referred to as 
simple or mixed, depending on whether the fatty acid groups are identical or dissimilar, 
respectively. The longer the chain length of the fatty acids, the higher the melting point of the 
base. Glycerides with low melting points are used as the oil phase in emulsions, while 
glycerides with higher melting points are employed as suppository base (Craig, 1995).  
Hard fat suppository bases are semi-synthetic glycerides consisting of mixtures of triglyceride 
esters of higher saturated fatty acids (C8-C18) along with varying proportions of mono- and 
diglycerides. The primary application of hard fat suppository bases is as a vehicle for the 
rectal or vaginal administration of a variety of drugs, either to exert local effects or to achieve 
systemic absorption. The most common method of manufacture involves the hydrolysis of 
natural vegetable oils such as coconut or palm kernel oil, followed by fractional distillation of 
the free fatty acids produced. The C8 to C18 fractions are then hydrogenated and re-esterified 
under controlled conditions with glycerol to form a mixture of tri-, di- and monoglycerides of 
the required characteristics and hydroxyl value (Rowe et al., 2003).  
In this study, suppository bases with different melting ranges are used (Witepsol® and 
Ovucire®). Witepsol® covers a range of suppository bases available in different melting 
ranges, consisting of a mixture of semi-synthetic glycerides with varying concentrations of 
mono- and diglycerides. To obtain a specific Witepsol® grade, the C12-C18 fraction is used in a 
specific ratio. Witepsol® H15 (melting range: 33.5-35.5°C) is a classical suppository base, 
while Witepsol® E85 (melting range: 42-44°C) is used in combination with Witepsol® H15 
for the formulation of melting point lowering drugs. Ovucire® is a vehicle for vaginal 
suppositories, consisting of semi-synthetic glycerides with an emulsifying additive to improve 
the dispersibility and wettability of the actives. 
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3.2.3 Polyglycolised glycerides 
The Gelucires® are a family of lipid-based excipients for oral drug delivery comprising  
mono-, di- and triglycerides mixed with mono- and diesters of fatty acids and polyethylene 
glycol (PEG) (Figure 3.3), hence a range of materials with different properties are available 
within the group. The presence of glycerides and PEG-esters renders hydrophobic as well as 
hydrophilic properties to the Gelucires®. Each Gelucire® is characterised by two numbers, the 
first referring to the (approximate) melting point of the base and the second to the 
hydrophilic-lipophilic balance value (HLB-value).  
 
    
 
Figure 3.3: Monoester (structure A) and diester (structure B) of fatty acid and polyethylene glycol. 
 
The most common method of synthesis of Gelucire® involves an alcoholysis reaction, 
whereby PEG with a molecular weight between 300 and 1500 reacts with hydrogenated 
vegetable oils from coconut, palm or palm kernel oil at 230°C under nitrogen. The 
triglycerides are broken down to their constituent fatty acids, which then esterify with the 
terminal alcohol groups of the PEG molecules. Alternatively, direct esterification may be 
used, whereby fatty acids from coconut oil, palmitic acid or stearic acid are esterified with 
glycerol and PEG. As these reactions do not reach completion, the bases will therefore consist 
of a mixture of glycerides and PEG esters of fatty acids. The chemical composition of the 
different bases may be controlled by altering the starting materials and manufacturing 
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conditions. In general, the higher the ratio of PEG esters to glycerides, the more hydrophilic 
the base will be. Similarly, the longer the chain length of the PEG and fatty acid fractions, the 
higher the melting point of the material (Craig, 1995).  
There has been considerable interest in the use of Gelucire® bases as matrices for oral 
administration, particularly with respect to Gelucire® 50/13 and Gelucire® 44/14. Gelucire® 
50/13 contains a large portion of PEG mono- and diesters with palmitic (C16) and stearic (C18) 
acid, while Gelucire® 44/14 is composed largely of esters of lauric acid (C12) (Craig, 1995). 
Despite their compositional similarities, these two materials exhibit different in vitro 
properties: Gelucire® 44/14 forming a micro-emulsion system on contact with water that 
appears to enhance absorption (Itoh et al., 2002; Barker et al., 2003), while Gelucire® 50/13 
swells in water and forms a barrier to drug release (Sutananta et al., 1995). 
3.3 METHODS 
3.3.1 Hot-melt extrusion of hollow ethylcellulose cylinders 
Prior to hot-melt extrusion of the hollow pipes, ethylcellulose was mixed with a plasticizer in 
a planetary mixer (Kenwood Major Classic, Hampshire, UK). Extrusion was performed using 
a MP 19 TC 25 laboratory scale co-rotating twin screw extruder of APV Baker (Newcastle-
under-Lyme, UK). The machine was equipped with a screw profile with two mixing sections, 
an annular die with metal insert for the production of the pipes (Fig. 3.4) and a twin screw 
powder feeder. During the formulation study of the ethylcellulose pipes the following 
extrusion conditions - based on preliminary research work - were used: a screw speed of 5 
rpm, a powder feed rate of 0.14 kg/h and a temperature profile of 125-125-115-105-80°C 
from the powder feeder towards the die. The extrudates were inspected on their ability to form 
a solid but flexible structure which can be cut into smaller segments without splintering. 
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Figure 3.4: Schematic drawing of the annular die used to produce the outer barrier (pipe) of the 
system. 
 
3.3.2 Production of matrix-in-cylinders 
The ethylcellulose pipes (internal diameter = 5 mm, wall thickness = 1 mm) were cut into 
pieces of 18 mm (= maximal length that fits in a hard gelatine capsule of size 000) and were 
filled with lipophilic materials. 
 
¾ Production of matrix-in-cylinders with a glyceride core 
The matrix-in-cylinder systems with Witepsol, Ovucire or Gelucire as core material were 
manufactured as follows: after heating Witepsol, Ovucire or Gelucire to 20°C above their 
melting point, the molten material was admixed with theophylline monohydrate (the 
theophylline monohydrate content was either 30% or 60% (w/w)) and homogenised. An 
amount of this mixture was manually spouted into the hollow pipes using a syringe. After 
cooling, excess material was cut off. 
metal insert 
(= diameter matrix core) 
annular die 
(gap = 1 mm = wall thickness of EC cylinder) 
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¾ Production of matrix-in-cylinders with a Gelucire 44/14 core containing a filler 
In a second part of this formulation study, a mixture of Gelucire 44/14 and a filler was 
evaluated as core material for the matrix-in-cylinder system. These matrix-in-cylinder systems 
were produced as follows: after heating Gelucire 44/14 to 65°C, the molten material was 
admixed with the filler and theophylline monohydrate (the theophylline monohydrate content 
was 5 % (w/w)) and homogenised. An amount of this mixture was manually spouted into the 
hollow pipes using a syringe. After cooling, excess material was cut off. 
 
3.3.3 In vitro evaluation 
¾ Dissolution testing 
The drug release from the matrix-in-cylinder was evaluated by in vitro dissolution testing. All 
dissolution tests were performed in threefold in a VK 7000 dissolution bath with a VK 8010 
autosampler (VanKel Industries, NJ, USA). The system operated at 37±0.5°C and 100 rpm 
using the paddle method (USP 27). Demineralised water was used as a dissolution medium. 
Sink conditions were maintained. Samples were taken at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h. 
The drug concentration in the samples was measured at 272 nm with a Perkin Elmer Lambda 
12 UV-Vis double beam spectrophotometer (Zaventem, Belgium).  
 
¾ Erosion experiments 
Erosion of the matrices was evaluated under the conditions of the dissolution tests described 
above (n = 3). Each device having an initial mass X was removed from the dissolution 
medium at preselected time intervals and after removing excess water dried at 80°C to a 
constant weight (= mass Y). Matrix erosion at each time point was calculated as:  
[(X-HP)-(Y-HP)] x 100 / (X-HP) with HP being the weight of the hollow pipe.  
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In order to assess the weight loss from the ethylcellulose pipes, due to plasticizer leaching out 
into the dissolution medium, an erosion test with empty ethylcellulose pipes was performed (n 
= 3). At each time point, the weight loss of the hollow pipes was less than 1.35 %.  
 
¾ Evaluation of the dissolution profiles 
The aim of this doctoral thesis was to develop an oral dosage form characterised by a 
sustained and zero-order drug release profile. Concerning the sustained release criterion, the 
objective was to formulate a once-a-day formulation, hence 80-100 % of the drug should be 
released within 20 to 24 h of dissolution testing.  
A zero-order dissolution profile can be described by the following mathematical model:  
Qt = Q0 + K0t 
where Qt is the amount of drug released (and dissolved) in time t, Q0 is the initial amount of 
drug in the solution (in most cases, Q0 = 0) and K0 is the zero-order release constant (Costa 
and Lobo, 2001). The fit of this zero-order model was assessed by the coefficient of 
determination (R²) of the plot ‘amount of drug released versus time’ (Costa and Lobo, 2001). 
The dissolution profile was considered as: 
- zero-order if R² ≥ 0.975 
- near zero-order if 0.950 < R² < 0.975 
- no zero-order if R² ≤ 0.950. 
Only those formulations having both a sustained (80-100 % drug release after 20-24 h) and 
zero-order (R² ≥ 0.975) drug release profile were considered for further in vivo analysis. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Hot-melt extrusion of hollow ethylcellulose cylinders 
In order to decrease the melt viscosity of ethylcellulose during thermal processing and to 
obtain flexible cylinders after extrusion, the addition of a plasticizer was required. Water-
soluble (triethyl citrate and triacetin) and water-insoluble (dibutyl phthalate and dibutyl 
sebacate) plasticizers were added to ethylcellulose in a concentration of 10, 20 or 30 % w/w. 
The use of water-soluble plasticizers resulted in brittle hollow cylinders, while the water-
insoluble plasticizers yielded cylinders with sufficient flexibility. This was expected since a 
plasticizer must be able to dissolve the polymer to promote chain mobility and flexibility, thus 
hydrophobic plasticizers are more effective for the hydrophobic ethylcellulose (Bindschaedler 
et al., 1983; Onions, 1986). Since the best cylinder quality was obtained with dibutyl sebacate 
at a concentration of 20 % w/w, it was decided to continue with this formulation. Using this 
formulation, the influence of process parameters (extrusion temperature, screw speed and 
powder feed rate) on the processing and the appearance of the hollow pipes was evaluated. 
When increasing the extrusion temperature to 130 and 140°C (over the entire barrel), 
ethylcellulose became too plastic resulting in a collapse of the hollow cylinders when leaving 
the extrusion die. At extrusion temperatures below 120°C (110°C and 100°C, over the entire 
barrel) ethylcellulose was not completely in the rubbery state and the cylinders were not 
transparant. An increase of the screw speed and the powder feed rate resulted a collapse of the 
cylinders. Based on these observations it was decided to continue with the initially used 
conditions for the hot-melt extrusion of hollow ethylcellulose cylinder: a temperature profile 
of 125-125-115-105-80°C (from the powder feeder towards the die), a screw speed of 5 rpm 
and a powder feed rate of 0.14 kg/h. 
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Figure 3.5: Hot-melt extruded ethylcellulose cylinders (containing 20 % dibutyl sebacate as a 
plasticizer) extruded at a temperature profile of 125-125-115-105-80°C (from the 
powder feeder towards the die), a screw speed of 5 rpm and a powder feed rate of 0.14 
kg/h. 
 
3.4.2 Selection of core material 
Triglyceride-bases with different melting ranges (Table 3.1), loaded with 30 % (±125 mg) or 
60 % (±250 mg) theophylline monohydrate, were tested on their potential as sustained release 
matrix core for the matrix-in-cylinder system. Dissolution experiments revealed that a higher 
melting range of the base resulted in a slower drug release rate (Figure 3.6 and Table 3.2). 
Increasing the drug loading of the core also slowed down drug release. However, none of the 
tested triglyceride-bases exhibited both a zero-order and sustained release profile.  
 
Table 3.1: Melting ranges of the triglyceride-bases.   
Triglyceride-base Melting range 
Ovucire® 3460 32.5-34.0°C 
Witepsol® H15 33.5-35.5°C 
Witepsol® H15/Witepsol® E85 (60/40 w/w) mixture 36.0-38.0°C 
Witepsol® H15/Witepsol® E85 (40/60 w/w) mixture 38.0-40.0°C 
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Figure 3.6: Mean drug release profiles (± S.D.) of matrix-in-cylinders containing 30 % 
theophylline / 70 % glycerides (closed symbols) and 60 % theophylline / 40 % 
glycerides (open symbols): Witepsol® H15 ♦ ◊, Ovucire® 3460 ● Ο. 
 
Table 3.2.: Evaluation of the dissolution profiles. 
Formulation R² Time needed to achieve complete drug release 
30 % TF / 70 % Ovucire® 3460 - 1 h 
30 % TF / 70 % Witepsol® H15 0.980±0.013 12 h 
30 % TF / 70 % Witepsol® H15:E85 (60:40) - 1.9 % after 24 h 
30 % TF / 70 % Witepsol® H15:E85 (40:60) 
 
- 0.9 % after 24 h 
60 % TF / 40 % Ovucire® 3460 0.948±0.010 20 h 
60 % TF / 40 % Witepsol® H15 0.779±0.173 54.6 % after 24 h 
60 % TF / 40 % Witepsol® H15:E85 (60:40) - 1.7 % after 24 h 
60 % TF / 40 % Witepsol® H15:E85 (40:60) 
 
- 1.1 % after 24 h 
30 % TF / 70 % Gelucire® 44/14 0.986±0.004 12 h 
30 % TF / 70 % Gelucire® 50/13 
 
0.992±0.007 12 h 
60 % TF / 40 % Gelucire® 44/14 ** 0.975±0.006 20 h 
60 % TF / 40 % Gelucire® 50/13 0.942±0.027 41.1 % after 24 h 
TF =  theophylline  
**  = formulation having both a sustained (80-100 % drug release after 20-24 h) and zero-order (R² ≥ 0.975) 
drug release profile. 
 
Next, polyglycolised glycerides (Gelucire® 44/14 and 50/13) were evaluated as core material. 
Figure 3.7 and Table 3.2 show that only Gelucire® 44/14 provided a (near) zero-order drug 
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release profile with moderate sustained release properties. To elucidate the drug release 
mechanism the erosion profiles of Gelucire® 44/14 cores, containing 0, 30 and 60 % 
theophylline monohydrate respectively, were determined (Figure 3.7). Examination of the 
erosion data of Gelucire® 44/14 indicated that erosion of the matrix was a linear process (R² = 
0.989 and 0.978, at 30 % and 60 % drug loading respectively) and that the drug release 
matched the erosion profile, providing strong evidence for an erosion-controlled drug release 
mechanism and for negligible diffusional release of the drug. Comparing the erosion profiles 
of the Gelucire® 44/14 core loaded with 0, 30 and 60 % theophylline monohydrate, it was 
obvious that a higher drug loading resulted in a slower erosion rate (due to the higher solids 
fraction in the core).  
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Figure 3.7: Mean drug release profiles (± S.D.) (full lines) and mean erosion profiles (± S.D.) 
(dotted lines) of matrix-in-cylinders containing 100 % Gelucire® 44/14 (x), 30 % 
theophylline monohydrate and 70 % Gelucire® 44/14 (●), 60 % theophylline 
monohydrate and 40 % Gelucire® 44/14 (♦). Mean drug release profiles (± S.D.) of 
matrix-in-cylinders containing 30 % theophylline monohydrate and 70 % Gelucire® 
50/13 (■), 60 % theophylline monohydrate and 40 % Gelucire® 50/13 (▲).  
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The previous experiments indicated that drug release from the matrix-in-cylinder system 
containing a Gelucire® 44/14 core met the proposed sustained release criterion (= 80-100 % 
drug release after 20-24 h) at high drug loading (60 % theophylline monohydrate) only. 
Therefore, it was attempted to sustain the drug release from a Gelucire® 44/14 core loaded 
with a low amount of drug (5 % theophylline monohydrate). The drug release profile of a 
matrix-in-cylinder system containing Gelucire® 44/14 and 5 % theophylline monohydrate as 
core material is shown in Figure 3.8. At first, the hydrophobicity of the matrix core was 
increased in order to slow down the drug release rate. This was obtained by incorporating 
Gelucire® 50/02 into the Gelucire® 44/14 matrix (in varying ratios). Gelucire® 50/02 is a 
Gelucire® base containing low concentrations of PEG esters, thus having a low HLB. 
Furthermore, its melting point (50°C) is higher than that of Gelucire® 44/14, which could also 
slow down drug release. Matrix-in-cylinders containing Gelucire® 44/14 – Gelucire® 50/02 
mixtures exhibited (near) zero-order kinetics (R² varied between 0.971 and 0.991), however it 
was difficult to tailor drug release to a once-a-day formulation as drug release was very 
sensitive to the Gelucire® ratio (Figure 3.8). 
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Figure 3.8: Mean drug release profiles (± S.D.) of matrix-in-cylinders containing 5 % theophylline 
monohydrate and 95 % of a mixture of Gelucire® 44/14 and Gelucire® 50/13. Ratio 
Gelucire® 44/14 vs. Gelucire® 50/13: 100/0 (■), 95/5 (●), 90/10 (♦), 80/20 (▲), 50/50 
(x). 
 
As slower erosion rates were observed when higher theophylline concentrations were 
incorporated in the Gelucire® 44/14 core, it was decided to increase the solids fraction of the 
core by incorporating an inert powder into the core to improve the sustained release 
characteristics of the system. A freely water-soluble and a poorly water-soluble filler (α-
lactose monohydrate and tribasic calcium phosphate, respectively) were used (Figure 3.9). 
Addition of α-lactose monohydrate to the Gelucire® 44/14 core of the matrix-in-cylinder 
system did not slow down the drug release rate, while the incorporation of tribasic calcium 
phosphate was able to sustain drug release however not in a linear way (R² = 0.944). Even a 
mixture of α-lactose monohydrate and tribasic calcium phosphate did not result in a linear (R² 
= 0.933) nor sufficiently sustained drug release.  
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Figure 3.9: Mean drug release profiles (± S.D.) of matrix-in-cylinders containing 5 % theophylline 
monohydrate combined with 95 % Gelucire® 44/14 (■), 55 % lactose monohydrate 
and 40 % Gelucire® 44/14 (♦), 35 % tribasic calcium phosphate and 60 % Gelucire® 
44/14 (x) or 45 % of a 50/50 (w/w) mixture lactose monohydrate/tribasic calcium 
phosphate and 50 % Gelucire® 44/14 (▲).  
Note: for each formulation the amount of filler in the Gelucire® 44/14 matrix was 
maximized, but due to their powder density the amount of lactose monohydrate (55 %) 
incorporated in Gelucire® was much higher compared to tribasic calcium phosphate 
(35 %). 
3.5 CONCLUSION 
From these experiments it could be concluded that a matrix-in-cylinder system with a 
Gelucire® 44/14 core showed sustained zero-order release properties at high drug loading (60 
% theophylline monohydrate). Decreasing the drug load resulted in an acceleration of drug 
release. Neither the incorporation of the more hydrophobic Gelucire® 50/02 nor the 
incorporation of inert fillers into the Gelucire® 44/14 core were able to provide a sustained 
and constant drug release from the matrix-in-cylinder system. 
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4 DEVELOPMENT AND EVALUATION 
OF A MATRIX-IN-CYLINDER SYSTEM 
WITH A HPMC-GELUCIRE® CORE 
 
Published in part in Journal of Controlled Release 94 (2004), 273-280. 
 
4.1 INTRODUCTION 
The previous experiments have shown that a matrix-in-cylinder system, containing Gelucire® 
44/14 as core material, resulted in a sustained drug release profile at high drug loading only. 
In order to sustain drug release from a Gelucire® 44/14 core loaded with a low amount of drug 
(5 % theophylline monohydrate), classical fillers of different water-solubility were 
incorporated in the Gelucire® base. However, these mixtures were not able to meet the zero-
order sustained release criterion. Therefore, it was chosen to mix Gelucire® 44/14 with 
hydroxypropyl methylcellulose (HPMC), because the gel forming capacities of HMPC could 
be advantageous to the sustained release properties of the dosage form. HPMC polymers 
swell upon contact with water or physiological fluids, forming a barrier to drug release. 
 
The combination of Gelucire® and HPMC is quite unique. Only one report, describing the 
combination of a gel forming polymer and polyglycolised glycerides, was found in literature 
(Barthelemy and Benameur, 2001). This formulation, a Self Micro Emulsifying Drug 
Delivery System for sustained drug release, consisted of an active pharmaceutical ingredient, 
a lipophilic phase (such as Gelucire®), a glyceride-based surfactant, a co-surfactant and a gel 
forming polymer (such as HPMC) and is capable of forming, in contact with physiological 
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fluids, a gelled polymer matrix releasing the microemulsified active agent in a continuous and 
sustained manner (Barthelemy and Benameur, 2001). 
 
This chapter describes the development of a matrix-in-cylinder system containing a HPMC-
Gelucire® 44/14 core for zero-order, sustained drug delivery. Different strategies to tailor the 
drug release rate were evaluated. 
 
4.2 MATERIALS 
Hydroxypropyl methylcellulose (HPMC) and methylcellulose (MC) (Methocel® Premium), 
available in different viscosity grades and substitution types (differing in their methoxyl and 
hydroxypropyl content), were received from Colorcon (Dartford, UK). Ethylcellulose 
(Ethocel® FP10) (ethoxyl content: 48-49.5 % (w/w); viscosity: 9-11 mPa.s (5 % solution in 
toluene-EtOH, 80:20, 25°C)) was kindly donated by the Dow Chemical Company (Horgen, 
Switzerland). Dibutyl sebacate was purchased from Sigma (St-Louis, USA). Gelucire® 44/14 
was a gift from Gattefossé (Saint-Priest, France). Theophylline monohydrate (Ludeco, 
Brussels, Belgium), propranolol hydrochloride (Medeva Pharma, Braine-l’Alleud, Belgium) 
and hydrochlorothiazide (Medeva Pharma, Braine-l’Alleud, Belgium) were selected as model 
drugs. 
4.2.1 Hydroxypropyl methylcellulose (HPMC) 
HPMC is a partly O-methylated and O-(2-hydroxypropylated) cellulose available in several 
grades which vary in degree of substitution and viscosity (Figure 4.1) (Rowe et al., 2003). 
The physicochemical properties of HPMC are affected by the methoxy-group content, the 
hydroxyproproxy-group content and the molecular weight. The USP distinguishes four 
different types of HPMC, classified according to their relative –OCH3 and –OCH2CHOHCH3 
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content: HPMC 1828, HPMC 2208, HPMC 2906 and HPMC 2910. The first two numbers 
indicate the percentage of methoxy-groups, the last two numbers the percentage of 
hydroxyproproxy-groups. The exact limits for the degree of substitution defining the 
respective HPMC types are shown in Table 4.1. The USP also describes a method to 
determine the apparent viscosity of an aqueous 2 % solution of the polymer, which serves as a 
measure for the average chain length of the polymer. 
 
     
Figure 4.1: Structure of hydroxypropyl methylcellulose. 
Table 4.1: USP specifications for different types of HPMC, classified according to their degree of 
methoxy- and hydroxypropoxy-substitution (U.S. Pharmacopeia and National 
Formulary, 2004).  
Methoxy (%) Hydroxypropoxy (%) 
Substitution type 
Min. Max. Min. Max. 
1828 16.5 20.0 23.0 32.0 
2208 19.0 24.0 4.0 12.0 
2906 27.0 30.0 4.0 7.5 
2910 28.0 30.0 7.0 12.0 
 
HPMC is the most important hydrophilic carrier used for the preparation of oral controlled 
release drug delivery systems, because of its non-toxicity, ease of manufacture and its high 
swellability. Upon contact with water or physiological fluids the liquid diffuses into the 
device, resulting in polymer chain relaxation with volume expansion. 
The specifications of the different HPMC types used during this study are given in Table 4.2. 
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Table 4.2: Specifications of the different hydroxypropyl methylcellulose and methylcellulose 
types used. 
Methocel® % Methoxyl % Hydroxypropyl Type Viscosity (mPa.s) 
K 19-24 7-12 HPMC 100, 4M, 100M 
E 28-30 7-12 HPMC 4M 
F 27-30 4-7.5 HPMC 4M 
A 27.5-31.5 0 MC 4M 
 
 
4.3 METHODS 
4.3.1 Production of hollow ethylcellulose pipes 
The hollow ethylcellulose cylinders were prepared according to the method described in 
Chapter 3. The pipes (internal diameter = 5 mm, wall thickness = 1 mm) were cut into pieces 
of 18 mm (unless otherwise stated).  
4.3.2 Production of matrix-in-cylinders with a HPMC–Gelucire 44/14 
core 
The matrix-in-cylinder systems with a HPMC-Gelucire® 44/14 core were manufactured as 
follows: after heating Gelucire 44/14 to 65°C, the molten material was admixed with the 
drug and HPMC and homogenised. An amount of this mixture was manually spouted into the 
hollow pipes using a syringe. After cooling, excess material was cut off.  
4.3.3 Production of HPMC–Gelucire 44/14 extrudates 
The HPMC-Gelucire®-drug matrices without ethylcellulose pipe were produced by means of 
extrusion using a MP 19 TC 25 laboratory scale co-rotating twin screw extruder of APV 
Baker (Newcastle-under-Lyme, UK). The machine was equipped with a screw profile with 
two mixing sections, a 5 mm-cylindrical die and a twin screw powder feeder. The following 
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extrusion conditions were used: a screw speed of 25 rpm, a powder feed rate of 0.8 kg/h 
(theophylline monohydrate and HPMC), a (molten) Gelucire® addition rate of 1.6 kg/h (with a 
peristaltic pump) and a barrel temperature of 28°C.  
4.3.4 In vitro evaluation 
The drug release from the matrix-in-cylinder was evaluated by in vitro dissolution testing. All 
dissolution tests were performed in threefold in a VK 7000 dissolution bath with a VK 8010 
autosampler (VanKel Industries, NJ, USA). The system operated at 37±0.5°C and 150 rpm 
using the paddle method (USP 27). A dissolution medium (aqueous NaCl solution) with an 
ionic strength of 0.14 was used. These dissolution conditions were used to provide 
physiologically relevant conditions (Abrahamsson et al., 1998). Sink conditions were 
maintained. Samples were taken at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h. The drug 
concentration in the samples was measured at 272 nm (for theophylline monohydrate and 
hydrochlorothiazide) and at 288 nm (for propranolol hydrochloride) with a Perkin Elmer 
Lambda 12 UV-Vis double beam spectrophotometer (Zaventem, Belgium).  
Erosion of the matrices was evaluated under the conditions of the dissolution tests described 
above (n = 3) and was determined according to the method described in Chapter 3. 
To compare the dissolution profiles, area under the curve (AUC) values were calculated with 
the trapezoidal method (Anderson et al., 1998). The AUC0-24h-values were statistically 
evaluated with an ANOVA test (one-way or two-way) at a significance level of 0.05. The 
normality of the data was checked by means of a Kolmogorov-Smirnov test and the 
homogeneity of variances by means of the Levene test. A multi comparison among pairs of 
means was performed using a Scheffé test with p < 0.05 as a significance level. All analyses 
were performed with SPSS 11.0 for Windows. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 Influence of viscosity grade and substitution type of HPMC 
As can be seen in Figure 4.2, drug release from the HPMC-Gelucire® cores was very slow and 
proceeded according to zero-order kinetics (R² = 0.986±0.003, 0.990±0.011, 0.991±0.008 and 
0.994±0.002 for Methocel® A4M, E4M, F4M and K4M, respectively). At constant viscosity 
grade, no differences were observed between the drug release rates of the different HPMC 
grades (Methocel® E, F and K). However, the methylcellulose (MC) type matrices (Methocel® 
A) exhibited a much faster drug release profile.  
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Figure 4.2: Mean drug release profiles (± S.D.) of matrix-in-cylinder systems with various HPMC 
substitution grades: (■) MC A4M; (◊) HPMC F4M; (●) HPMC E4M and (▲) HPMC 
K4M. Each matrix-in-cylinder consists of 5 % theophylline monohydrate, 30 % 
HPMC or MC and 65 % Gelucire® 44/14 as the inner core, surrounded by an 
ethylcellulose pipe. As a reference, (x) shows the dissolution profile of a matrix-in-
cylinder system with 5 % theophylline monohydrate and 95 % Gelucire® 44/14 as core 
material. 
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To find an explanation for this difference in drug release rate, the matrix erosion profiles were 
examined. In general, drug release rates increased with increased matrix erosion rates. This 
indicated that the swelling kinetics of the matrix, which control the matrix dissolution, are an 
important determinant for drug release (Sung et al., 1996). Comparison of the drug release 
and the erosion profiles of the MC matrices indicated that the drug release matched the 
erosion profile (Figure 4.3). Microscopic examination revealed that the MC-Gelucire® cores, 
surrounded by an ethylcellulose pipe, were unable to form a gel upon exposure to an aqueous 
medium, resulting in quick erosion of this matrix (Figure 4.4a). On the contrary, the HPMC-
Gelucire® matrices formed a gel plug, which was much more resistant to erosion, releasing 
the drug slowly (Figure 4.4b). Figure 4.3 indicated that drug delivery from the HPMC-type 
matrices was initially erosion-controlled, switching after about 8 hours to a release 
mechanism by means of a combination of erosion and diffusion. A possible explanation for 
this shift in the release mechanism is the low hydrodynamics inside the hollow pipe: the 
gelled polymer matrix near the open ends of the system eroded due to the strong agitation of 
the dissolution medium, however as the erosion front moved inwards during the initial hours 
of dissolution testing the stagnant dissolution medium in the pipe eroded the matrix more 
slowly, yielding a combined erosion-diffusion drug release mechanism (Figure 4.5).  
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Figure 4.3: Mean drug release profiles (± S.D.) (▲: HPMC K4M; ■: MC A4M) and mean erosion 
profiles (± S.D.) (∆: HPMC K4M; ': MC A4M) of matrix-in-cylinders consisting of 5 
% theophylline monohydrate, 30% HPMC or MC and 65 % Gelucire® 44/14, 
surrounded by an ethylcellulose pipe. 
 
(a) MC        (b) HPMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Matrix-in-cylinder system containing (a) a MC-Gelucire® 44/14 core or (b) a HPMC-
Gelucire® 44/14 core after 0.5 h dissolution testing.  
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Figure 4.5: Matrix-in-cylinder system containing a HPMC-Gelucire® 44/14 core after 8 h 
dissolution testing.  
 
Drug release from the matrix depended on the viscosity of HPMC (Figure 4.6): a matrix-in-
cylinder containing 30 % HPMC K100 (the lowest evaluated viscosity grade) showed the 
quickest release profile (60 % drug released within 24 h) as this polymer had the highest 
susceptibility to erosion. Examination of the erosion profile of the matrix-in-cylinder 
containing 30 % HPMC K100 indicated that drug release proceeded by means of erosion 
(Figure 4.6). Similar drug release and erosion profiles were observed when incorporating high 
viscosity HPMC grades (the K4M and K100M formulations releasing 40 % of the drug over 
24 h). The lack of difference in the drug release profiles for the K4M and K100M 
formulations suggested the existence of a ‘limiting HPMC viscosity’, i.e. for the system 
studied, the drug release rate did not decrease when the viscosity grade was increased above 
4000 mPa.s. A ‘limiting HPMC viscosity’ was already described by Gao et al. (1996) and 
Sung et al. (1996) for HPMC-based tablets and was attributed to a similar drug diffusivity 
resulting from an identical gel layer thickness above the limiting viscosity grade.  
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Figure 4.6: Mean drug release profiles (± S.D.) (full lines) and mean erosion profiles (± S.D.) 
(dotted lines) of matrix-in-cylinder systems with different HPMC viscosity grades: 
each matrix-in-cylinder contained 5 % theophylline monohydrate, 30 % HPMC and 65 
% Gelucire® 44/14 ((■) K100; (●) K4M; (▲) K100M)). Mean drug release profiles (± 
S.D.) of matrix-in-cylinder systems containing 5 % theophylline monohydrate, 20 % 
HPMC and 75 % Gelucire® 44/14 ((ٱ) K100; (Ο) K4M; (∆) K100M).  
 
Based on these results the concept of a HPMC-Gelucire® core surrounded by an 
ethylcellulose pipe seemed very promising to formulate a matrix system with zero-order 
release kinetics. However, drug release was too slow as in most cases less than 50 % of the 
drug was released within 24 hours. To achieve complete release of the drug, the composition 
of the inner core as well as the dimensions of the hollow pipe were modified in order to 
increase the erosion rate of the gelled polymer matrix.  
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4.4.2 Modification of core formulation 
Reducing the HPMC concentrations suspended in Gelucire® from 30 % to 20 % (w/w) 
induced a higher drug release rate (Figure 4.6). Nevertheless, it was considered that the 
incorporation of 30 % HPMC was essential to obtain a constant and reproducible erosion rate 
as at lower concentration a significant burst effect and large standard deviations on the 
dissolution profiles were observed. Another approach to increase the erosion rate of the gel 
core of the matrix-in-cylinder system was to replace part of the HPMC by MC as the MC 
polymers might affect the gel strength. Figure 4.7 shows that it was possible to achieve 
complete drug release at a 1:5 HPMC/MC-ratio, according to zero-order kinetics (R² = 
0.977±0.003). 
 
0
20
40
60
80
100
0 5 10 15 20 25
time (h)
%
 d
ru
g 
re
le
as
ed
 
Figure 4.7: Mean drug release profiles (± S.D.) of matrix-in-cylinder systems with different HPMC 
(K4M)/ MC (A4M) ratios: (■) 1:5; (♦) 1:2; (▲) 1:1 and (●) 2:1. Each matrix-in-
cylinder consisted of 5 % theophylline monohydrate, 30 % HPMC-MC mixture and 65 
% Gelucire® as the inner core, surrounded by an ethylcellulose pipe. 
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4.4.3 Modification of dimensions 
In order to determine the influence of the dimensions of the hollow pipe on drug release, 
matrix-in-cylinders with varying length (12, 15, 18 mm) and varying diameter (3, 5, 7 mm) 
were produced. Dissolutions tests were performed (Figure 4.8) and the influence of the length 
and the diameter of the matrix-in-cyilinder on the AUC0-24h of the dissolution profiles was 
evaluated statistically (Table 4.3). A two-way ANOVA revealed no significant interaction  
(p > 0.05) between the length and the diameter. However, there was a significant main effect 
of the length of the matrix-in-cylinder (p < 0.001). A posthoc analysis (Scheffé procedure) 
revealed that the AUC0-24h’s of the matrix-in-cylinder systems with a length of 12 mm, 15 mm 
and 18 mm differed significantly from each other. It can be concluded that shortening the 
matrix-in-cylinder resulted in a quicker drug release. For example, short matrix-in-cylinders (l 
= 12 mm, d = 5 mm), containing 5 % theophylline monohydrate, 30 % HPMC K100 and 65 
% Gelucire® 44/14, released 100 % of the drug over 24 h in a linear way (R² = 0.994±0.001), 
thus meeting the proposed zero-order sustained release citerion.  
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Figure 4.8: Mean drug release profiles (± S.D.) of matrix-in-cylinder systems having a length of 
12 mm (▲), 15 mm (■) or 18 mm (x) and a diameter of 3 mm (black line), 5 mm (red 
line) or 7 mm (blue line). Core material: 5 % theophylline monohydrate, 30 % 
Methocel K100 and 65 % Gelucire 44/14. 
 
Table 4.3: Influence of the length and the diameter of the matrix-in-cylinder system (containing 5 
% theophylline monohydrate, 30 % HPMC K100 and 65 % Gelucire 44/14 as core 
material) on the AUC0-24h of the dissolution profiles (data are presented as the mean 
data ± S.D.)  
AUC0-24h 
 d = 3 mm n d = 5 mm n d = 7 mm n Main effect length n
l = 12 mm 1446.8±101.8 3 1398.0±67.6 3 1351.2±48.4 3 1394.3±48.5b 9
l = 15 mm 1053.5±106.6 3 1037.9±56.4 3 1097.4±53.3 3 1062.9±30.9c 9
l = 18 mm 971±60.9 3 854.5±11.7 3 872.9±16.1 3 900.3±64.1d 9
Main effect 
diameter 
 
1157.9±253.3a 9 1092.5±269.5a 9 1107.2±239.3a 9   
a,b,c,d : groups with the same superscript are not significantly different from each other (p > 0.05, Scheffé test) 
Note: d = diameter, l = length 
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The diameter of the ethylcellulose pipe did not have a significant effect on the AUC0-24h (p = 
0.103). This is surprising because an accelerated drug release rate with increasing diameter 
and thus increasing surface area was expected. This could be explained by calculation of the 
relative surface area (absolute surface area/absolute volume) of the matrix core of the matrix-
in-cylinder system. The absolute surface area of a cylinder equals the surface area of each end 
( = 2πr²) plus the surface area of the side ( = 2πrl). The matrix core of the matrix-in-cylinder 
system is surrounded by an impermeable ethylcellulose cylinder, hence drug release is only 
possible through both open ends of the cylinder, resulting in an absolute surface area of only 
2πr².  
 
Relative surface area = absolute surface area/absolute volume = 2πr² / πr²l = 2 / l 
 
The relative surface area of the matrix core and consequently the drug release rate appears to 
be independent of the diameter of the matrix-in-cylinder, it is only a function of the length. 
Thus, an increased diameter results in an increased surface area through which the drug can 
be delivered, but this is compensated by the increased volume and consequently increased 
drug content of the dosage form whereby the relative drug release rate remains unchanged.  
Nevertheless, hollow pipes with an increased diameter might be used to incorporate higher 
amounts of drugs into the HPMC-Gelucire® matrix. From these experiments it can be 
concluded that the (relative) drug release rate from the matrix-in-cylinder dosage form can be 
tailored by modifying the length of the hollow pipes. 
4.4.4 Impact of the hollow pipe 
As mentioned before, the development of the matrix-in-cylinders was based on a restriction of 
the surface area exposed to the dissolution medium, resulting in a decreased matrix hydration 
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and a reduced surface through which the drug can be delivered. To evaluate the impact of the 
hollow pipe on the dissolution profiles, dissolutions with matrix systems not surrounded by an 
ethylcellulose pipe were performed. These matrices consisted of 5 % theophylline 
monohydrate, 30 % HPMC K100 and 65 % Gelucire® 44/14 and were produced by means of 
extrusion. It was clear that the ethylcellulose-sheet played a crucial role in obtaining the 
targeted release profile as drug release was completed within 2 to 4 h (even when using high 
viscosity grades of HPMC).  
4.4.5 Influence of drug solubility and drug loading 
The matrix effect of the HPMC-Gelucire® system was independent of the solubility of the 
drug as no significant differences in the AUC0-24h values of the dissolution profiles (at 5, 10, 
20 and 30 % drug loading) were detected when incorporating a freely water-soluble 
(propranolol HCl; aqueous solubility (25°C): 50 g/l) and a poorly soluble 
(hydrochlorothiazide; solubility in 0.1N HCl (25°C): 0.25 g/l) drug into the formulation 
instead of the medium soluble theophylline monohydrate (aqueous solubility (25°C): 8.33 g/l) 
(Table 4.4). The reason for the limited influence of drug solubility on the drug dissolution 
rates was probably the improved wettabillity (especially important for hydrochlorothiazide). 
The dispersed drug particles in the matrix core are surrounded by a water-soluble polymer 
(HPMC) and by an amphiphilic additive (Gelucire® 44/14), resulting in an improved wetting 
of the drug particles by the dissolution medium (Lippold and Ohm, 1986). Especially 
Gelucire® 44/14 has been recognized as a powerful solubilisation agent, having a critical 
micellar concentration of only 2 µg/ml in an aqueous solution (Kawakami et al., 2004). 
Kawakami et al. (2004) demonstrated that the surface tension of an aqueous solution 
decreased with increasing Gelucire® 44/14 concentration (e.g. the surface tension was 70 
mM/m and 32 mM/m at 0.01 µg/ml and 100 µg/ml Gelucire® 44/14 in water, respectively). A 
matrix-in-cylinder system (with 5 % drug) contained ±185 mg Gelucire® 44/14 resulting in a 
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concentration of ±206 µg/ml Gelucire® 44/14 in water at the end of the dissolution test, which 
is about 100 times higher than the critical micellar concentration.  
An increase of the drug loading, respecting the same HPMC K100 to Gelucire® 44/14 ratio 
(1:2.17), induced a significant (p < 0.05) acceleration of the drug release (Table 4.4). This 
effect was expected as higher drug loadings reduced the polymer/Gelucire® content of the 
matrix. 
 
Table 4.4: Influence of drug solubility and drug loading on the AUC0-24h of the drug release 
profiles (data are presented as the mean data ± S.D.). 
AUC0-24h 
 propranolol n theophylline n HCT n Main effect  drug loading n
5 % 914.4±17.6 3 1094.6±11.9 3 974.6±85.4 3 994.5±91.8a 9
10 % 920.6±100.0 3 983.7±18.8 3 895.5±11.2 3 933.3±45.4 a 9
20 % 1069.8±21.5 3 1048.8±13.0 3 NP  1059.3±14.8b 6
30 % 1151.5±9.8 3 1173.1±20.0 3 NP  1162.3±15.3c 6
Main effect 
drug 
solubility 
1014.0±116.4a 12 1075.1±79.7a 12 -    
a, b, c : groups with the same superscript are not significantly different from each other (p > 0.05, Scheffé test) 
Note: dissolutions with 20 % and 30 % hydrochlorothiazide were not performed because sink conditions were 
not fulfilled, therefore mean effect of drug solubility was not shown for hydrochlorothiazide. No significant 
differences in AUC0-24h were observed at 5 % and at 10 % drug loading between propranolol, theophylline and 
hydrochlorothiazide (one-way ANOVA, p > 0.05).  
NP = not performed; HCT = hydrochlorothiazide 
 
Performing a matrix erosion study, it was obvious that drug solubility did not influence the 
drug release mechanism. At 5 % drug loading, the erosion profiles indicated erosion-
controlled, zero-order drug release for theophylline monohydrate as well as for propranolol 
HCl and hydrochlorothiazide. Independent of the drug loading, a good correlation between 
drug release and matrix erosion was found for each drug. Figure 4.9 shows the drug release 
and erosion profiles of a matrix-in-cylinder system containing 5 % or 30 % propranolol HCl. 
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Figure 4.9: Mean drug release profiles (± S.D.) (full lines) and mean erosion profiles (± S.D.) 
(dotted lines) of matrix-in-cylinders containing 5 % propranolol (▲) or 30 % 
propranolol (●) suspended in a HPMC K100:Gelucire® 44/14 (1:2.17) mixture.  
 
4.4.6 Stability study 
¾ Introduction 
A number of studies have indicated that Gelucire products may exhibit ageing effects, 
whereby a range of physical properties (e.g. melting point) may change during storage 
(Charro et al., 1993; Sutananta, 1994; San Vicente et al., 2000). The mechanism responsible 
for ageing of glyceride-products has been attributed to either the conversion of triglycerides to 
more stable polymorphic forms (Liversidge et al., 1981) or the conversion from an amorphous 
to a crystalline state (Coben and Lordi, 1980; Laine et al., 1988). Since polymorphic 
transformations are able to alter drug release profiles, this potential biopharmaceutical 
instability must be addressed in the early stages of formulation development.  
Therefore, the stability of a matrix-in-cylinder system (length = 12 mm, diameter = 5 mm), 
containing 5 % theophylline monohydrate, 30 % HPMC K100 and 65 % Gelucire® 44/14, was 
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evaluated by performing a dissolution test, Karl Fischer titration, differential scanning 
calorimetry and X-ray diffraction after 0, 3, 6, 9 and 12 months of storage at room 
temperature (RT)/60 ± 5 % relative humidity (RH) and at 30 ± 2 °C/75 ± 5 % RH. Although 
the USP recommends storage at 40 ± 2 °C and 75 ± 5 % RH, a storage temperature of only 
30°C was used because of the low melting point of Gelucire® 44/14 (at 40°C the HPMC-
Gelucire® 44/14 cores melted and leached out of the EC-pipes).   
 
¾ Methods 
The matrix-in-cylinder systems were manufactured according to the method previously 
described in this chapter. 
Dissolution tests were performed under the conditions described in paragraph 4.3.4 (n = 3). 
The AUC0-24h-values of the dissolution profiles were statistically evaluated with a one-way 
ANOVA at a significance level of 0.05. The normality of the data was checked by means of a 
Kolmogorov-Smirnov test and the homogeneity of variances by means of the Levene test. 
SPSS 11.0 for Windows was used. 
The water content of the core of the matrix-in-cylinder was determined using a Mettler DL35 
Karl Fisher titrator (Mettler-Toledo, Beersel, Belgium) in combination with a Mettler DO337 
oven operated at 105°C (n = 2). The samples were placed in a Pyrex vessel inside the oven. 
During 10 min the moisture evaporated from the sample was carried to the titration vessel by 
a nitrogen stream (300 ml/min), after which the titration was started. Hydranal® Composite 5 
(Riedel-de Haën, Seelze, Germany) with a theoretical titer of 2 mg H2O/ml was used as titrant 
solution.  
For differential scanning calorimetry (T.A. Instruments, TA 2920) the samples (3-6 mg in a 
hermetic Al-pan) were heated from 0°C to 100°C at a rate of 3°C/min in the presence of a 
refrigerated cooling system (R.C.S.).  
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The X-ray patterns were determined using a D5000 Cu Kα Diffractor (λ = 1.54 Å) (Siemens, 
Germany) with a voltage of 40 kV and a current of 40 mA in the angular range of 4°<2Ө<90° 
in a step scan mode (step width = 0.02°, counting time = 0.8 s/step).  
 
¾ Results 
Figure 4.10 shows that the matrix-in-cylinder system was stable for at least 12 months during 
storage at RT/60 % RH and at 30°C/75 % RH. Statistical comparison of the AUC0-24h-values 
indicated no significant difference between the dissolution curves obtained before and after 
storage at the different conditions.  
The moisture content of the core material increased as a function of time and relative 
humidity during storage. The water content was 0.1 %, 5.6 % and 10.2 % immediately after 
production, after 12 months storage at RT/60 % RH and after 12 months storage at 30°C/75 % 
RH, respectively. This increased moisture uptake is probably due to the hydrophilic HPMC 
and the amphiphilic Gelucire 44/14 present in the core formulation, but had no effect on the 
behaviour of the matrix (Svensson et al., 2004).  
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Figure 4.10 : Mean drug release profiles (± S.D.) of matrix-in-cylinders, containing 5 % 
theophylline monohydrate, 30 % HPMC K100 and 65 % Gelucire® 44/14, stored 
during 0 (—), 3 (●), 6 (▲), 9 (■) and 12 (x) months at (a) room temperature/60 ± 5 % 
RH and at (b) 30 ± 2 °C/75 ± 5 % RH.  
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Under both storage conditions, the X-ray diffraction patterns of the matrix core of the dosage 
form obtained after 3, 6, 9 and 12 months were similar to these at time 0, since the 
predominant peaks from Gelucire 44/14 appeared at the same position (around 19° and 23°) 
(Figure 4.11). This indicated that Gelucire 44/14 did not undergo a change of its crystalline 
structure on ageing. The DSC-experiments confirmed these results as the melting peak 
temperature (at approximately 44°C) from the samples after 3, 6, 9 and 12 months storage 
was identical to that of a freshly prepared sample (Figure 4.12). This is in accordance with the 
findings of Roussin and Lafôret (1997), who stated that Gelucire 44/14 exists in only one 
solid form that exhibits a single transition with increasing temperature (related to its melt). 
After storage under different conditions, no change of this form was found, suggesting a good 
physical stability (Roussin and Lafôret, 1997). 
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Figure 4.11: X-ray diffractogram of core material immediately after preparation (red line), after 12 
months storage at RT/60 % RH (black line) and after 12 months storage at 30°C/75 % 
RH (blue line). 
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Figure 4.12: DSC thermograms of core material (a) immediately after preparation, (b) after 12 
months storage at RT/60 % RH and (c) after 12 months storage at 30°C/75 % RH. 
 
4.4.7 Physicochemical characterisation of the HPMC-Gelucire® 44/14 
mixture 
 
¾ Introduction 
The HPMC-Gelucire 44/14 mixture was subjected to solid state Nuclear Magnetic 
Resonance (NMR) analyses in order to determine if there are intensive interactions between 
both excipients. Solid state NMR spectroscopy and relaxometry is a powerful non-invasive 
and non-destructive technique to investigate the segmental chain dynamics and molecular 
miscibility of molecules on the nanometer level (Komoroski, 1986; Fedotov and Schneider, 
1989; Schmidt-Rohr and Speiss, 1996; Adriaensens et al., 2002). Below the glass transition 
temperatures (Tg), the proton relaxation decay times T1H and T1ρH provide information about 
the level of heterogeneity (phase morphology) of a mixture on the nm scale due to the process 
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of proton spin diffusion. Under the condition of spin diffusion, both proton decay times can be 
directly related to the dimensions of the molecular domains. The proton T1ρH decay time 
(spin-lattice relaxation time in the rotating frame), in the order of milliseconds, will be 
averaged out over a short distance (in the order of 1-2 nanometer), making it a local property. 
Since the T1ρH decay time is sensitive to molecular frequency motions of several tens of 
kilohertz, it reflects the motion of short segments in the polymer chain. The T1H decay time 
(spin-lattice relaxation time) on the other hand, in the order of seconds, is sensitive to the 
spectral density of Larmor frequency motions (here 200 MHz) and is averaged out over a 
larger distance (in the order of tens of nanometers), making it a more large-scale molecular 
property. The maximum pathlength L, over which proton-proton spin-diffusion can occur, is 
approximately given by  
L ≈ (6DTiH)1/2       (1) 
where D is the spin diffusion coefficient (≈10-16m2/s for rigid solids) and TiH the decay time 
T1H or T1ρH (McBrierty and Douglas, 1981). Measuring the proton decay times via the 
chemical shift selective carbon signals by means of the 13C-CP/MAS (Cross 
Polarisation/Magic Angle Spinning) technique, allows to obtain information about the degree 
of phase separation in mixtures.  
 
¾ Methods 
Solid state NMR analyses were performed by Dr. Peter Adriaensens and Prof. Dr. Jan Gelan 
at the Institute for Materials Research (IMO), Division Chemistry, Limburgs Universitair 
Centrum (LUC) (Diepenbeek, Belgium). 
Solid-state 13C-CP/MAS NMR spectra were recorded at room temperature on an Inova 200 
Varian spectrometer operating at a static magnetic field of 4.7 T. Magic angle spinning was 
performed at 6.5 kHz, making use of ceramic Si3N4 rotors.  
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¾ Results 
Figure 4.13 presents a 13C-CP/MAS spectrum of HPMC, Gelucire® 44/14 and a mixture of 
HPMC and Gelucire® 44/14. The signals of HPMC appear around 102, 82-74, 60 and 18 ppm, 
while the carbon resonances of Gelucire® 44/14 appear around 71 and 29 ppm. Looking at the 
carbon spectrum of the HPMC-Gelucire® mixture, five carbon resonances around 102, 82-74, 
60, 18 ppm (HPMC; the small Gelucire® signal at 71 ppm lies under the huge 82-74 signal of 
HPMC) and 29 ppm (Gelucire®) can be distinguished.  
Table 4.5 shows the T1H decay times of HPMC, Gelucire® 44/14 and a mixture of HPMC and 
Gelucire® 44/14. In the HPMC-Gelucire® mixture, the T1H decay time obtained via the HPMC 
resonances is clearly different from this observed via the Gelucire® resonances. This means 
that both components in the mixture have to be phase separated into molecular domains of 
which the length scale exceeds several tens of nm. From equation 1, it can be concluded that 
the molecular domains of HPMC should exceed 21 nm and those of Gelucire® 25 nm. 
-20020406080100120140
ppm
 
Figure 4.13: Carbon spectra of HPMC (red line), Gelucire® 44/14 (black line) and HPMC-
Gelucire® 44/14 mixture (blue line). 
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Table 4.5: T1H decay times of HPMC, Gelucire® 44/14 and HPMC-Gelucire® 44/14 mixture. 
HPMC      
Carbon signal (ppm) 102 82-74 60 18  
T1H (s) 0.92 0.90 0.91 0.91  
Gelucire 44/14      
Carbon signal 71 29    
T1H (s) 1.12 1.15    
HPMC-Gelucire® 44/14 mixture      
Carbon signal 102 82-74 60 18 29 
T1H (s) 0.76 0.78 0.78 0.77 1.05 
 
 
¾ Conclusion 
From these solid state NMR analyses, it can be concluded that HPMC is clearly phase 
separated from Gelucire® 44/14 (T1H of the HPMC signals is clearly different from this of 
Gelucire® in the mixture).  
 
4.5 CONCLUSION 
Sustained zero-order erosion-controlled drug release was obtained when formulating a matrix-
in-cylinder system consisting of a barrier in the form of a hot-melt extruded ethylcellulose 
pipe surrounding a HPMC-Gelucire® 44/14 core. A flexible drug delivery system was 
developed whereby the drug release characteristics could be modified by changing the length 
of the system. Furthermore, the dosage forms appeared to be stable for at least 12 months.  
 
 
 
 
Development and evaluation of a matrix-in-cylinder system with a HPMC-Gelucire® core 74
4.6 REFERENCES 
Abrahamsson, B., Alpsten, M.,  Bake, B., Larsson, A. and Sjögren, J. (1998). In vitro and in 
vivo erosion of two different hydrophilic gel matrix tablets. Eur. J. Pharm. Biopharm., 46, 
69-75. 
 
Adriaensens, P., Storme, L., Carleer, R., Gelan, J. and Du Prez, F.E. (2002). Comparative 
morphological study of poly(dioxolane)/poly(methyl methacrylate) segmented networks 
and blends by 13C solid state NMR and thermal analysis. Macromolecules, 35, 3965-
3970.  
 
Anderson, N.H., Bauer, M., Boussac, N., Khan-Malek, R., Munden, P. and Sardaro, M. 
(1998). An evaluation of fit factors and dissolution efficiency for the comparison of in 
vitro dissolution profiles. J. Pharm. Biomed. Anal., 17, 811-822. 
  
Barthelemy, P. and Benameur, H. (2001). Composition with sustained release of active 
principle, capable of forming a microemulsion. U.S. Patent 6 309 665 B2, Gattefossé. 
 
Charro, M.B.D., Rial, I.L. and Jato, J.L.V. (1993). Aging of sustained-release formulations of 
amoxicillin and Gelucire® 64/02. Drug Dev. Ind. Pharm., 19, 473-482. 
 
Coben, L.J. and Lordi, N.G. (1980). Physical stability of semisynthetic suppository bases. J. 
Pharm. Sci., 69, 655-690. 
 
Fedotov, V.D. and Schneider, H. (1989). Molecular motion in bulk polymers. In: Structure 
and Dynamics of Bulk Polymers by NMR-methods (Diehl, P., Fluck, E., Günther, H., 
Kosfeld, R. and Seelig, J., ed.), Springer-Verlag, Heidelberg, pp. 107-141.  
 
Gao, P., Skoug, J.W., Nixon, P.R., Ju, T.R., Stemm, N.L. and Sung, K. (1996). Swelling of 
hydroxypropyl methylcellulose matrix tablets. Mechanistic study of the influence of 
formulation variables on matrix performance and drug release. J. Pharm. Sci., 85, 732-
740. 
 
Kawakami, K., Miyoshi, K. and Ida, Y. (2004). Solubilisation behaviour of poorly soluble 
drugs with combined use of Gelucire 44/14 and cosolvent. J. Pharm. Sci., 93, 1471-1479. 
 
Komoroski, R.A. (ed.) (1986). High-Resolution Solid-State NMR of Protons in Polymers. In: 
High Resolution NMR spectroscopy of Synthetic Polymers in  
Bulk, VCH Publishers, New York, pp. 307-334.  
Development and evaluation of a matrix-in-cylinder system with a HPMC-Gelucire® core 75
Laine, E., Auramo, A. and Kahela, A. (1988). On the structural behaviour of triglycerides 
with time. Int. J. Pharm., 43, 241-247. 
 
Lippold, B.C. and Ohm, A. (1986). Correlation between wettability and dissolution rate of 
pharmaceutical powders. Int. J. Pharm., 28, 67-74. 
 
Liversidge, G.G., Grant, D.J.W. and Padfield, J.M. (1981). Influence of physico-chemical 
interactions on the properties of suppositories: 1. Interactions between the constituents of 
fatty suppository bases. Int. J. Pharm., 7, 211-233.  
 
McBrierty, V.J. and Douglas, D.C. (1981). Recent advances in the NMR of solid polymers. J. 
Pol. Sci.: Macromolecular Reviews, 16, 295-366.   
 
Roussin, P. and Lafôret, J.P. (1997). Gelucire® 44/14: a high-performance system to enhance 
bioavailability of poorly water soluble drugs. Journées Galéniques Gattefossé, 90, 51-58. 
 
Rowe, R.C., Shesky, P.J. and Weller, P.J. (ed.) (2003). Handbook of Pharmaceutical 
Excipients (Fourth Edition). American Pharmaceutical Association and Pharmaceutical 
Press, Washington D.C. 
 
San Vicente, A., Hernandez, R.M., Gascon, A.R., Calvo, M.B. and Pedraz J.L (2000). Effect 
of aging on the release of salbutamol sulfate from lipid matrices. Int. J. Pharm., 208, 13-
21. 
 
Schmidt-Rohr, K. and Speiss, H.W. (ed.) (1996). Domain sizes and internuclear distances 
from spin diffusion and dipolar couplings. In: Multidimensional solid-state NMR and 
Polymers, Academic Press, San Diego, pp. 402-438.  
 
Sung, K.C., Nixon, P.R., Skoug, J.W., Ju, T.R., Gao, P., Topp, E.M. and Patel, M.V. (1996). 
Effect of formulation variables on drug and polymer release from HPMC-based matrix 
tablets. Int. J. Pharm., 142, 53-60. 
 
Sutananta, W., Craig, D.Q.M. and Newton, J.M. (1994). The effects of aging on the thermal-
behaviour and mechanical-properties of pharmaceutical glycerides. Int. J. Pharm., 111, 
51-62. 
 
Svensson, A., Neves, C. and Cabane, B. (2004). Hydration of an amphiphilic excipient, 
Gelucire 44/14. Int. J. Pharm., 281, 107-118. 
 
Development and evaluation of a matrix-in-cylinder system with a HPMC-Gelucire® core 76
U.S. Pharmacopeia XXVII & National Formulary 22 (2004). The United States 
Pharmacopeial Convention, Rockville, MD, USA. 
In vitro and in vivo evaluation of the matrix-in-cylinder system 77
5 IN VITRO AND IN VIVO EVALUATION 
OF THE MATRIX-IN-CYLINDER 
SYSTEM 
Published in part in Journal of Controlled Release 96 (2004), 261-271. 
5.1 INTRODUCTION 
Chapter 4 demonstrated that a matrix-in-cylinder system consisting of a hot-melt extruded 
non-erodible ethylcellulose pipe surrounding a drug containing HPMC-Gelucire® matrix core 
was able to sustain in vitro drug release in a zero-order way. In an aqueous medium, the 
HPMC-Gelucire® core forms a gel plug, which releases the drug - through the open ends of 
the ethylcellulose pipe - by means of erosion. Erosion of the gel core is thus the most critical 
parameter in order to obtain the desired drug release rate and consequently the desired plasma 
concentration profiles in vivo. In vivo, the varying conditions along the gastrointestinal (GI)-
tract can potentially affect the erosion of the gel core of the matrix-in-cylinder system and 
thereby alter the drug release rate. Among the GI-factors, many studies have been conducted 
on pH conditions and GI-transit rates of dosage forms, but little is known about the physical 
factors in the GI-tract such as hydrodynamic flow and mechanical destructive forces due to 
digestive actions. Katori et al. (1995) and Sako et al. (1996) determined the hydrodynamic 
flow in a dog’s GI-tract to be relatively low (equivalent to an in vitro dissolution test run at a 
paddle speed of 25 to 50 rpm), although greater than in humans. Knowledge regarding the 
mechanical destructive forces exerted by the different motility patterns in the GI-tract is also 
limited (Aoki et al., 1993; Shameem et al., 1995; Katori et al., 1996). However, these forces 
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are important for sustained release products, because their unexpected destruction or erosion 
can cause dose-dumping. Since current pharmacopoeial in vitro dissolution tests do not take 
into account the mechanical destruction or friction forces, modified dissolution tests that 
better predict the in vivo performance of drug products are required. Therefore, Aoki et al. 
(1992, 1993) proposed a paddle-beads method to introduce a mechanical impact force. 
In this part of the research project, the influence of hydrodynamics and mechanical forces and 
the effect of different ‘physiologically relevant’ dissolution media on the in vitro drug release 
of the matrix-in-cylinder system were evaluated. Next, an in vivo study in dogs was 
performed to reveal the bioavailability of the matrix-in-cylinder system and its in vivo 
behaviour was compared to a commercially available sustained release system. 
Theophylline monohydrate was not used as a model drug in this study because it is a highly 
dosed drug. High amounts of drug can not be incorporated into one matrix-in-cylinder system 
so it was decided to use propranolol hydrochloride, a low dosed drug applicable in the domain 
of sustained release (a sustained release formulation contains 80 mg or 160 mg propranolol).  
5.2 MATERIALS 
Hydroxypropyl methylcellulose (HPMC) (Methocel® Premium K100) (methoxyl content: 19-
24 %, hydroxypropyl content: 7-12 %, viscosity: 100 mPa.s (2% (w/w) aqueous solution at 
20°C)) was received from Colorcon (Dartford, UK). Ethylcellulose (EC) (Ethocel® FP10) 
(ethoxyl content: 48-49.5 % (w/w); viscosity: 9-11 mPa.s (5 % solution in toluene-EtOH, 
80:20, 25°C)) was kindly donated by the Dow Chemical Company (Horgen, Switzerland). 
Gelucire® 44/14 (melting point: 44°C, HLB = 14) was a gift from Gattefossé (Saint-Priest, 
France). Propranolol hydrochloride was supplied by Roig Farma (Terrassa, Spain). Dibutyl 
sebacate, pancreatin, bile salt and sodium taurocholate (min. 97 %) were purchased from 
Sigma (St-Louis, USA). Egg-phosphatidylcholine (Lipoid E PC) was a gift from Lipoid 
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(Ludwigshafen, Germany). Potassium dihydrogen phosphate, potassium chloride and sodium 
hydroxide were obtained from Merck (Darmstadt, Germany).  
Inderal retard mitis was obtained from Astra Zeneca (Brussels, Belgium). Each capsule 
contained 80 mg propranolol hydrochloride and consisted of coated pellets. 
5.2.1 Propranolol 
Propranolol is a non-selective β–blocker for the treatment of hypertension, cardiac 
arrhythmias, angina pectoris and prophylaxis after recovery from myocardial infarction. It is 
commercially available as a hydrochloride-salt (Inderal, Astra Zeneca), used for immediate 
release as well as sustained release dosage forms. Propranolol hydrochloride (pKa 9.5 (25°C)) 
has a nearly pH-independent solubility (aqueous solubility (25°C): 50 g/l) over a 
physiological pH-range (1 – 7). The drug is almost completely (90-100 %) absorbed from the 
GI-tract, but has a systemic bioavailability of only 25-30 % due to the extensive hepatic first 
pass elimination (Silber et al., 1983). The metabolism of propranolol in dog is similar to that 
in man. Propranolol is metabolised in the liver via three major metabolic pathways: aromatic 
ring hydroxylation at the 4-position, side-chain N-desisopropylation and direct 
glucuronidation. The metabolite 4-hydroxypropranolol is also pharmacologically active. No 
gut metabolism has been reported for dogs (Lo et al., 1982; Mills et al., 2004). Propranolol 
exhibits non-linear kinetics, is subjected to a high protein binding (90-94 %) and has an 
elimination half-life of 3 - 6 h in man (Fitzgerald, 1980). 
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Figure 5.1: Structure of propranolol. 
5.3 METHODS 
5.3.1 Production of the matrix-in-cylinder system 
The matrix-in-cylinder system consisted of 27 % propranolol hydrochloride (equivalent to 80 
mg propranolol HCl), 23 % Methocel® K100 and 50 % Gelucire 44/14, surrounded by an 
ethylcellulose pipe having a length of 14 mm and an internal diameter of 5 mm. It was 
prepared according to the method described in Chapter 4. 
The core formulation of the matrix-in-cylinder system was also administered orally to dogs in 
a hard gelatine capsule (core-in-capsule formulation) and rectally as a suppository. To prepare 
these dosage forms an amount (equivalent to 80 mg propranolol HCl) of the drug-Methocel-
Gelucire mixture was poured into a hard gelatine capsule and an aluminium suppository 
mould, respectively.  
5.3.2 In vitro evaluation 
The drug release from the matrix-in-cylinder system and from the core-in-capsule formulation 
was evaluated by in vitro dissolution testing. All dissolution tests (n = 3) were performed in a 
VK 7000 dissolution bath with a VK 8010 autosampler (VanKel Industries, NJ, USA). The 
system operated at 37±0.5°C, using the paddle method (USP 27). Sink conditions were 
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maintained. Samples of 5 ml were taken at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h for the 
matrix-in-cylinder system and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5 h for the core-in-capsule 
formulation. The drug concentration in the samples was measured at 288 nm with a Perkin 
Elmer Lambda 12 UV-Vis double beam spectrophotometer (Zaventem, Belgium). To evaluate 
the influence of hydrodynamic stress, different paddle speeds (10, 25, 50 and 150 rpm) were 
used during dissolution testing, using 900 ml demineralised water as a dissolution medium. 
To determine the effect of mechanical stress, the paddle-beads method of Aoki et al. (1992, 
1993) was used. This method of dissolution testing adds polystyrene beads (diameter 6.35 
mm, specific density 1.05 g/cm³) to the dissolution medium, causing a mechanical impact 
force on the dosage form during dissolution. The number of beads used was 500, 1000, 2000 
and 3000 for 500 ml of demineralised water as dissolution medium. The paddles rotated at 25 
or 50 rpm. To evaluate the influence of different dissolution media, the paddle speed was 150 
rpm using 900 ml Simulated Intestinal Fluid USP 27 (SIF), Fasted State Simulated Intestinal 
Fluid (FaSSIF), Fed State Simulated Intestinal Fluid (FeSSIF) (Table 5.1) (Dressman et al., 
1998; Galia et al., 1998) and a 4 % aqueous bile salt solution (consisting of a mixture of 
sodium cholate and sodium deoxycholate) as dissolution media. As it was not possible to 
determine the propranolol concentration spectrophotometrically in these dissolution media, 
the analysis was performed using a validated HPLC – UV method. The same 
chromatographic system as described in paragraph 5.3.4 was used, except the detector being a 
UV-detector (L 4000, UV detector, Hitachi, Tokyo, Japan) set at 288 nm. After filtration (0.2 
µm filters), the samples were injected directly onto the column.  
The AUC0-24h-values (for the matrix-in-cylinder system) and the AUC0-1h-values (for the core-
in-capsule formulation) of the dissolution profiles were statistically evaluated with a one-way 
ANOVA at a significance level of 0.05. The normality of the data was checked by means of a 
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Kolmogorov-Smirnov test and the homogeneity of variances by means of the Levene test 
(significance level = 0.05). All analyses were performed with SPSS 11.0 for Windows. 
 
Table 5.1: Composition of Fasted State and Fed State Simulated Intestinal Fluid. 
Fasted State Simulated Intestinal Fluid 
(FaSSIF) 
Fed State Simulated Intestinal Fluid  
(FeSSIF) 
pH 
Osmolality 
Sodium taurocholate 
Lecithin 
KH2PO4 
KCl 
NaOH 
Desionized water 
 
 
 
 
 
 
qs 
qs 
 
6.5 
270±10 mOsm 
3 mM 
0.75 mM 
3.9 g 
7.7 g 
pH 6.5 
1 liter 
pH 
Osmolality 
Sodium taurocholate 
Lecithin 
Acetic acid 
KCl 
NaOH 
Desionized water 
 
 
 
 
 
 
qs 
qs 
 
5.0 
635±10 mOsm 
15 mM 
3.75 mM 
8.65 g 
15.2 g 
pH 5.0 
1 liter 
 
5.3.3 In vivo study 
All experimental procedures were performed in accordance with the guidelines and approval 
of the local Institutional Animal Experimentation Ethics Committee. 
Male mixed-breed dogs (weight 35 - 41 kg) were used in this study. The following 
formulations were administered: 
F-1: matrix-in-cylinder system, consisting of 27 % propranolol HCl (equivalent with 80 
mg), 23 % Methocel K100 and 50 % Gelucire 44/14 surrounded by an 
ethylcellulose pipe (length = 14 mm, internal diameter = 5 mm) (n = 6). 
F-2: hard gelatine capsule filled with an amount (equivalent with 80 mg propranolol HCl) 
of a mixture consisting of 27 % propranolol HCl, 23 % Methocel K100 and 50 % 
Gelucire 44/14 (n = 3). 
F-3: Inderal retard mitis, a commercially available multiparticulate sustained release 
formulation containing 80 mg propranolol hydrochloride (n = 3). 
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F-4: rectal formulation consisting of 27 % propranolol HCl, 23 % Methocel K100 and 50 
% Gelucire 44/14 (equivalent with 80 mg propranolol HCl) (n = 3). 
 
The formulations were administered in a randomized cross-over sequence with a washout 
period of at least 7 days. On the experimental days the dogs were fasted since the previous 
evening at 8 p.m., water was available ad libitum. Each propranolol formulation (F-1, F-2, F-
3) was orally administered together with 20 ml water. The rectal formulation (F-4) was 
inserted in the rectum 4 cm from the anus. Blood samples were obtained at 0.5, 1, 2, 3, 4, 5, 6, 
8, 12 and 24 h after intake of F-1 and F-3, at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 h after intake 
of F-2 and at 0.5, 1, 1.5, 2.5, 3, 4, 5, 6 and 8 h after administration of F-4. The blood samples 
were collected in dry heparinized tubes and centrifuged for 5 min at 1500g within 1 h after 
collection. The plasma was stored at –20°C until assay of propranolol. No food was 
administered to the dogs during the blood sampling period. Water could be taken freely.  
5.3.4 Propranolol assay  
The propranolol plasma concentrations were determined by a validated HPLC-fluorescence 
method developed by Voorspoels (1997). All chemicals were of analytical or HPLC grade. 
25 µl of an internal standard solution (1 µg/ml of 4-methylpropranolol in methanol) was 
evaporated to dryness under a nitrogen stream, the residue was redissolved in 1 ml plasma. 
The drug was extracted using a solid phase extraction method (SPE). The SPE columns were 
conditioned consecutively with 1 ml methanol, 1 ml water and 1 ml PBS. Next, the plasma 
samples were transferred quantitatively on the SPE columns. The rinsing step was performed 
with 1 ml methanol/water (60/40 v/v) and the elution with 1 ml methanol. The obtained 
eluates were evaporated to dryness under a nitrogen stream, the residue was redissolved in 
200 µl eluens and 100 µl was injected. The plasma concentrations were determined via a 
calibration curve. The standards for the calibration curve were treated as the samples: 25 µl of 
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internal standard solution and 25 µl of a standard solution with known concentration of 
propranolol in methanol were evaporated to dryness under a nitrogen stream, the residue was 
redissolved in 1 ml blank plasma.  
The HPLC equipment consisted of a solvent pump (L-6000 pump, Hitachi, Tokyo, Japan) set 
at a constant flow rate of 1 ml/min, a variable wavelength detector (L-7480 fluorescence 
detector, Hitachi, Tokyo, Japan) set at 250 nm (for propranolol and for 4-methylpropranolol) 
as excitation wavelength and 360 nm (for propranolol) and 365 nm (for 4-methylpropranolol) 
as emission wavelength, a reversed phase column and precolumn (LiChro-CART® 125-4 and 
4-4, LiChrospher® 60 RP-select B 5 µm; Merck, Darmstadt, Germany) and an automatic 
integration system (L-7000, Hitachi, Tokyo, Japan). The SPE-equipment consisted of OASIS 
HLB (1 cc 30 mg) cartridges (Waters, Brussels, Belgium) and a 16-port vacuum manifold 
(Alltech Europe, Laarne, Belgium). The eluens had the following composition: 700 ml of a 
buffer solution (consisting of 5mM KH2PO4 and 1 mM triethylamine) adjusted to pH 5 with 1 
N H3PO4, 200 ml acetonitrile, 50 ml methanol and 50 ml tetrahydrofuran. 
5.3.5 Validation of the HPLC method  
The HPLC analysis method was validated based on the guidelines stated by the International 
Conference on Harmonisation (ICH) for validation of analytical procedures (1994). The 
following characteristics were considered: specificity, linearity, accuracy, precision, recovery, 
detection and quantification limit. 
 
Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of interfering 
components.  
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Voorspoels (1997) assessed the specificity of the HPLC method by comparing the 
chromatogram of blank plasma with the chromatogram obtained after extraction of blank 
plasma spiked with propranolol, internal standard 4-methylpropranolol and possible 
metabolites (4-OH-propranolol, N-desisopropylpropranolol, propranololglycol and 1-
naphthoxylactic acid). Figure 5.2 shows the chromatograms after the extraction of (a) blank 
plasma, (b) plasma spiked with propranolol, 4-methylpropranolol and the possible metabolites 
and (c) plasma of a dog after intake of propranolol. It is clear that the method is selective to 
determine propranolol in plasma, since no interfering peaks were observed. 
 
Linearity 
The linearity of an analytical procedure is its ability – within a given range – to obtain test 
results, which are directly proportional to the concentration of analyte in the sample.  
During the validation of the HPLC method and the analysis of the samples, several calibration 
curves were analysed. The linearity of the calibration curves was evaluated by the 
determination coefficient R². The mean determination coefficient for the calibration curves (n 
= 7) was 0.9987, indicating that the relationship between response (y) and concentration (x) 
was linear. The equation of the mean calibration curve was:  
y = 0.052x + 0.0159 
with  x = concentration of propranolol HCl (ng/ml) and y = fluorescence 
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Figure 5.2: Specificity of the HPLC method. Chromatogram after extraction of (a) blank plasma, 
  (b) plasma spiked with propranolol, 4-methylpropranolol, 4-OH-propranolol, N- 
  desisopropylpropranolol, propranololglycol and 1-naphthoxylactic acid (not  
  detectable) (Voorspoels, 1997) and (c) plasma of a dog after intake of   
  propranolol (retention time propranolol: 9.05 min, retention time 4-methylpropranolol: 
  15.11 min, calculated concentration propranolol: 4.16 ng/ml).  
(c) 
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Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between the 
true value and the determined value and is expressed as the percent agreement between the 
mean determined value and the true concentration. 
The accuracy was investigated at three concentration levels on plasma spiked with known 
amounts of the analyte, then treating the resulting solution as indicated by the method. Each 
concentration was determined six times. The mean accuracies (± S.D.) are listed in Table 5.2. 
 
Table 5.2: Mean accuracies (± S.D.) of the HPLC method (n = 6). 
Concentration Accuracy (%) 
(ng/ml) Within-day Between-day 
5  110.5 ± 10.1 109.8 ± 9.1 
25 106.1 ± 2.3 97.4 ± 2.2 
200 105.3 ± 3.0 99.7 ± 2.9 
 
All mean values were within ± 15 % of the actual concentration (Acceptance criteria: within 
15 % of the actual value, Shah et al., 1992).  
 
Precision 
The precision expresses the closeness of agreement between repeated determinations. It may 
be considered at three levels: repeatability (intra-assay precision), intermediate precision 
(within laboratory precision) and reproducibility (between laboratory precision). Precision is 
expressed as the coefficient of variation (%) of a series of measurements of the calibration 
standards. 
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Since the measurements were performed in the same laboratory, by the same person using the 
same equipment only the repeatability (within-day and between-day) of the measurements 
was evaluated (Table 5.3). The acceptance criteria are coefficients of variation less than 15 %.  
 
Table 5.3: Precision (expressed as coefficient of variation) of the HPLC method (n = 6). 
Concentration Precision (% CV) 
(ng/ml) Within-day Between-day 
5 6.2 9.4 
15 - 4.9 
25 8.2 4.9 
50 - 3.8 
100 - 1.2 
200 1.1 3.5 
 
 
Recovery 
The recovery was determined for the calibration standards (at three concentration levels) and 
for the internal standard and can be expressed as the closeness of agreement (in %) between 
the surface areas of an extracted sample versus a non-extracted sample. The mean recoveries 
(± S.D.) for the calibration standards and for the internal standard are shown in Table 5.4. 
 
Table 5.4: Mean recoveries (n = 6) (± S.D.) for the calibration standards and for the internal 
standard. 
 Concentration 
(ng/ml) 
Recovery 
(%) 
propranolol 5 66.7 ± 5.1 
 25 71.5 ± 5.0 
 200 87.1 ± 9.1 
   
4-methylpropranolol 25 51.6 ± 3.1 
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Detection and quantification limit 
The detection limit of an analytical procedure is the lowest amount of analyte in a sample 
which can be detected but not necessarily quantitated as an exact value. The quantification 
limit is the lowest amount of analyte in a sample which can be adequately determined with 
suitable precision and accuracy. Both values were estimated from the mean calibration curve 
(International Conference on Harmonisation, 1994): 
 
DL = 3.3 x σ 
                     S 
 
with DL = detection limit 
 σ = standard deviation of the Y-intercept of the mean calibration curve 
 S = slope of the mean calibration curve 
 
QL = 10 x σ 
                     S 
 
with QL = quantification limit 
 σ = standard deviation of the Y-intercept of the mean calibration curve 
 S = slope of the mean calibration curve 
 
The detection and quantification limits of propranolol in dog plasma were determined at 0.3 
and 0.9 ng/ml, respectively. 
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5.3.6 Data analysis 
The peak plasma concentration (Cmax) and the time to reach Cmax (tmax ) were determined from 
the individual plasma concentration profiles. The extent of absorption (AUC) was calculated 
using the MW-PHARM program version 3.0 (Mediware 1987-1991).  
The pharmacokinetic parameters of the formulations (Cmax and AUC) were statistically 
evaluated by a two-way ANOVA. The normality of the data was checked by means of the 
Kolmogorov-Smirnov test and the homogeneity of variances using the Levene’s test. A 
significance level of 0.05 was used. 
5.3.7 Determination of gastrointestinal transit time 
For the determination of the gastrointestinal (GI) transit time of the matrix-in-cylinder system, 
a hollow ethylcellulose pipe (l = 14 mm, d = 5 mm) was filled with barium sulphate and both 
open ends of the pipe were closed with silicone. This barium sulphate containing 
ethylcellulose pipe was administered to a fasted dog (n = 2). The GI-transit was determined 
by periodic roentgenography of the unanaesthetised dog. No food was administered to the 
dogs during the experiment.  
This experiment was performed by Dr. Ingrid Gielen and Prof. Dr. Henri Van Bree at the 
Department of Medical Imaging of Domestic Animals, Faculty of Veterinary Medicine, Ghent 
University (Merelbeke, Belgium). 
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5.4 RESULTS AND DISCUSSION 
5.4.1 In vitro dissolution tests 
¾ Influence of hydrodynamic stress 
The influence of hydrodynamic stress on the drug release rate of the matrix-in-cylinder 
system was evaluated by carrying out dissolution experiments at different paddle speeds (10, 
25, 50, 150 rpm). The dissolution profiles indicated that drug release from the matrix-in-
cylinder system was fairly insensitive to different hydrodynamic conditions (Table 5.5). 
Statistical evaluation revealed only a significant difference between the AUC0-24h values of the 
dissolution profiles at 10 and 150 rpm paddle speed (p < 0.05). This was surprising as erosion 
of the gel core of the matrix-in-cylinder system is the predominant mechanism of drug release 
(Chapter 4). Generally, the influence of the hydrodynamic stress on the release rate is 
negligible for a diffusion-controlled system, but has a major influence on an erosion-based 
system (Lindner and Lippold, 1995). The independence of the matrix-in-cylinder system 
towards agitation stress could be explained by the limited surface area of the matrix core 
directly exposed to the dissolution medium, thereby reducing the susceptibility to 
hydrodynamics. In order to examine the protective effect of the surrounding ethylcellulose 
pipe on the matrix core, dissolution experiments at different paddle speeds were carried out on 
hard gelatine capsules filled with the core formulation (Table 5.5). The results clearly 
indicated that a higher paddle speed induced a significant (p < 0.05) increase of the drug 
release rate from the matrix core, meaning that the gel core as such is affected by the 
hydrodynamic flow of the dissolution medium but as soon as this core material is surrounded 
by an ethylcellulose pipe its dependency of hydrodynamics is for the largest part eliminated. 
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Table 5.5: Influence of hydrodynamic stress on the AUC (mean ± S.D.) of the drug release 
profiles of the matrix-in-cylinder system (F-1) and the core-in-capsule formulation  
(F-2). 
 Paddle rotational speed 
 10 rpm 25 rpm 50 rpm 150 rpm 
Matrix-in-cylinder system 
(AUC0-24h) 
945.9±17.5a 1028.6±71.5a,b 1069.6±57.5a,b 1106.2±15.6b 
Core-in-capsule  
(AUC0-1h) 
10.2±1.0c 19.5±6.6c,d 38.7±2.2d,e 55.3±10.3e 
a,b,c,d,e : groups with the same superscript are not significantly different from each other  
(p > 0.05, Scheffé test) 
 
 
¾ Influence of mechanical stress 
It was assumed that the motion of the beads inside the dissolution vessel reflected the in vivo 
GI-motility (Aoki et al., 1992, 1993). The relationship between the number of beads and the 
release profile of propranolol HCl from the matrix-in-cylinder system at (a) 25 rpm and (b) 50 
rpm is shown in Figure 5.3.  
Using 500 beads at 25 rpm the drug release proceeded slower than without beads, since a 
stagnant bead layer covered the matrix-in-cylinder system at the bottom of the dissolution 
vessel as the paddle was not immersed in the bead layer, thereby slowing down drug release. 
When more than 1000 beads were added the release rate was significantly higher than without 
beads. However, there is no significant difference (p > 0.05) between 1000, 2000 and 3000 
beads (Table 5.6). At a paddle speed of 50 rpm, the dissolution with 500 beads did not result 
in a stagnant bead layer probably due to the higher hydrodynamics caused by the higher 
paddle speed. From Figure 5.3b (50 rpm), it seems that the addition of beads increased the 
drug release rate, however there was no significant difference (p = 0.121) between AUC0-24h 
of the drug release profiles with and without beads (Table 5.6). 
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Figure 5.3: Mean drug release profiles (± S.D.) of the matrix-in-cylinder system using the paddle-
beads method at (a) 25 rpm and (b) 50 rpm: (▲) 0 beads; (●) 500 beads; (♦) 1000 
beads; (□) 2000 beads; (x) 3000 beads. 
 
 
     (b) 
     (a) 
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Table 5.6: Influence of mechanical stress on the AUC0-24h (mean ± S.D.) of the drug release 
profiles of the matrix-in-cylinder system. 
 25 rpm 50 rpm 
0 beads 1035.2±65.3a 1098.1±104.8d 
500 beads 716.9±112.3b 1423.9±196.7d 
1000 beads 1227.8±83.2a,c 1586.5±90.0d 
2000 beads 1392.7±73.7c 1458.1±91.6d 
3000 beads 1421.4±42.0c 1337.3±285.3d 
a,b,c,d : groups with the same superscript are not significantly different from each other  
(p > 0.05, Scheffé test) 
 
 
The faster drug release in the presence of beads is most obvious during the first 4 hours of 
dissolution. On contact with the dissolution medium, the HPMC-Gelucire core swells at each 
end approximately 2 mm outside the ethylcellulose pipe (Figure 5.4). This part of the gel core 
is thus not protected by the ethylcellulose pipe and consequently more sensitive to the 
mechanical forces exerted by the polystyrene beads, resulting in an accelerated erosion and 
drug release rate. After the first 4 hours of dissolution, drug release with and without beads 
appeared to be similar. At 25 and 50 rpm, the slopes of the dissolution profiles between 4 h 
and 20 h with and without beads were not significantly different (p > 0.05). Thus, it can be 
concluded that – after the initial swelling of the HPMC-Gelucire core outside the 
ethylcellulose shell - the ethylcellulose pipe protected the core against the mechanical forces 
exerted by the polystyrene beads.  
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Figure 5.4: Matrix-in-cylinder system after 0.5 h dissolution testing: HPMC-Gelucire core 
swollen outside the ethylcellulose pipe. 
 
In order to confirm the protective effect of the ethylcellulose pipe, the paddle-beads 
dissolution method was applied to hard gelatine capsules filled with the same core 
formulation as the matrix-in-cylinder system. Looking at Figure 5.5, it is clear that an 
increasing amount of polystyrene beads resulted in a gradual increase of drug release rate (due 
to the quicker matrix erosion), confirming the protective effect of the ethylcellulose pipe. 
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Figure 5.5: Mean drug release profiles (± S.D.) of the core-in-capsule formulation using the 
paddle-beads method at (a) 25 rpm and (b) 50 rpm: (▲) 0 beads; (●) 500 beads; (♦) 
1000 beads; (□) 2000 beads; (x) 3000 beads. 
  (a) 
(b) 
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¾ Influence of dissolution medium 
The effect of four physiologically relevant dissolution media (SIF USP 27, FaSSIF, FeSSIF, 
bile salt solution) on drug release from the matrix-in-cylinder was investigated. SIF according 
to USP 27 was selected as it contains lipases, amylases and proteases. Especially the lipases 
are interesting since they might affect Gelucire 44/14 (polyglycolised glycerides) and 
consequently the drug release from the HPMC-Gelucire matrix (Mathis and Heimendinger, 
1989). FaSSIF and FeSSIF are dissolution media representing the fasted and fed state in the 
upper jejunum, containing lecithin and sodium taurocholate to form mixed micelles (Galia et 
al., 1998; Dressman et al., 1998). An aqueous bile salt solution consisting of a mixture of 
sodium cholate and sodium deoxycholate was also used. As a reference, a dissolution in 
demineralised water was performed. The results of the dissolution tests are shown in Figure 
5.6. FaSSIF and FeSSIF did not affect drug release from the matrix-in-cylinder system (p > 
0.05). SIF caused an acceleration of drug release after 12 h dissolution, which may be 
attributed to hydrolysis of the ester components of Gelucire 44/14. The bile salt solution 
resulted in a slightly decreased drug release. 
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Figure 5.6: Influence of dissolution medium on the drug release profile of the matrix-in-cylinder 
system: (□) demineralised water; (♦) Simulated Intestinal Fluid; (x) Fasted State 
Simulated Intestinal Fluid, (▲) Fed State Simulated Intestinal Fluid; (■) Bile salt 
solution. 
 
¾ Conclusion 
From these in vitro dissolution tests, it can be concluded that the ethylcellulose pipe has a 
protective effect on the drug containing HPMC-Gelucire core as it largely protects the core 
against hydrodynamics and mechanical stress. Furthermore, drug release from the matrix-in-
cylinder system is only slightly affected by the composition of the dissolution medium. These 
observations suggest that drug release from the matrix-in-cylinder will probably be 
independent of the GI-tract conditions. 
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5.4.2 In vivo study 
Figure 5.7 shows the in vitro release profiles of propranolol hydrochloride from Inderal® 
retard mitis and the matrix-in-cylinder dosage form. The matrix-in-cylinder system exhibited 
an in vitro sustained release profile closer to zero-order release compared with the 
commercially available reference product. 
0
20
40
60
80
100
0 5 10 15 20 25
time (h)
%
 d
ru
g 
re
le
as
ed
 
Figure 5.7:  Mean drug release profiles (± S.D.) (n = 3) in demineralised water at 150 rpm paddle 
speed: (♦) Inderal® retard mitis and (x) matrix-in-cylinder system. 
 
Figure 5.8 shows the mean plasma concentration-time profiles after oral administration of 80 
mg propranolol as the matrix-in-cylinder system, as the core-in-capsule formulation and as 
Inderal® retard mitis. The pharmacokinetic parameters are shown in Table 5.7. 
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Figure 5.8:  Mean plasma concentration-time profiles (± S.D.) after oral administration of 80 mg 
propranolol hydrochloride to dogs as the matrix-in-cylinder system (F-1) (♦), the core-
in-capsule formulation (F-2) (▲), Inderal® retard mitis (Astra Zeneca) (●) and after 
rectal administration of the core formulation (F-4) (x). 
 
Table 5.7:  Mean pharmacokinetic parameters (± S.D.) after oral administration of 80 mg 
propranolol hydrochloride to dogs as the matrix-in-cylinder system (F-1) (n = 6), the 
core-in-capsule formulation (F-2) (n = 3) and Inderal® retard mitis (F-3) (n = 3): 
 
 
 
Cmax 
(ng/ml) 
AUC0-24h 
(ng.ml-1.h) 
tmax 
(h) 
Matrix-in-cylinder 12.8±0.7a 146.0±44.2c - 
Core-in-capsule 11.8±1.8a 39.2±20.0d 1.2±0.7 
Inderal® 3.3±0.8b 35.8±4.7d - 
a ,b,c,d:  groups with the same superscript are not significantly different from each other  
(p > 0.05, Scheffé test) 
 
 
Administration of the matrix-in-cylinder system resulted in plasma concentrations maintained 
at a level of 8-10 ng/ml during the first 6 h, then dropping slightly to a plateau at 5-6 ng/ml. 
Cmax of the core-in-capsule formulation was not significantly different from Cmax of the 
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matrix-in-cylinder system, however the core-in-capsule formulation was not able to sustain 
drug release confirming that the surrounding ethylcellulose pipe is essential to obtain the in 
vivo sustained release profile. The plasma levels of Inderal® were much lower than with the 
matrix-in-cylinder system. For the matrix-in-cylinder, the mean plasma level after 24 h was 
still 4.9 ng ml-1, while only 1.1 ng ml-1 for Inderal®. The mean AUC0-24h of the matrix-in-
cylinder system and of Inderal® were 146.0 and 35.8 ng ml-1 h-1, respectively; hence the 
relative bioavailability of the matrix-in-cylinder system to Inderal® is about 400 %. The 
bioavailability of the core-in-capsule is similar to that of Inderal®.  
The results of the present in vivo study have demonstrated that the matrix-in-cylinder system 
increased the bioavailability of propranolol in dogs when compared with a commercial 
sustained release formulation (Inderal). The higher Cmax values after the administration of 
the matrix-in-cylinder system (compared with Inderal) could be explained by the immediate 
swelling of the HPMC-Gelucire core (outside the ethylcellulose pipe) upon contact with the 
GI-fluids and the quick erosion of this unprotected part of the gel core, resulting in high initial 
propranolol plasma levels. This “burst release effect” was also noticed during the in vitro 
paddle-beads dissolution tests. Inderal, on the other hand, is a diffusion-controlled pellet 
system characterised by a high tmax and a low Cmax which is typical for sustained release 
formulations. The improved bioavailability of propranolol observed with the matrix-in-
cylinder system is not only due to the higher Cmax, since the high plasma levels were 
maintained over 24 h. The GI-transit time of the matrix-in-cylinder system was determined by 
roentgenography, which revealed that the dosage form moved quickly through the gut 
reaching the rectum already after 1.75-2 h (Figure 5.9). This result is in agreement with the 
GI-transit times of large single unit solid dosage forms in fasted dogs reported in literature 
(Kabanda et al., 1994; Sako et al., 1996; Shimono et al., 2002). The GI-transit time of pellet 
systems such as Inderal® has been reported to be in a range of 2 to 4 h (Akimoto et al., 1993; 
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Farrugia et al., 1998). As both formulations exhibit similar GI-transit times and as propranolol 
is known to be well absorbed in the entire GI-tract, a different extent of absorption can not 
explain the difference in bioavailability.  
Propranolol is a drug with extensive hepatic first pass elimination after oral administration, 
with a reported systemic bioavailability of about 25-30 % (Silber et al., 1983). The improved 
bioavailability of the matrix-in-cylinder could possibly be the result of partially bypassing the 
hepatic clearance through rectal absorption of propranolol. There are 2 rectal routes avoiding 
hepatic first pass elimination: the haemorrhoidal veins and the lymphatics (Rytting and Fix, 
2002). The rectum is drained by at least 3 veins. The superior rectal vein perfusing the upper 
part of the rectum, drains into the portal vein and subsequently into the liver, whereas the 
middle and inferior rectal veins drain the lower part of the rectum and enter into the inferior 
vena cava, bypassing the liver before entering the general circulation. Furthermore, the rectal 
cavity is also drained by extensive lymphatic circulation which has direct access to the 
systemic circulation. Clinical studies have shown a higher systemic bioavailability of 
propanolol in dogs and humans when administered rectally compared with oral administration 
(Iwamoto and Watanabe, 1985; Cid et al., 1986). In order to confirm whether propranolol is 
absorbed rectally from the matrix-in-cylinder system, the core material of the matrix-in-
cylinder system was administered rectally to the dogs. The entire matrix-in-cylinder system 
could not be administered rectally as the dogs excreted these dosage forms quickly after 
insertion. Figure 5.8 shows the plasma concentrations of propranolol after rectal 
administration of a suppository consisting of 27 % propranolol hydrochloride, 23 % 
Methocel K100 and 50 % Gelucire 44/14 (equivalent with 80 mg propranolol 
hydrochloride). It is clear that propranolol was well absorbed rectally from the core 
formulation, resulting in plasma levels similar to those obtained with the matrix-in-cylinder 
system. Thus, the large difference in bioavailability between the matrix-in-cylinder system 
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t = 2 min p = stomach fundus t = 75 min p = descending colon
t = 15 min p = jejunum
t = 2 min p = stomach fundus
t  30 i   stomach fundust = 15 min p = jejunum
t = 60 min p = ileum
t = 30 min p = ileum
t = 90 min p = descending colon
t = 105 min p = rectum
t = 120 min p = not visible on this RX, but not yet 
excreted (thus probably in rectum)
 
Figure 5.9: Roentgen photographs of a dog’s abdomen after oral administration of an EC-pipe 
filled with barium sulphate. t = time; p = position of the EC-pipe in the GI-tract. 
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and Inderal could be ascribed to rectal absorption (either via the haemorrhoidal veins or via 
the lymphatics) of propranolol released from the matrix-in-cylinder system. 
5.5 CONCLUSION 
Although drug release is erosion-controlled, hot-melt extruded ethylcellulose cylinders 
containing a HPMC-Gelucire core are a robust tool to control drug release. The in vitro drug 
release from the matrix-in-cylinder system was only slightly affected by hydrodynamics, 
mechanical stress and the composition of the dissolution medium. From the in vivo data, it can 
be concluded that the matrix-in-cylinder system provides a promising drug delivery system 
for sustained release. Furthermore, administration of the matrix-in-cylinder increased the 
bioavailability of propranolol in dogs when compared with a commercial sustained release 
formulation (Inderal).  
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6 HUMAN BIOAVAILABILITY OF 
PROPRANOLOL FROM THE MATRIX-
IN-CYLINDER SYSTEM 
6.1 INTRODUCTION 
Chapter 5 showed that administration of the matrix-in-cylinder dosage form to dogs resulted 
in constant plasma concentration levels (maintained over 24 h) and a 4-fold increase of the 
propranolol bioavailability compared to a commercial sustained release formulation 
(Inderal®).  
For sustained release dosage forms, co-administration with food can result in dose-dumping 
whereby the complete dose is more rapidly released from the dosage form than intended, 
creating a potential safety risk for the patients. Especially erosive systems, such as the matrix-
in-cylinder dosage form, are highly sensitive to food intake due to the intensive mechanical 
destructive forces exerted by the different motility patterns in the gastrointestinal tract (Singh, 
1999).   
The aim of this study was to compare the in vivo behaviour of the matrix-in-cylinder system 
in humans to that of Inderal® retard mitis and to investigate the effect of concomitant food 
intake on the in vivo performance of the experimental formulation.  
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6.2 MATERIALS 
Hydroxypropyl methylcellulose (HPMC) (Methocel® Premium K100) (methoxyl content: 19-
24 %, hydroxypropyl content: 7-12 %, viscosity: 100 mPa.s (2% (w/w) aqueous solution at 
20°C)) was received from Colorcon (Dartford, UK). Ethylcellulose (EC) (Ethocel® FP10) 
(ethoxyl content: 48-49.5 % (w/w); viscosity: 9-11 mPa.s (5 % solution in toluene-EtOH, 
80:20, 25°C)) was kindly donated by the Dow Chemical Company (Horgen, Switzerland). 
Gelucire® 44/14 (melting point: 44°C, HLB = 14) was a gift from Gattefossé (Saint-Priest, 
France). Propranolol hydrochloride was supplied by Roig Farma (Terrassa, Spain). Dibutyl 
sebacate was purchased from Sigma (St-Louis, USA). Inderal retard mitis (Astra Zeneca, 
Brussels, Belgium) contained 80 mg propranolol hydrochloride and consisted of coated 
pellets. 
6.3 METHODS 
6.3.1 Production of the matrix-in-cylinder system 
The matrix-in-cylinder systems (l = 14 mm, d = 5 mm) were manufactured according to the 
method described in Chapter 4. The matrix cores of the dosage form consisted of 27 % 
propranolol hydrochloride, 23 % Methocel® K100 and 50 % Gelucire 44/14. 
6.3.2 In vivo study 
Subjects and study design 
The study was performed at the Drug Research Unit Ghent (D.R.U.G.), Ghent University 
Hospital (Gent, Belgium). 
A group of ten Caucasian volunteers, male and female aged between 18 and 55 years, gave 
written informed consent to participate in the study, which was approved by the Medical 
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Ethics Committee of the Ghent University Hospital. The study was conducted in accordance 
with the Declaration of Helsinki (Hong Kong, September 1989). The subjects were non-
smokers and their weight was within 15 % of their ideal weight. They were judged healthy on 
the basis of medical history, physical examination, electrocardiogram and investigation of 
biochemical and haematological parameters in blood and urine. The subjects abstained from 
intake of medication from two weeks prior to and during the whole study and from the intake 
of grapefruit, grapefruit juice or beverages containing alcohol or quinine between 24 hours 
before and 48 hours after drug dosing per experimental period. 
The following formulations were tested: 
F-1:  matrix-in-cylinder system, containing 80 mg propranolol hydrochloride, administered 
under fasted conditions. 
F-2: matrix-in-cylinder system, containing 80 mg propranolol hydrochloride, administered 
together with a high-fat, high-calorie breakfast consisting of 2 eggs, 2 slices of baked 
bacon, 2 slices of white bread, 1 croissant with 1 slice of cheese and 240 ml high-fat 
milk (according to the Guidance for Industry: Food Effect Bioavailability and Fed 
Bioequivalence Studies – F.D.A.-C.D.E.R., December 2002).  
F-3: Inderal retard mitis, a commercially available multiparticulate sustained release 
formulation containing 80 mg propranolol hydrochloride, administered under fasted 
conditions. 
Formulations F-1 and F-2 were filled in hard gelatine capsules (n° 00) for administration to 
the volunteers. The formulations were administered in a randomised cross-over sequence with 
a washout period of at least 6 days between the different experimental sessions. 
On the experimental days the subjects were fasting since the previous evening at 8 p.m., 
although the intake of water was allowed until 6.30 a.m. Before the administration of the 
formulation, an intravenous cannula was placed in an antecubital vein and a blank blood 
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sample (5 ml) was obtained. The cannula was kept patent by use of a saline solution. The 
propranolol formulation was administered together with 200 ml of water. Blood samples (5 ml 
at each sampling) were obtained at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours after intake. 
The blood samples were collected in dry heparinized tubes and centrifuged for 5 minutes at 
3000 rpm within one hour after collection. The plasma was stored at –20°C until assay of 
propranolol. No food or water could be taken until 2 hours after drug administration. During 
this time, the subjects remained in a sitting position. From 2 hours after drug intake, water 
could be taken freely. A standard lunch and dinner were provided after 4 and 10 hours, 
respectively. From 14 hours post-administration, the volunteers could leave the clinical unit 
and resume their usual diet except for grapefruit, grapefruit juice, alcohol and quinine 
containing beverages, which were not allowed till 48 hours after the ingestion of propranolol.  
6.3.3 Propranolol assay 
The propranolol plasma concentrations were determined by a validated HPLC-fluorescence 
method. All chemicals were of analytical or HPLC grade. 
The drug was extracted using a liquid-liquid extraction method based on the procedure 
described by Braza et al. (2000). 100 µl of an internal standard solution (250 ng/ml of 4-
methylpropranolol in water) and 100 µl of water were mixed with 1 ml plasma. The plasma 
was deproteinated by adding 3 ml ethanol, mixing and centrifuging for 5 min at 2000g. The 
supernatans was transferred in another glass tube and treated with 0.1 ml of 1 M sodium 
hydroxide. After homogenisation and subsequent addition of 6 ml dichloromethane, the 
mixture was vortexed for 10 min and centrifuged for 10 min at 2000g. The organic layer was 
isolated and evaporated to dryness under a nitrogen stream. The residue was dissolved in 150 
µl of mobile phase and 100 µl was injected into the chromatographic system. 
The HPLC equipment consisted of a solvent pump (L-6000 pump, Hitachi, Tokyo, Japan) set 
at a constant flow rate of 1 ml/min, a variable wavelength detector (L-7480 fluorescence 
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detector, Hitachi, Tokyo, Japan) set at 280 nm as excitation wavelength and 333 nm as 
emission wavelength, a reversed phase column and precolumn (LiChro-CART® 125-4 and 4-
4, LiChrospher® 60 RP-select B 5 µm; Merck, Darmstadt, Germany) and an automatic 
integration system (L-7000, Hitachi, Tokyo, Japan). The mobile phase had the following 
composition: 700 ml of a buffer solution (consisting of 5mM KH2PO4 and 1 mM 
triethylamine) adjusted to pH 5 with 1 N H3PO4, 200 ml acetonitrile, 50 ml methanol and 50 
ml tetrahydrofuran. 
6.3.4 Validation of the HPLC method 
The HPLC analysis method was validated based on the guidelines stated by the International 
Conference on Harmonisation (ICH) for validation of analytical procedures (1994). The 
following characteristics were considered: specificity, linearity, accuracy, precision, recovery, 
detection and quantification limit. 
 
Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of interfering 
components. It was assessed by comparing the chromatogram of blank plasma with the 
chromatogram obtained of blank plasma spiked with propranolol and internal standard 4-
methylpropranolol. Figure 6.1 shows the chromatograms after the extraction of (a) blank 
plasma and (b) plasma of a human volunteer after intake of propranolol. As no interfering 
peaks were observed, it was concluded that the method is selective to determine propranolol 
in human plasma. 
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Figure 6.1: Specificity of the HPLC method. Chromatogram after extraction of (a) blank plasma 
and (b) plasma of a human volunteer after intake of propranolol (retention time 
propranolol: 9.03 min, retention time 4-methylpropranolol:  14.97 min, calculated 
concentration propranolol: 3.73 ng/ml). 
 
Linearity 
The linearity of an analytical procedure is its ability – within a given range – to obtain test 
results, which are directly proportional to the concentration of analyte in the sample.  
During the validation of the HPLC method and the analysis of the samples, several calibration 
curves were analysed. The linearity of the calibration curves was evaluated by the 
determination coefficient R². The mean determination coefficient for the calibration curves  
(a) 
(b) 
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(n = 8) was 0.9990, indicating that the relationship between response (y) and concentration (x) 
was linear. The equation of the mean calibration curve was:  
y = 0.109x – 0.0854 
with x = concentration of propranolol HCl (ng/ml) and y = fluorescence 
 
Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between the 
true value and the determined value and is expressed as the percent agreement between the 
mean determined value and the true concentration. 
The accuracy was investigated at three concentration levels on plasma spiked with known 
amounts of the analyte, then treating the resulting solution as indicated by the method. Each 
concentration was determined six times. The mean accuracies (± S.D.) are listed in Table 6.1. 
 
Table 6.1: Mean accuracies (± S.D.) of the HPLC method (n = 6). 
Concentration Accuracy (%) 
(ng/ml) Within-day Between-day 
3.13            109.2 ± 8.5   110.1 ± 10.1 
25 103.5 ± 3.6 104.9 ± 6.7 
100 101.7 ± 2.6 103.0 ± 3.2 
 
All mean values were within ± 15 % of the actual concentration (Acceptance criteria: within 
15 % of the actual value, Shah et al., 1992).  
 
Precision 
The precision expresses the closeness of agreement between repeated determinations. It may 
be considered at three levels: repeatability (intra-assay precision), intermediate precision 
(within laboratory precision) and reproducibility (between laboratory precision). Precision is 
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expressed as the coefficient of variation (%) of a series of measurements of the calibration 
standards. 
 
Since the measurements were performed in the same laboratory, by the same person using the 
same equipment only the repeatability (within-day and between-day) of the measurements 
was evaluated (Table 6.2). The acceptance criteria are coefficients of variation less than 15 %.  
 
Table 6.2: Precision (expressed as coefficient of variation) of the HPLC method (n = 6). 
Concentration Precision (% CV) 
(ng/ml) Within-day Between-day 
3.13 5.3 8.2 
6.25 - 5.1 
12.5 3.0 5.0 
25 - 8.4 
50 - 6.9 
100 3.5 6.6 
 
 
Recovery 
The recovery was determined for the calibration standards (at three concentration levels) and 
for the internal standard and can be expressed as the closeness of agreement (in %) between 
the surface areas of an extracted sample versus a non-extracted sample. The mean recoveries 
(± S.D.) for the calibration standards and for the internal standard are shown in Table 6.3. 
 
Table 6.3: Mean recoveries (n = 6) (± S.D.) for the calibration standards and for the internal 
standard. 
 Concentration 
(ng/ml) 
Recovery 
(%) 
propranolol 3.13 83.9 ± 4.2 
 12.5 80.9 ± 6.0 
 100 80.5 ± 5.5 
4-methylpropranolol 25 86.3 ± 4.3 
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Detection and quantification limit 
The detection limit of an analytical procedure is the lowest amount of analyte in a sample 
which can be detected but not necessarily quantitated as an exact value. The quantification 
limit is the lowest amount of analyte in a sample which can be adequately determined with 
suitable precision and accuracy. Both values were estimated from the mean calibration curve 
(International Conference on Harmonisation, 1994): 
 
DL = 3.3 x σ 
                     S 
 
with DL = detection limit 
 σ = standard deviation of the Y-intercept of the mean calibration curve 
 S = slope of the mean calibration curve 
 
QL = 10 x σ 
                     S 
 
with QL = quantification limit 
 σ = standard deviation of the Y-intercept of the mean calibration curve 
 S = slope of the mean calibration curve 
The detection and quantification limits of propranolol in dog plasma were determined at 0.1 
and 0.4 ng/ml, respectively. 
6.3.5 Data analysis 
The peak plasma concentration (Cmax), the time to reach Cmax (tmax) and the extent of 
absorption (AUC0-48h) were calculated using the MW-PHARM program version 3.0 
(Mediware 1987-1991, Utrecht, the Netherlands).  
The pharmacokinetic parameters of the formulations were statistically evaluated by a two-way 
ANOVA test. The normality of the data was checked by means of the Kolmogorov-Smirnov 
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test and the homogeneity of variances by means of the Levene test. A significance level of 
0.05 was used. All statistical analyses were performed using SPSS 11.0 for Windows.  
6.4 RESULTS AND DISCUSSION 
6.4.1 In vivo evaluation 
Figure 6.2 shows the mean (n = 10) plasma concentration-time profiles after oral 
administration of 80 mg propranolol hydrochloride as the matrix-in-cylinder system under 
fasted conditions (F-1), the matrix-in-cylinder system under fed conditions (F-2) and Inderal® 
retard mitis (F-3), respectively. The pharmacokinetic parameters are reported in Table 6.4. 
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Figure 6.2: Mean plasma concentration-time profiles (± S.D.) after oral administration of 80 mg 
propranolol hydrochloride to humans (n = 10) as the matrix-in-cylinder system under 
fasted conditions (F-1) (■), the matrix-in-cylinder system under fed conditions (F-2) 
(▲), Inderal® retard mitis (Astra Zeneca) (♦). 
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Table 6.4: Mean pharmacokinetic parameters (± S.D.) after oral administration of 80 mg 
propranolol hydrochloride as the matrix-in-cylinder system under fasted conditions (F-
1), the matrix-in-cilinder system under fed conditions (F-2) and Inderal® retard mitis 
(F-3) to 10 human volunteers: 
 Cmax tmax AUC0-48h 
Matrix-in-cylinder fasted 25.1±14.0a 13.1±5.2c 488.0±247.0e,f 
Matrix-in-cylinder fed 61.5±34.2b 12.4±0.9c 694.6±235.1e 
Inderal® 19.3±8.5a 7.1±3.1d 312.9±107.5f 
a,b,c,d,e,f: groups with the same superscript are not significantly different from each other (p > 0.05) 
 
It is clear that administration of the matrix-in-cylinder system resulted in plasma levels similar 
to the reference formulation Inderal® during the initial 10 h after administration. From 10 h 
post-administration, an increase of the propranolol plasma levels was noticed. This second 
peak in plasma concentration was most pronounced for the experimental dosage form co-
administered with food. The matrix-in-cylinder system had a relative bioavailability of 156.0 
% (fasted conditions) and 222.0 % (fed conditions) compared to the marketed reference 
product. Statistical comparison of AUC0-48h of the matrix-in-cylinder system administered 
under fasted conditions and Inderal® (also administered under fasted conditions) showed that 
their bioavailability was not significantly different (p=0.054). Concomitant intake of a high-
fat, high-calorie breakfast did not alter the bioavailability of the matrix-in-cylinder system 
(p=0.064). Although drug release from the matrix-in-cylinder is erosion-controlled, co-
administration of food did not cause dose-dumping, proving that the ethylcellulose pipe 
protects the matrix core from the mechanical forces exerted by the different motility patterns 
in the GI-tract during food digestion. Under fed conditions a slight delay in the onset of the 
plasma profile was noticed, possibly due to a delayed gastric emptying in the presence of 
food.  
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From this human bioavailability study it could be concluded that during the first 10 h after 
administration of the matrix-in-cylinder system, the propranolol plasma levels were similar to 
those obtained with Inderal®. However, between 10 and 24 h after administration of the 
experimental formulation the propranolol bioavailability was higher (especially when co-
administered with food). In order to explain this increased bioavailability (and the second 
plasma concentration peak) observed for the matrix-in-cylinder system, different hypotheses 
can be formulated:   
- food effect on propranolol absorption 
- formulation effect on propranolol absorption  
- inhibition of the presystemic metabolism of propranolol  
- (partial) bypass of the presystemic metabolism. 
6.4.2 Food effect on propranolol absorption 
Food ingestion is known to increase the bioavailability of immediate release propranolol 
formulations, due to transient changes in hepatic blood flow in response to a meal, increasing 
the propranolol delivery rate, causing saturation of the hepatic enzymes and consequently a 
reduced hepatic first pass elimination (McLean et al., 1978, 1980; Schneck and Vary, 1983; 
Olanoff et al., 1986). However, Byrne et al. (1984) reported that the co-administation of food 
did not alter the bioavailability of Inderal® retard due to the slower propranolol delivery rate 
inherent of sustained release formulations. So it can be stated that the different plasma 
concentration profile observed for the matrix-in-cylinder system under fed conditions is not 
drug but formulation-related, since no food effect was noticed for Inderal® retard (Byrne et 
al., 1984).  
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6.4.3 Formulation effect on propranolol absorption 
The second hypothesis comprises a difference in extent of propranolol absorption from the 
matrix-in-cylinder system compared to the Inderal®-formulation, due to the different 
composition of the formulations. Especially Gelucire® 44/14 could be responsible for this, 
since it is a self-emulsifying excipient. It produces a fine oil-in-water emulsion when 
introduced into an aqueous phase under gentle agitation, improving solubility (and 
consequently bioavailability) of poorly water-soluble drugs (Chambin et al., 2004). 
Furthermore, fatty acids or fatty acid esters have also shown to increase the intestinal 
absorption of poorly absorbed water-soluble drugs, probably due to an increased intestinal 
membrane permeability (Muranishi, 1985; Murakami et al., 1986; Palin et al., 1986; Ishizawa 
et al., 1987; van Hoogdalem et al., 1989; Mori et al., 2004). However, propranolol is a Class I 
drug according to the Biopharmaceutical Classification System, showing good aqueous 
solubility and good permeability along the entire gastrointestinal tract (Kasim et al., 2004). 
Thus it is unlikely that an improved dissolution or absorption of propranolol - in presence of 
Gelucire® 44/14 - is responsible for the increased bioavailability. 
Another possible explanation is inhibition of P-glycoprotein (P-gp) by Gelucire® 44/14, since 
surfactants and co-surfactants have been reported to have P-gp inhibiting properties (Nerurkar 
et al., 1996; Johnson et al., 2002; Chiu et al., 2003; Cornaire et al., 2004). P-gp is an integral 
membrane protein, about 170-180 kDa, encoded by the MDR1 gene in humans and contains 
12 putative transmembrane domains and two ATP binding sites. In the small intestine and 
colon, P-gp is expressed almost exclusively within the brush border membrane of mature 
enterocytes, where it acts as an energy-dependent drug efflux pump expelling the absorbed 
drug from the enterocyte into the gastrointestinal lumen, thereby limiting the absorption of 
drugs from the GI-tract (Figure 6.3). Although P-gp appears to be distributed throughout the 
GI-tract, its levels are higher in more distal regions. Moreover, several studies have shown 
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that P-gp and CYP3A (metabolism) have similar substrate specificity (Benet et al., 1999). The 
colocalisation of P-gp and CYP3A in the mature enterocytes and their overlapping substrate 
specificity reasonably suggest that the function of these two proteins may be synergistic and 
appears to be coordinately regulated (Watkins, 1997).  
 
 
 
Figure 6.3: Schematic representation of the enteral cycling of a drug that is a substrate for P-
glycoprotein and CYP3A (Benet and Cummins, 2001). 
 
Propranolol is known to have minimal binding capacities to P-gp (McGinnity et al., 2000; 
Eneroth et al., 2001; Stephens et al., 2002; Augustijns and Mols, 2004), however some 
authors reported about propranolol being a substrate for P-gp (Wacher et al., 1995; 
D’Emanuele et al., 2004). In order to check if the increased propranolol bioavailability could 
be ascribed to P-gp inhibition, the influence of HPMC and Gelucire® 44/14 (excipients of the 
matrix-in-cylinder formulation) on the permeability of propranolol in a Caco-2 system was 
determined. 
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¾ Effect of Gelucire® 44/14 (and HPMC) on the permeability of propranolol in a 
Caco-2 system 
 
Introduction 
Several methods have been developed to understand the mechanism of absorption of chemical 
compounds. The most common method uses the immortalised cell line, Caco-2. The Caco-2 
cell line is derived from a human colon adenocarcinoma and undergoes spontaneous 
enterocytic differentiation in culture, forming monolayers of polarized enterocytes. Despite 
their colonic origin, Caco-2 cells express the majority of the morphological and functional 
characteristics of small intestinal absorptive cells, including phase I and phase II enzymes. 
However CYP3A, which is present in almost all intestinal cells, is very weakly expressed in 
Caco-2 cells. Caco-2 cells also express a variety of transport systems including P-glycoprotein 
(P-gp). Several research groups have reported a good correlation between drug permeability 
measured in the Caco-2 system and the oral absorption of the same drug in humans (Artursson 
and Karlsson, 1991; Yee, 1997; Yamashita et al., 1997). 
Caco-2 cells form a monolayer when grown on a microporous membrane (Figure 6.4), thus 
creating an apical and a basolateral compartment, which correspond to the intestinal lumen 
side and the serosal side, respectively. The complete morphological and functional 
differentiation of Caco-2 monolayers requires two weeks in culture under the conditions 
described below. 
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Figure 6.4: Schematic representation of a Caco-2 monolayer cultured on a microporous 
membrane. 
 
The objective of this experiment was to investigate whether the functionality of P-
glycoprotein efflux carriers can be modulated by the excipients formulated in the matrix-in-
cylinder (HPMC and Gelucire® 44/14) and if so, whether the modulatory effect of P-gp can 
affect the absorption of propranolol. Therefore, the influence of HPMC and Gelucire® 44/14 
on the permeability for marker compounds of paracellular transport (atenolol), transcellular 
transport (propranolol) and P-gp functionality (talinolol) in a Caco-2 system was determined. 
The effect of HPMC and Gelucire® 44/14 on membrane integrity was also investigated.  
The Caco-2 experiments were performed by Raf Mols and Prof. Dr. Patrick Augustijns of the 
Laboratory for Pharmacotechnology and Biopharmacy, Faculty of Pharmaceutical Sciences, 
Katholieke Universiteit Leuven (K.U. Leuven) (Leuven, Belgium).  
 
Materials 
All chemicals used for culturing the Caco-2 cells were purchased from Invitrogen (Merelbeke, 
Belgium). Cell culture medium consisted of Dulbecco’s modified Eagle’s medium 
supplemented with 10 % fetal bovine serum, 1 % MEM non-essential amino acids solution 
and 100 IU ml-1 penicillin-streptomycin. Transport medium (TM) consisted of Hanks’ 
Human bioavailability of propranolol from the matrix-in-cylinder system 124
balanced salt solution containing 25 mM D-(+)-glucose (Sigma Chemical Co., St. Louis, MO) 
and 10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES); pH was adjusted 
to 7.4 at 37°C with sodium hydroxide (2 M) (BDH, Poole, England). Talinolol was a gift of 
Arzneimittelwerk Dresden (Radebeul, Germany). Atenolol and propranolol were purchased 
from Sigma-Aldrich (St. Louis, MO). Methanol was from Fisher Scientific (Leicestershire, 
UK). Sodium acetate was obtained from Vel (Leuven, Belgium). Acetic acid was from Fluka 
Chemika (Bucks, Switzerland). Sodium fluorescein was provided by UCB (Brussels, 
Belgium).  
 
Cell culture 
Caco-2 cells were purchased from Cambrex Biosciences (Walkersville, MD). Caco-2 cells 
were grown in 75 cm² culture flasks at 37°C in an atmosphere of 5 % CO2 and 90 % relative 
humidity. Cells were passaged every 3-4 days (at 70-80 % confluence) at a split ratio of 1-7. 
Cells were negative for mycoplasma infection. 
 
Transport experiments 
For transport experiments, Caco-2 cells were plated at a density of 40,000 cells cm-2 on 
Costar® Transwell membrane inserts (3 µm pore diameter, 12 mm diameter; Corning Inc., 
NY). Confluence was reached within 3-4 days after seeding and the monolayers were used for 
the experiments 17 days post-seeding. Cell passage 78 was used in the experiments. 
Transepithelial electrical resistance-values (TEER values) were measured with an EndOhm 
Voltohmmeter (WPI, Aston, England). TEER measurements are a means to check the 
integrity of the monolayer and can reveal toxicity or an opening of tight junctions induced by 
the drug or excipients. Only monolayers with initial TEER values higher than 250 Ω.cm² were 
used. All volumes amounted to 0.5 ml at the apical side of the monolayer and 1.5 ml at the 
basolateral side. 
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After rinsing the monolayers three times with TM, a pre-incubation step (30 min) with TM 
(control) was performed. TEER values were measured and transport was initiated by adding 
atenolol, talinolol and propranolol to the donor compartment. Samples were taken from the 
acceptor compartment after 60 min and TEER values were measured again. As an additional 
control of the monolayer integrity, sodium fluorescein flux was measured at the end of the 
experiment. Briefly, sodium fluorescein (1 mg ml-1) - a low permeability marker - was added 
to the apical compartment and after 60 min samples were taken from the basolateral 
compartment, followed by TEER measurement. The amount of sodium fluorescein appearing 
in the basolateral compartment was measured by UV spectrophotometry (Uvikon 810P 
spectrophotometer, Kontron Instruments, Watford, England) at 490 nm. Sodium fluorescein 
flux values across the monolayers were typically below 0.6 %h-1cm-2.  
 
HPLC analysis 
Concentrations of atenolol, talinolol and propranolol were analysed with a validated HPLC-
fluorescence method developed by Augustijns and Mols (2004). A high-performance liquid 
chromatographic system equipped with a model 600E Controller and Pump, a model 717plus 
autosampler and a Multi λ Fluorescence Detector (Waters 2475) (Waters, Milford, MA) was 
used. Fluorescence signals were monitored and the obtained peaks integrated using a Digital 
personal computer running Waters Millennium 32 Chromatography software. The column 
used was a Waters Novapak C-18 column (4 µm). The flow rate amounted to 1.65 ml min-1. 
Mobile phase A consisted of sodium acetate (50 mM; pH adjusted to 3.3 with acetic acid) and 
methanol (85:15 v/v). Mobile phase B consisted of sodium acetate (50 mM; pH adjusted to 
3.3 with acetic acid) and methanol (20:80 v/v). The column was initially equilibrated at 85 % 
mobile phase A and 15 % mobile phase B. After injection, the concentration of mobile phase 
B was increased to 55 % and the flow rate decreased to 1.55 ml min-1 over 6 min. After 10 
min, the system was returned to the original conditions and equilibrated for 2 min before the 
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next injection. All water was purified by a Maxima system (Elga, High Wycombe Bucks, 
England). The volume injected amounted to 50 µl. The retention times of atenolol, talinolol 
and propranolol were 2.6, 8.3 and 8.8 min, respectively. The samples from the Caco-2 system 
were analysed by direct injection into the HPLC-system (Augustijns and Mols, 2004).  
A programmed wavelength fluorescence method was used for the measurement of the 
individual compounds. The optimal excitation and emission wavelengths were 271-302, 249-
333 and 283-340 nm for atenolol, talinolol and propranolol, respectively. As the optimal 
wavelengths did not correspond for the different compounds, two different detection 
conditions were used corresponding to the elution of the different compounds. For the first 
period, the optimal detection conditions of atenolol were used, while in the second time 
period, the excitation and emission were adjusted to those optimal for talinolol. Although 
propranolol elutes in the second time period under sub-optimal detection conditions, no 
further changes were made to optimise the excitation and emission wavelength, based on the 
reasoning that a satisfactory response would be obtained as propranolol has a high 
fluorescence yield. The wavelengths were adjusted after 6 min (Augustijns and Mols, 2004). 
 
Calculations    
Results of the transport experiments with the Caco-2 monolayers are expressed as 
permeability coefficients (in cm s-1), which were calculated as follows: 
Papp =  ∆Q    1       
 ∆ t   AC0 
 
with ∆Q / ∆ t the amount of drug appearing in the acceptor compartment in function of time 
(nmols s-1), C0 the initial concentration in the donor compartment (µM) and A the surface area 
(cm²) across which the transport occurred. Values are expressed as mean ± S.D. (n = 3).  
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Results 
In this experiment, different apical conditions were used while the basolateral conditions were 
kept constant. To the basolateral side, atenolol (50 µM), talinolol (25 µM) and propranolol 
(10 µM) were added.   At the apical side side, the following conditions were studied: 
- transport medium (TM) (used as a reference)  
- 0.0128 % (w/v) HPMC dissolved in TM  
- 0.028 % (w/v) Gelucire® 44/14 dissolved in TM  
- 0.0128 % (w/v) HPMC and 0.028 % (w/v) Gelucire® 44/14 dissolved in TM  
The marker compounds (atenolol, talinolol and propranolol) were added on the basolateral 
side, while the excipients were added apically. This approach was used because when marker 
compounds and excipients are both included in the same compartment of the Caco-2 system 
the drugs can be included in the micelles formed by Gelucire® 44/14, which complicates the 
interpretation of the results regarding P-gp functionality. Therefore, drugs and excipients were 
each added at a different side of the cell monolayer.  
Figure 6.5 shows the appearance of atenolol, talinolol and propranolol in the apical 
compartment after administration of the drugs to the basolateral side of the Caco-2 
monolayers. It can be concluded that HPMC does not affect the permeability of the marker 
compounds. Regarding the effect of Gelucire® 44/14 on permeability, a slighty decreased 
permeability of atenolol was noticed in the presence of Gelucire® although atenolol is 
expected to cross the monolayers especially by the paracellular route. This observation is in 
agreement with the findings of Augustijns and Mols (2004), who ascribed this observation to 
the fact that atenolol may be partially subjected to transcellular transport and that it may be a 
substrate for efflux carriers. The transport of the P-gp substrate talinolol was decreased in 
presence of Gelucire®, indicating the P-gp blocking potential of Gelucire® (in a concentration 
of 0.028 % (w/v)). However, in presence of HPMC, Gelucire® did not affect the transport of 
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talinolol. Despite the P-gp inhibiting properties of Gelucire®, no effect of Gelucire® on the 
permeability of propranolol was observed. Thus, propranolol is not a substrate for P-gp. 
 
(a) Atenolol (marker compound of paracellular transport) 
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(c) Propranolol (marker compound of transcellular transport) 
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Figure 6.5: Influence of the presence of Gelucire® 44/14 (0.028 % (w/v) and HPMC (0.0128 % 
w/v) in the apical medium on the basolateral to apical transport of (a) atenolol, (b) 
talinolol and (c) propranolol (in the basolateral compartment) (n = 3).  
 
The use of HPMC and Gelucire®, in a concentration of 0.0128 % and 0.028 % (w/v) 
respectively, did not damage the Caco-2 monolayers as was shown by the TEER-values 
(Figure 6.6) and the sodium fluorescein transport (a low permeability marker) in comparison 
to the control group (TM) (Figure 6.7).    
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Figure 6.6: Influence of the presence of Gelucire® 44/14 and HPMC in the apical medium on the 
TEER values. 
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Figure 6.7: Sodium fluorescein flux across the monolayers at the end of the experiment. 
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Conclusion 
From this experiment, it can be concluded that the presence of Gelucire® and HPMC did not 
affect the transport of propranolol across Caco-2 monolayers. Thus, the increased propranolol 
bioavailability can not be ascribed to the inhibition of the functionality of P-gp by Gelucire® 
44/14. 
6.4.4 Inhibition of presystemic metabolism of propranolol 
Orally administered drugs are subjected to presystemic metabolism, comprising three 
subtypes of mechanisms: lumenal metabolism, first pass intestinal metabolism and first pass 
hepatic metabolism. Lumenal drug metabolism is supposed to be triggered by digestive 
pancreas enzymes and by enzymes derived from the bacterial flora of the gut. First pass 
intestinal metabolism includes brush border metabolism (occurring at the surface of the 
enterocytes by the enzymes present within the brush border membrane) and intracellular 
metabolism in the enterocytes (involving the major phase I metabolising enzymes 
(cytochrome p450), several phase II conjugating enzymes and others such as esterases). 
Recently, intestinal metabolism has been shown to decrease the bioavailability of some drugs 
such as cyclosporine and midazolam. CYP3A4 is the most abundant enzyme involved in the 
intestinal first pass metabolism, but also other CYPs such as CYP1A2 have been identified in 
the intestinal mucosa. However, for most drugs the dominant process of presystemic 
clearance is the hepatic first pass metabolism. A drug absorbed from the gastrointestinal tract 
is carried to the liver via the hepatic portal vein and a fraction of the administered dose is 
biotransformed by the liver enzymes before it reaches the systemic circulation (Kim and 
Singh, 2002). Propranolol is a drug with an extensive first pass clearance after oral 
administration. Inhibition of this presystemic metabolism can possibly explain the improved 
bioavailability of the matrix-in-cylinder system. Especially intestinal first pass metabolism is 
focused here since some surfactants have been reported to inhibit CYP3A and consequently to 
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increase bioavailability of drugs metabolized by this enzyme (Mountfield et al., 2000; 
Gonzalez et al., 2004). However, propranolol is primarly metabolized by CYP1A2 (it is not a 
substrate for CYP3A-enzymes) and it is not known to have an appreciable gut metabolism 
(Lo et al., 1982; Mills et al., 2004). Thus, it seems that inhibition of the intestinal metabolism 
by Gelucire® 44/14 is not likely to be responsible for the different plasma concentration 
profile after administration of the matrix-in-cylinder system. Inhibition of the hepatic first 
pass metabolism by Gelucire® components might also be a possible explanation, however 
knowledge regarding the absorption of Gelucire® 44/14 is limited. On a theoretical basis, 
Gelucire® 44/14 is composed of PEG esters and glycerides. The latter components are known 
to be sensitive to lipolysis in the gastrointestinal tract and are absorbed as monoglycerides, 
glycerol and fatty acids. On the other hand, there is nearly no literature on the absorption of 
PEG esters. However, absorption of the Gelucire® components is assumed to be very low 
(personal communication from Gattefossé), suggesting that inhibition of the hepatic first pass 
metabolism by Gelucire® is not likely to occur. 
6.4.5 Bypass of presystemic metabolism of propranolol 
A (partial) bypass of the presystemic metabolism could be another possible explanation of the 
increased propranolol bioavailability observed with the matrix-in-cylinder. A drug absorbed 
in the gastrointestinal tract can gain access to the systemic circulation via two separate 
absorption pathways: the portal vein (subjecting the drug to hepatic first pass metabolism) and 
the intestinal lymphatics (delivering the drug to the vena cava and thus bypassing hepatic 
clearance). The improved bioavailability of the matrix-in-cylinder system may be due to a 
partial bypass of the hepatic clearance through lymphatic uptake of propranolol. The potential 
for intestinal lymphatic drug transport is known to be dependent on the lipophilicity of the 
drug. The log P (octanol/water) of propranolol base is 3.26 (Irwin and Belaid, 1987), which is 
quite low in comparison with other drugs that are transported via the intestinal lymphatics 
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(log P > 5). However, recent reports have described formulation approaches to redirect drugs 
with little inherent affinity for the lymphatics to the intestinal lymphatics (White et al., 1991; 
Barnwell et al., 1992, 1996). The aim of these studies was to develop a formulation capable of 
redirecting the absorption of propranolol via the intestinal lymphatics, thereby decreasing first 
pass metabolism and increasing oral bioavailability. The initial report by White et al. (1991) 
examined lymphatic transport of propranolol in a pig model after oral administration of a 
commercial propranolol formulation (Inderal®) and two test formulations containing mixtures 
of propranolol and bile salts. Higher lymph concentrations of propranolol were detected in the 
first 30 min after administration of the test formulations compared with Inderal®, and an 
increase in systemic concentrations of propranolol was noted over the same time period 
relative to portal blood concentrations. These findings led to the conclusion that the test 
formulations had redirected propranolol to the systemic circulation via the intestinal 
lymphatics. In subsequent studies the authors evaluated a drug delivery system (HALO®) 
containing oleic acid in humans, which resulted in a statistically significant increase of the 
mean plasma AUC values of propranolol (compared to Inderal® retard mitis). They again 
credited this increased bioavailability to lymphatic transport of propranolol due to its 
lipophilicity (by formation of a potential ion-pair between oleic acid and propranolol) and to 
the reported hormone-like effects of oleic acid in stimulating secretion of VLDL and 
chylomicrons.  
Aungst and Hussain (1992) also reported about an increased oral bioavailability of 
propranolol. These authors described the use of propranolol laurate, a fatty acid salt of 
propranolol, as an alternative for polymeric formulations to sustain the release of propranolol 
HCl. This approach resulted in a significant increase of the oral bioavailability of propranolol 
in dogs. The authors suggested that the increased bioavailability was the result of a reduction 
of first pass metabolism, by an association of propranolol and lauric acid in solution or 
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micellar solubilisation of propranolol and lauric acid. An ion-pair association of propranolol 
and lauric acid has been described and was suggested to be responsible for increasing the 
partition coefficient and skin permeation of propranolol (Osigo and Shintani, 1990). Aungst 
and Hussain (1992) reasoned that if this associated or encapsulated form remained intact after 
absorption, there could have been absorption via the lymphatics or less efficient extraction by 
the liver.  
Based on these findings, the increased propranolol plasma levels observed for the matrix-in-
system might be on to the lymphatic uptake of propranolol, possibly due to Gelucire® 44/14 
present in the formulation. In order to investigate the involvement of lymphatic uptake, the 
intestinal lymphatic transport of propranolol after administration of a matrix-in-cylinder 
system was examined in a lymph cannulated dog model. 
 
¾ Examination of lymphatic transport of propranolol in a lymph-cannulated dog 
model after administration of a matrix-in-cylinder system 
 
Objective 
Khoo et al. (2001) developed a conscious dog model that allows to study lymphatic drug 
absorption by cannulating a dog in the thoracic lymph duct. Dogs were selected as animal 
model since they have pre- and postprandial intestinal environments representative of humans 
(Dressman and Yamada, 1991; Kararli, 1995) and they are capable of ingesting human-
relevant dosage forms. The aim of this experiment was to determine the intestinal lymphatic 
transport, and systemic appearance, of propranolol after post-prandial administration of a 
matrix-in-cylinder system to lymph duct cannulated dogs (n = 2).  
The dog experiment was performed by Prof. Dr. Christopher Porter and Prof. Dr. William 
Charman of the Department of Pharmaceutics, Victorian College of Pharmacy, Monash 
University (Parkville, Australia). 
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Surgical procedures 
All surgical and experimental procedures were performed in accordance with the guidelines 
and approval of the local Institutional Animal Experimentation Ethics Committee. Studies 
were conducted in male greyhound dogs and their health status was verified by a veterinarian 
prior to the study. In order to cannulate the thoracic lymph duct, surgery was performed as 
described by Khoo et al. (2001). Each dog was fed a small lipid meal prior to surgery to 
facilitate identification of the thoracic lymph duct. Surgical premedication included a 
subcutaneous injection of acetylpromazine maleate (0.5 mg/kg), after which anaesthesia was 
induced with an intravenous injection of propofol (3-6 mg/kg), and surgical anaesthesia was 
maintained by delivery of halothane and oxygen. The dogs received an intravenous infusion 
of saline during surgery as well as a postoperative injection of antibiotic (cephazolin, 20 
mg/kg) and analgesic (carprofen, 4 mg/kg). 
Following surgery, dogs recovered unrestrained in a closed run for 12 h during which they 
returned to normal ambulatory movement. The temperature, blood pressure, breathing and 
level of activity were monitored. In the initial period of recovery, fluids were administered 
intravenously to ensure that the dogs were adequately hydrated and to prevent 
hypoproteinaemia. A catheter was then inserted into the cephalic vein prior to drug 
administration to enable serial blood sampling during the study. At the conclusion of the 
study, each dog was sacrificed by an intravenous injection of pentobarbitone.    
 
Experimental procedures 
The dogs were fed a can of standard dog food 30 min prior to drug administration. The 
matrix-in-cylinder system (containing 80 mg propranolol hydrochloride) was orally 
administered to the dogs (n = 2) with 50 ml water. To limit possible dehydration due to 
collection of thoracic lymph, 25 ml normal saline was administered hourly by I.V. bolus 
during the sampling period. Water was available ad libitum throughout the study.  
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Systemic blood samples (2.5 ml), collected into tubes containing disodium EDTA as 
anticoagulant, were taken from the cephalic vein via the inserted catheter. Blood samples 
were collected at 0, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 h post-dosing. Within 30 minutes of taking 
each blood sample, the blood was centrifuged for 10 min at 300g and the plasma was stored at 
-80°C.  
After administration of the experimental formulation, lymph was collected continuously into 
lymph collection bags (which were changed and replaced at half-hourly intervals for the first 
4 h and then every hour for the next 6 h). A 1 ml aliquot of the total volume of lymph 
collected in each sampling period was dispensed into tubes and stored at -80°C. 
The triglyceride concentrations present in the collected lymph samples were determined as an 
external means for determining the integrity of the lymphatic cannulations and to ensure the 
collection of all thoracic lymph. The acceptance criterion included the recovery of at least 85 
% (by mass) of the triglyceride lipid administered (present in the food) in thoracic duct lymph 
and correspondingly low systemic plasma triglyceride concentrations. Plasma triglyceride 
levels are typically similar in either fed or fasted lymph cannulated animals. High plasma 
triglyceride concentrations in lymph-cannulated dogs are usually indicative of a colateral 
lymph duct which was not isolated and ligated, allowing passage of lymph into the systemic 
blood.  
 
Propranolol assay 
Propranolol was extracted from the lymph using a solid phase extraction (SPE) method based 
on that described by White et al. (1991). Solid phase extractions of lymph were carried out on 
C18 Bond-Elut colums (1 cc 100 mg) using a 16-port vacuum manifold (Alltech Europe, 
Laarne, Belgium). The columns were initially activated by sequentially washing with 2 ml 
0.1M HCl, 2 ml acetonitrile and 2 ml destilled water. 100 µl internal standard solution (250 
ng/ml 4-methylpropranolol) and 100 µl destilled water were mixed with 1 ml lymph. The 
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insoluble protein-based components in the lymph were removed by adding 1 ml acetonitrile, 
mixing and centrifuging for 5 min at 2000g. The supernatans was transferred on the SPE 
columns. The columns were washed with 1 ml water:acetonitrile (9:1) and 1 ml acetonitrile. 
Elution was performed with 1 ml acetonitrile:0.1M HCl (1:1). The obtained eluates were 
evaporated to dryness under a nitrogen stream, the residue was dissolved in 150 µl mobile 
phase and 50 µl was injected. The same chromatographic system and chromatographic 
conditions as described in Chapter 5 were used. The propranolol lymph concentrations were 
determined via a calibration curve. The standards for the calibration curve were treated as the 
samples: 100 µl internal standard solution and 100 µl of a standard solution with known 
concentration in water were mixed with 1 ml blank lymph.  
To determine the propranolol plasma concentrations the same extraction method and HPLC-
fluorescence method as described in Chapter 5 were used.  
 
Validation of the HPLC method 
The HPLC method used to analyse the lymph samples was validated based on the guidelines 
stated by the International Conference on Harmonisation (ICH) for validation of analytical 
procedures (1994). The same characteristics as described in paragraph 6.3.4 were considered. 
 
Specificity 
Figure 6.8 shows the chromatograms after the extraction of (a) blank lymph and (b) lymph of 
a dog after intake of propranolol. As no interfering peaks were observed, it was concluded 
that the method is selective to determine propranolol in dog lymph. 
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Figure 6.8: Specificity of the HPLC method. Chromatogram after extraction of (a) blank lymph 
and (b) lymph of a dog after intake of propranolol (retention time propranolol: 8.92 
min, retention time 4-methylpropranolol: 14.94 min, calculated concentration 
propranolol: 9.05 ng/ml). 
 
Linearity 
The mean determination coefficient for the calibration curves (n = 3) was 0.9990, indicating 
that the relationship between response (y) and concentration (x) was linear. The equation of 
the mean calibration curve was: 
y = 0.0673x – 0.0884 
with x = concentration of propranolol HCl (ng/ml) and y = fluorescence 
(a) 
(b) 
Human bioavailability of propranolol from the matrix-in-cylinder system 139
Accuracy 
The mean within-day accuracies (± S.D.) are listed in Table 6.5. Between-day accuracy was 
not assessed since all analyses were performed on the same day. 
 
Table 6.5: Mean accuracies (± S.D.) of the HPLC method (n = 3). 
Concentration Accuracy (%) 
(ng/ml)          Within-day  
3.13                                105.6 ± 6.7  
25         101.0 ± 4.2  
100          100.4 ± 2.2  
 
All mean values were within ± 15 % of the actual concentration (Acceptance criteria: within 
15 % of the actual value, Shah et al., 1992).  
 
Precision 
Since the measurements were performed in the same laboratory, by the same person using the 
same equipment only the repeatability (within-day) of the measurements was evaluated (Table 
6.6). The acceptance criteria are coefficients of variation less than 15 %.  
 
Table 6.6: Precision (expressed as coefficient of variation) of the HPLC method (n = 3). 
Concentration Precision (% CV) 
(ng/ml) Within-day  
3.13 6.8  
12.5 5.3  
100 4.2  
 
 
Recovery 
The mean recoveries (± S.D.) for the calibration standards and for the internal standard are 
shown in Table 6.7. 
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Table 6.7: Mean recoveries (n = 3) (± S.D.) for the calibration standards and for the internal 
standard. 
 Concentration 
(ng/ml) 
Recovery 
(%) 
propranolol 3.13 85.9 ± 5.3 
 12.5 88.2 ± 2.3 
 100 89.3 ± 6.1 
4-methylpropranolol 25 75.5 ± 2.1 
 
 
Detection and quantification limit 
The detection and quantification limits of propranolol in dog lymph were determined at 0.2 
and 0.6 ng/ml, respectively. 
 
Results 
Table 6.8 shows the lymph and systemic plasma concentrations after oral administration of 80 
mg propranolol hydrochloride as the matrix-in-cylinder system to lymph duct cannulated dogs 
(n = 2).  
Since the propranolol lymph concentrations were similar to the plasma concentrations, it was 
concluded that most of the drug had accessed the lymph via equilibration across capillary 
beds and that specific transport into the lymph probably did not occur. When direct lymphatic 
transport is significant, the concentrations in the lymph are typically several orders of 
magnitude higher than in systemic plasma. As all lymph draining from the thoracic duct was 
collected, the exact mass of propranolol transported by the lymph could be calculated by 
multiplying the lymph drug concentration by the corresponding volume of lymph at each 
sampling interval. This calculation revealed that only a very small portion of the dose was 
transported by the lymph (Table 6.8). This experiment showed that the increased propranolol 
plasma levels observed with the matrix-in-cylinder could not be ascribed to a liver bypass due 
to intestinal lymphatic uptake of propranolol and that the 4-fold increase of propranolol 
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bioavailability after administration of the matrix-in-cylinder to dogs (Chapter 5) is due to 
rectal absorption of propranolol via the haemorrhoidal veins (thus not via the lymphatics).  
 
Table 6.8: Propranolol lymph and plasma concentrations after oral administration of a matrix-in-
cylinder system (containing 80 mg propranolol HCl) to lymph duct cannulated dogs  
(n = 2): 
LYMPH PLASMA 
Sampling 
interval 
DOG 1 
Propr. concentr. 
(ng/ml) 
DOG 2 
Propr. concentr. 
(ng/ml) 
Sampling 
interval 
DOG 1 
Propr. concentr. 
(ng/ml) 
DOG 2 
Propr. concentr. 
(ng/ml) 
0 0 0 0 h 0 0 
0-0.5 h 0.3 0 0.5 h 11.6 12.9 
0.5-1 h 2.1 2.3 1 h 11.1 11.7 
1-1.5 h 3.0 5.4 2 h 8.1 9.1 
1.5-2 h 5.1 5.5 3 h 9.9 6.9 
2-2.5 h 6.9 7.9 4 h 7.2 5.4 
2.5-3 h 6.7 6.1 5 h 6.5 6.7 
3-3.5 h 5.9 no sample 6 h 8.8 7.5 
3.5-4 h 5.0 4.3 8 h 6.9 5.9 
4-5 h 5.1 9.6 10 h 7.5 8.1 
5-6 h 2.4 10.1   
6-7 h 2.2 6.9   
7-8 h 3.6 5.3   
8-9 h 9.8 4.1   
9-10 h 10.0 4.3   
Total mass propranolol transported by lymph = 3541.0 ng for dog 1, 3787.9 ng for dog 2 
% of dose* transported by lymph = 0.009 % for dog 1 and 0.009 % for dog 2  
* It was assumed that half of the dose propranolol (= 40 mg) was released from the matrix-in-cylinder after 10 h. 
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6.5 CONCLUSION 
Administration of the matrix-in-cylinder system to humans resulted in an increased 
propranolol bioavailability. This effect was most pronounced when the matrix-in-cylinder 
system was taken together with a high-fat, high-calorie breakfast. In order to explain this 
increased bioavailability, different hypotheses were checked. However none of them was able 
to provide a conclusive answer. Most probably the first pass metabolism of propranolol is 
reduced, but its mechanism is still unknown. Furthermore, it should be noted that for high-
clearance drugs such as propranolol even a small reduction of the first pass metabolism may 
cause a significant increase of the total bioavailability.  
As the increased propranolol bioavailability after administration of the matrix-in-cylinder 
system is intriguing, it should be further investigated, for example by incorporating other 
drugs than propranolol into the dosage form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human bioavailability of propranolol from the matrix-in-cylinder system 143
6.6 REFERENCES 
Artursson, P. and Karlsson, J. (1991). Correlation between oral drug absorption in human and 
apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. 
Biochem. Biophys. Res. Commun., 175, 880-885. 
 
Augustijns, P. and Mols, R. (2004). HPLC with programmed wavelength fluorescence 
detection for the simultaneous determination of marker compounds of integrity and P-gp 
functionality in the Caco-2 intestinal absorption model. J. Pharm. Biomed. Anal., 34, 971-
978.  
 
Aungst, B.J. and Hussain, M.A. (1992). Sustained propranolol delivery and increased oral 
bioavailability in dogs given a propranolol laurate salt. Pharm. Res., 9, 1507-1509. 
 
Barnwell, S.G., Laudanski, T., Story, M.J., Mallinson, C.B., Harris, R.J., Cole, S.K., Keating, 
M. and Attwood, D. (1992). Improved oral bioavailability of propranolol in healthy 
human volunteers using a liver bypass drug delivery system containing oleic acid. Int. J. 
Pharm., 88, 423-432. 
 
Barnwell, S.G., Burns, S.J., Higginbottom, S., Whelan, I., Corness, D., Hay, G., Rosenberg, 
E. and Attwood, D. (1996). Demonstration of the importance of biphasic oleic acid 
delivery for enhancing the bioavailability of propranolol in healthy volunteers. Int. J. 
Pharm., 128, 145-154. 
 
Benet, L.Z., Izumi, T., Zhang, Y., Silverman, J.A. and Wacher, V.J. (1999). Intestinal MDR 
transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. 
Release, 62, 25-31. 
 
Benet, L.Z. and Cummins, C.L. (2001). The drug efflux-metabolism alliance: biochemical 
aspects. Adv. Drug Del. Rev., 50, S3-S11. 
 
Braza, A.J., Modamio, P. and Mariño, E.L. (2000). Two reproducible and sensitive liquid 
chromatographic methods to quantify atenolol and propranolol in human plasma and 
determination of their associated analytical error functions. J. Chromatogr. B, 738, 225-
231. 
 
Byrne, A.J., McNeil, J.J., Harrison, P.M., Louis, M., Tonkin, A.M. and McLean, A.J. (1984). 
Stable oral availability of sustained release propranolol when co-administered with 
hydralazine or food: evidence implicating substrate delivery rate as a determinant of 
presystemic drug interactions. Br. J. Clin. Pharmac., 17, 45S-50S. 
Human bioavailability of propranolol from the matrix-in-cylinder system 144
 
Chambin, O., Jannin, V., Champion, D., Chevalier, C., Rochat-Gonthier, M.-H. and 
Pourcelot, Y. (2004). Influence of cryogenic grinding on properties of a self-emulsifying 
formulation. Int. J. Pharm., 278, 79-89. 
 
Chiu, Y.Y., Higaki, K., Neudeck, B.L., Barnett, J.L., Welage, L.S. and Amidon, G.L. (2003). 
Human jejunal permeability of cyclosporine A: influence of surfactants on P-glycoprotein 
efflux in Caco-2 cells. Pharm. Res., 20, 749-756. 
 
Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C. and Houin, G. (2004). 
Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. 
Int. J. Pharm., 278, 119-131. 
 
D’Emanuele, A., Jevprasesphant, R., Penny, J. and Attwood, D. (2004). The use of a 
dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral 
bioavailability. J. Control. Release, 95, 447-453. 
 
Dressman, J.B. and Yamada, K. (1991). Animal models for oral drug absorption. In: 
Pharmaceutical Bioequivalence (Welling, P.G., Tse, F.L.S. and Dighe, S.V., ed.), Marcel 
Dekker, New York, pp. 235-266.  
 
Eneroth, A., Åström, E., Hoogstraate, J., Schrenk, D., Conrad, S., Kauffmann, H.M. and 
Gjellan, K. (2001). Evaluation of a vincristine resistant Caco-2 cell line for use in a 
calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci., 
12, 211-215.   
 
Gonzalez, R.C.B., Huwyler, J., Boess, F., Walter, I. and Bittner, B. (2004). In vitro 
investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and 
Sotulol HS 15 on the metabolism of midazolam. Biopharm Drug Disp., 25, 37-49. 
 
Guidance for Industry: Food Effect Bioavailability and Fed Bioequivalence Studies – F.D.A.-
C.D.E.R., December 2002. 
 
International Conference on Harmonisation (ICH) (1994). Text on validation of analytical 
procedures. ICH Harmonised Tripartite Guideline, http://www.eudra.org/emea.html. 
 
Irwin, W.J. and Belaid, K.A. (1987). Drug delivery by ion exchange. Physicochemical 
properties of ester prodrugs of propranolol. Drug Dev. Ind. Pharm., 13, 2033-2045. 
 
Human bioavailability of propranolol from the matrix-in-cylinder system 145
Ishizawa, T., Hayashi, M. and Awazu, S. (1987). Enhancement of jejunal and colonic 
absorption of fosfomycin by promoters in the rat. J. Pharm. Pharmacol., 39, 892-895. 
 
Johnson, B.M., Charman, W.N. and Porter, C.J.H. (2002). An in vitro examination of the 
impact of polyethylene glycol 400, Pluronic P85 and vitamin E d-a-tocopheryl 
polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based 
metabolism in excised rat intestine. AAPS Pharm Sci, 4, art. n° 40.  
 
Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lenneras, H., Hussain, A., 
Junginger, H.E., Stavchansky, S.A., Midha, K.K., Shah, V.P. and Amidon, G.L. (2004). 
Molecular properties of WHO essential drugs and provisional biopharmaceutical 
classification. Molecular Pharmaceutics, 1, 85-96. 
 
Kararli, T. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry 
of humans and commonly used laboratory animals. Biopharm. Drug Disp., 16, 351-380. 
 
Khoo, S.-M., Edwards, G..A., Porter, C.J.H. and Charman, W.N. (2001). A conscious dog 
model for assessing the absorption, enterocyte-based metabolism and intestinal lymphatic 
transport of halofantrine. J. Pharm. Sci., 90, 1599-1607. 
 
Kim, K.H. and Singh, B.N. (2002). Drug delivery – oral route. In: Encyclopedia of 
Pharmaceutical Technology (Swarbrick, J. and Boylan, J.C., ed.), Marcel Dekker, New 
York, pp. 886-909.  
 
Lo, M.W., Effeney, D.J., Pond, S.M., Silber, B.M. and Riegelman, S. (1982). Lack of 
gastrointestinal metabolism of propranolol in dogs after portocaval transposition. J. 
Pharmacol. Exp. Ther., 221, 512-515. 
 
McGinnity, D.F., Parker, A.J., Soars, M. and Riley, R.J. (2000). Automated definition of the 
enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. 
Drug Metab. Dispos., 28, 1327-1334. 
 
McLean, A.J., McNamara, P., duSouich, P., Gibaldi, M. and Lalka, D. (1978). Food, 
splanchnic blood-flow, and bioavailability of drugs subject to first pass metabolism. Clin. 
Pharmacol. Ther., 24, 5-10. 
 
McLean, A.J., Skews, H., Bobik, A. and Dudley, F.J. (1980). Interaction between oral 
propranolol and hydralazine. Clin. Pharmacol. Ther., 27, 726-732. 
 
Human bioavailability of propranolol from the matrix-in-cylinder system 146
Mills, P.C., Siebert, G.A. and Roberts, M.S. (2004). A model to study intestinal and hepatic 
metabolism of propranolol in the dog. J. Vet. Pharmacol. Therap., 27, 45-48.  
 
Mori, S., Matsuura, A., Rama Prasad, Y.V. and Takada, K. (2004). Studies on the intestinal 
absorption of low molecular weight heparin using saturated fatty acids and their 
derivatives as an absorption enhancer in rats. Biol. Pharm. Bull., 27, 418-421. 
 
Mountfield, R.J., Senepin, S., Schleimer, M., Walter, I. and Bittner, B. (2000). Potential 
inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. J. 
Pharm., 211, 89-92. 
 
Murakami, M., Yoshikawa, H., Takada, K. and Muranishi, S. (1986). Effect of oleic acid 
vesicles on intestinal absorption of carboxyfluorescein in rats. Pharm. Res., 3, 35-40. 
 
Muranishi, S. (1985). Modification of intestinal absorption of drugs by lipoidal adjuvants. 
Pharm. Res., 2, 108-118. 
 
Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1996). The use of surfactants to enhance 
the permeability of peptides through Caco-2 cells by inhibition of an apically polarized 
efflux system. Pharm. Res., 13, 528-534. 
 
Olanoff, L.S., Walle, T., Cowart, T.D., Walle, U.K., Oexmann, M.J. and Conradi, E.C. (1986)  
Food effects on propranolol systemic and oral clearance – support for a blood flow 
hypothesis. Clin. Pharmacol. Ther., 40, 408-414. 
 
Osigo, T. and Shintani, M. (1990). Mechanism for the enhancement effect of fatty acids on 
the percutaneous absorption of propranolol. J. Pharm. Sci., 79, 1065-1071. 
 
Palin, K.J., Phillips, A.J. and Ning, A. (1986). The oral absorption of cefoxitin from oil and 
emulsion vehicles in rat. Int. J. Pharm., 33, 99-104. 
 
Schneck, D.W. and Vary, J.E. (1983). Mechanism by which hydralazine alters the 
bioavailability of propranolol. Clin. Pharmacol. Ther., 33, 260.   
 
Shah, V.P., Midha, K.K., Dighe, S., McGilveray, I.J., Skelly, J.P., Yacobi, A., Layloff, T., 
Viswanathan, C.T., Cook, C.E., McDowall, R.D., Pittman, K.A. and Spencer, S. (1992). 
Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic 
studies. J. Pharm. Sci., 81, 309-312. 
 
Human bioavailability of propranolol from the matrix-in-cylinder system 147
Singh, B.N. (1999). Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet., 
37(3), 213-255.  
 
Stephens, R.H., Tanianis-Hughes, J., Higgs, N.B., Humphrey, M. and Warhurst, G. (2002). 
Region-dependent modulation of intestinal permeability by drug efflux transporters: in 
vitro studies in mdr1a(-/-) mouse intestine. J. Pharmacol. Exp. Ther., 303, 1095-1101. 
 
van Hoogdalem, E.J., de Boer, A.G. and Breimer, D.D. (1989). Intestinal drug absorption 
enhancement: an overview. Pharmac. Ther., 44, 407-443.  
 
Wacher, V.J., Wu, C.Y. and Benet, L.Z. (1995). Overlapping substrate specificities and tissue 
distribution of cytochrome P450 3A and p-glycoprotein: implications for drug delivery 
and activity in cancer chemotherapy. Mol. Carcinorg., 13, 129-134. 
 
Watkins, P.B (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. 
Adv. Drug Del. Rev., 27, 161-170. 
 
White, D.G., Story, M.J. and Barnwell, S.G. (1991). An experimental animal model for 
studying the effects of a novel lymphatic drug delivery system for propranolol. Int. J 
Pharm., 69, 169-174. 
 
Yamashita, S., Tanaka, T., Endoh, Y., Taki, Y., Sakane, T., Nadai, T. and Sezaki, H. (1997). 
Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo 
drug absorption. Pharm. Res., 14, 486-491.   
 
Yee, S. (1997). In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small 
intestinal) absorption in man - fact or myth. Pharm. Res., 14, 763-766. 
 
General conclusion 148
7 GENERAL CONCLUSION 
 
The objective of this doctoral thesis was to develop a partially ‘coated’ matrix in order to 
obtain zero-order sustained drug release by means of a simple and flexible manufacturing 
method. The matrix-in-cylinder system, consisting of a drug-containing HPMC-Gelucire® 
44/14 matrix inserted in an ethylcellulose pipe, showed to be a flexible tool to obtain linear, 
sustained drug release. However, the production of the dosage forms described in this thesis 
proceeded manually, thus the automation of the production (e.g. by co-extrusion or injection 
moulding) should be further investigated. Due to the increased propranolol bioavailability 
from the matrix-in-cylinder system, observed in the canine as well as in the human in vivo 
study, the challenge of the last part of this research work was to further investigate this 
increased bioavailability phenomenon (instead of developing an economically feasible 
automated manufacturing method). Improving bioavailability of drugs is of great interest 
nowadays, since a lot of recently discovered drugs are characterised by a poor bioavailability 
(due to poor aqueous solubility and/or poor intestinal permeability), causing formulation 
problems. Future work to follow up on this research project includes the incorporation of 
other drugs in the matrix-in-cylinder system to investigate if the dosage form is able to 
increase bioavailability of BCS Class II, III or IV-drugs. 
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SUMMARY 
 
Matrix systems are commonly used as an oral sustained release dosage form, however their 
drug release profile is generally characterised by a burst release effect. Since constant rate 
delivery is the primary goal of sustained release systems, considerable efforts have been made 
in the development of new drug delivery concepts in order to avoid the burst effect and to 
obtain zero-order drug release. Chapter 1 describes the different strategies proposed to limit 
burst release from matrix systems. Of the suggestions made, partial ‘coating’ of a matrix 
appeared to be the most successful method however the production process is complicated 
and time-consuming. The objective of this thesis was to develop a partially ‘coated’ matrix by 
means of a simple, flexible and economically feasible manufacturing method. Therefore, the 
properties of a ‘matrix-in-cylinder system’, based on a drug-containing matrix inserted into an 
impermeable hollow cylinder, were evaluated. Chapter 2 gives an overview of other 
pharmaceutical dosage forms using the principle of hollow cylinders as a method to control 
drug release.  
 
Chapter 3 describes the formulation study of the matrix-in-cylinder system. The first part of 
this study focused on the production of the hollow cylinders using ethylcellulose as the 
hollow fiber forming material and hot-melt extrusion as the manufacturing method. The 
influence of formulation and process parameters on the quality of the extruded cylinders was 
evaluated. Another objective was to identify a core material for the matrix-in-cylinder system, 
which released the drug in a sustained and zero-order manner. Therefore, the ethylcellulose 
cylinders (l = 18 mm, d = 5 mm) were filled with triglyceride-bases (Witepsol®, Ovucire®) 
and saturated polyglycolised glycerides (Gelucire®) with different melting ranges (containing 
theophylline monohydrate as the model drug), and were evaluated by dissolution testing. 
From these experiments it could be concluded that a matrix-in-cylinder system with a 
Gelucire® 44/14 core met the proposed sustained zero-order drug release criterion, however at 
high drug loading only (60 % theophylline monohydrate). Decreasing the drug load resulted 
in an acceleration of drug release. Neither the incorporation of the more hydrophobic 
Gelucire® 50/02 nor the incorporation of inert fillers into the Gelucire® 44/14 core were able 
to provide a sustained and constant drug release from the matrix-in-cylinder system. 
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In Chapter 4 it was proposed to use a mixture of hydroxypropyl methylcellulose (HPMC) and 
Gelucire® 44/14 as the core material for the matrix-in-cylinder system, because the gel 
forming capacities of HMPC could be advantageous to the sustained release properties of the 
dosage form. In vitro drug release from matrix-in-cylinders containing 5 % theophylline 
monohydrate, 30 % HPMC (varying substitution type and viscosity grade) and 65 % 
Gelucire® 44/14 proceeded according to zero-order kinetics, but was too slow (in most cases 
< 50 % of the drug was released within 24 h). To achieve complete release of the drug, the 
composition of the inner core as well as the dimensions of the hollow pipe were modified in 
order to increase the erosion rate of the gelled polymer matrix. Reducing the HPMC 
concentrations suspended in Gelucire® nor replacing part of the HPMC by methylcellulose 
resulted in the targeted drug release profile. The influence of the dimensions of the hollow 
pipe on drug release was determined by subjecting matrix-in-cylinders with varying length 
(12, 15, 18 mm) and varying diameter (3, 5, 7 mm) to dissolution testing. Shortening the 
matrix-in-cylinder resulted in a quicker drug release, while changing the diameter did not 
affect drug release. Thus, the drug release rate from the matrix-in-cylinder dosage form could 
be tailored by modifying the length of the hollow pipes. The effect of drug solubility and drug 
loading on the matrix effect of the HPMC-Gelucire® system was also investigated. Drug 
solubility had a limited influence on drug release rates, while an increase of the drug loading 
induced a significant acceleration of the drug release. The formulations were stable for at least 
12 months during storage at room temperature/60 % relative humidity (RH) and at 30°C/75 % 
RH.  
 
Chapter 4 demonstrated that a matrix-in-cylinder system consisting of a hot-melt extruded 
non-erodible ethylcellulose pipe surrounding a drug-containing HPMC-Gelucire® matrix core 
could be used to formulate a once-a-day formulation characterized by a zero-order drug 
release profile. In an aqueous medium, the HPMC-Gelucire® core forms a gel plug, which 
releases the drug - through the open ends of the ethylcellulose pipe - by means of erosion. 
Erosion of the gel core is the most critical parameter in order to obtain the desired drug 
release rate and consequently the desired plasma concentration profiles in vivo. In vivo, the 
varying conditions along the gastrointestinal (GI)-tract (mechanical and hydrodynamic stress, 
presence of digestive enzymes and bile salts) can potentially affect the erosion of the gel core 
of the matrix-in-cylinder system and thereby alter the drug release rate. Therefore, the 
influence of hydrodynamics (dissolution at varying paddle speed) and mechanical forces 
(paddle-beads method) and the effect of different ‘physiologically relevant’ dissolution media 
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on the in vitro drug release of the matrix-in-cylinder system, using propranolol hydrochloride 
as the model drug, were evaluated in Chapter 5. These experiments showed that the 
ethylcellulose pipe had a protective effect on the drug-containing HPMC-Gelucire core as it 
largely protected the core against hydrodynamics and mechanical stress. Furthermore, drug 
release from the matrix-in-cylinder system was only slightly affected by the composition of 
the dissolution medium. These observations suggested that drug release from the matrix-in-
cylinder is probably independent of the GI-tract conditions. 
The bioavailability from the matrix-in-cylinder systems, using propranolol hydrochloride as 
the model drug, was also described in Chapter 5. During the in vivo evaluation an oral dose of 
80 mg propranolol HCl was administered to 6 male mixed-breed dogs in a randomized cross-
over study. The matrix-in-cylinders consisted of 27 % propranolol HCl (equivalent with 80 
mg), 23 % HPMC and 50 % Gelucire 44/14 and the bioavailability of the experimental 
formulation was compared to the in vivo behaviour of a hard gelatine capsule filled with an 
amount (equivalent with 80 mg propranolol HCl) of the core material of the matrix-in-
cylinder system (core-in-capsule formulation) and to a commercial sustained release 
formulation (Inderal retard mitis, 80 mg propranolol HCl). Propranolol plasma 
concentrations were determined with a validated HPLC-fluorescence method. 
Administration of the matrix-in-cylinder system resulted in plasma concentrations maintained 
at a level of 8-10 ng/ml during the first 6 h, then dropping slightly to a plateau at 5-6 ng/ml. 
Cmax of the core-in-capsule formulation was not significantly different from Cmax of the 
matrix-in-cylinder system, however the core-in-capsule formulation was not able to sustain 
drug release confirming that the surrounding ethylcellulose pipe is essential to obtain the in 
vivo sustained release profile. The plasma levels of Inderal® were much lower than with the 
matrix-in-cylinder system. The mean AUC0-24h of the matrix-in-cylinder system and of 
Inderal® were 146.0 and 35.8 ng ml-1 h-1, respectively; hence the relative bioavailability of the 
matrix-in-cylinder system to Inderal® is about 400 %. The bioavailability of the core-in-
capsule is similar to that of Inderal®. The results of this in vivo study demonstrated that the 
matrix-in-cylinder system increased the bioavailability of propranolol in dogs when compared 
with a commercial sustained release formulation (Inderal). Since propranolol is a drug with 
extensive hepatic first pass elimination after oral administration, the improved bioavailability 
of the matrix-in-cylinder was ascribed to a partial bypass of the hepatic clearance through 
rectal absorption of propranolol: either via the haemorrhoidal veins or via the lymphatics, 
both having direct access to the systemic circulation. 
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Chapter 6 describes the human bioavailability of propranolol from the matrix-in-cylinder 
system. During the in vivo evaluation an oral dose of 80 mg propranolol HCl was 
administered to healthy volunteers (n = 10) in a randomized cross-over study. The matrix-in-
cylinders consisted of 27 % propranolol HCl (equivalent with 80 mg), 23 % HPMC and 50 % 
Gelucire 44/14 and were administered under fasted as well as under fed conditions 
(concomitant intake of a high-fat, high-calorie breakfast). Inderal retard mitis was 
administered as reference product. Administration of the matrix-in-cylinder system resulted in 
similar plasma levels as the reference formulation Inderal®, during the initial 10 h after 
administration. 10 h after administration of the matrix-in-cylinder system, an increase of the 
propranolol plasma levels was noticed. This increase was most pronounced for the 
experimental dosage form co-administered with food. The matrix-in-cylinder system had a 
relative bioavailability of 156.0 % (fasted conditions) and 222.0 % (fed conditions) compared 
to the marketed reference product. In order to explain this increased bioavailability observed 
for the matrix-in-cylinder system, different hypotheses were checked. However none of them 
was able to provide a conclusive answer. To find out the exact mechanism by which the 
propranolol bioavailability was increased, further studies should be performed (for example: 
the incorporation of other drugs than propranolol in the matrix-in-cylinder system). 
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SAMENVATTING 
 
Monolithische matrices worden vaak aangewend voor de orale, vertraagde vrijgave van 
geneesmiddelen. Het voornaamste nadeel van een matrix systeem is dat het vrijstellingsprofiel 
gekarakteriseerd wordt door een ‘burst release’ fenomeen. Aangezien een constante 
vrijstellingssnelheid van primordiaal belang is voor ‘sustained release’ formulaties, is reeds 
heel wat onderzoek verricht naar nieuwe geneesmiddelvormen die gekenmerkt worden door 
een nulde orde vrijstellingsprofiel. Hoofdstuk 1 beschrijft de in de literatuur vermelde 
strategieën om ‘burst release’ van matrices te beperken of zelfs te elimineren. Uit dit 
literatuuronderzoek bleek dat partiële omhulling van een matrix de meest succesvolle 
methode is om het ‘burst release’ effect te vermijden, maar het productieproces van dergelijke 
geneesmiddelvormen is gecompliceerd en tijdrovend. De doelstelling van deze 
doctoraatsthesis is het ontwikkelen van een partieel omhulde matrix met behulp van een 
eenvoudige, flexibele en economisch interessante productiemethode. Dit resulteerde in een 
‘matrix-in-cilinder systeem’, bestaande uit een geneesmiddel-bevattende matrix ingebed in 
een impermeabele holle cilinder. Hoofdstuk 2 geeft een overzicht van andere 
geneesmiddelvormen die eveneens gebruik maken van een holle cilinder om de 
geneesmiddelvrijstelling te controleren. 
 
Hoofdstuk 3 beschrijft het formulatie-onderzoek van het matrix-in-cilinder systeem. Het 
eerste deel van deze formulatie-studie spitste zich toe op de productie van de holle cilinders, 
die als omhulling van de geneesmiddelkern worden gebruikt, waarbij ethylcellulose 
aangewend werd als bouwsteen van de cilinders en ‘hot-melt’ extrusie als productiemethode. 
Gedurende deze fase werd de invloed van formulatie- en procesparameters op de extrusie-
eigenschappen van de holle cilinders onderzocht. In een volgend stadium van het onderzoek 
werd gezocht naar een geschikt kernmateriaal voor het matrix-in-cilinder systeem, dat in staat 
is het geneesmiddel vertraagd en met een constante snelheid vrij te geven. Hiervoor werden 
de holle ethylcellulose cilinders (l = 18 mm, d = 5 mm) opgevuld met triglyceride-basissen 
(Witepsol®, Ovucire®) en polyglycosideerde glyceriden (Gelucire®), elk met verschillende 
smelttrajecten. Theofylline monohydraat werd gebruikt als het modelgeneesmiddel. De 
formulaties werden geëvalueerd met behulp van dissolutietesten. Deze experimenten toonden 
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aan dat enkel het matrix-in-cilinder systeem met Gelucire® 44/14 als kernmateriaal aan het 
vooropgestelde objectief van vertraagde, nulde orde geneesmiddelvrijstelling voldeed, dit was 
echter enkel het geval bij een hoge geneesmiddelbelading van de kern (60 % theofylline 
monohydraat). Een lagere geneesmiddelbelading van de kern leidde tot een duidelijk 
versnelde geneesmiddelvrijgave. Noch de incorporatie van het meer hydrofobe Gelucire® 
50/02, noch de incorporatie van inerte vulstoffen in Gelucire® 44/14 resulteerde in een 
vertraagde, constante geneesmiddelvrijstelling uit de matrix-in-cilinder formulatie.  
 
In Hoofdstuk 4 werd geopteerd om gebruik te maken van een mengsel van 
hydroxypropylmethylcellulose (HPMC) en Gelucire® 44/14 als kernmateriaal voor het 
matrix-in-cilinder systeem, omdat verondersteld werd dat de gelvormende eigenschappen van 
HPMC een vertragend effect konden hebben op de geneesmiddelvrijgave. Het in vitro 
vrijstellingsprofiel van een matrix-in-cilinder opgevuld met 5 % theofylline monohydraat, 30 
% HPMC (variërende substitutiegraad en viscositeit) en 65 % Gelucire® 44/14 verliep wel 
lineair, maar te traag (bij de meeste formulaties werd < 50 % geneesmiddel vrijgesteld over 
24 u). Om een snellere geneesmiddelvrijstelling te bekomen, werden zowel de samenstelling 
van het kernmateriaal als de afmetingen van de omhullende holle cilinder gewijzigd (om zo 
de erosiesnelheid van de gelvormige matrixkern te versnellen). Het verminderen van de 
HPMC concentratie gesuspendeerd in Gelucire®, noch het vervangen van een deel van de 
HPMC door methylcellulose leidde tot het beoogde dissolutieprofiel. In een volgende fase 
werd de invloed van de afmetingen van de holle cilinder op de geneesmiddelvrijgave 
onderzocht door matrix-in-cilinders met verschillende lengte (12, 15, 18 mm) en verschillende 
diameter (3, 5, 7 mm) aan dissolutietesten te onderwerpen. Hieruit bleek dat het verkorten van 
matrix-in-cilinders de geneesmiddelvrijstelling versnelde, terwijl het wijzigen van de diameter 
de geneesmiddelvrijstelling niet beïnvloedde. Dit betekende dat het in vitro vrijstellingsprofiel 
van het matrix-in-cylinder systeem kon aangepast worden door middel van het variëren van 
de lengte van de holle cilinders. De invloed van geneesmiddeloplosbaarheid en –belading op 
de dissolutie-eigenschappen van de matrix-in-cilinder formulatie (met HPMC-Gelucire® kern) 
werd eveneens onderzocht. Het effect van geneesmiddeloplosbaarheid op de 
vrijstellingssnelheid bleek beperkt. Het verhogen van de geneesmiddelbelading induceerde 
een significante versnelling van de geneesmiddelvrijgave. De stabiliteit van de matrix-in-
cilinder formulaties werd aangetoond gedurende 12 maanden bewaring bij kamertemperatuur 
en een relatieve vochtigheid (RV) van 60 %, evenals bij 30°C en 75 % RV. 
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Hoofdstuk 4 toonde aan dat een matrix-in-cilinder systeem, op basis van een geëxtrudeerde 
impermeabele holle ethylcellulose cilinder opgevuld met een geneesmiddel-bevattende 
HPMC-Gelucire® 44/14 kern, aangewend kan worden als ‘once-a-day’ formulatie met een 
nulde orde vrijstellingsprofiel. In een waterig milieu vormt de HPMC-Gelucire® kern een 
gelvormige matrix die het geneesmiddel door middel van erosie vrijstelt via de open uiteinden 
van de holle cilinder. Erosie van deze gelkern is dus de meest kritische parameter voor het 
bereiken van het beoogde geneesmiddelvrijstellingsprofiel en dus ook de gewenste in vivo 
plasmaspiegels. In het gastro-intestinaal stelsel wordt een geneesmiddelvorm blootgesteld aan 
mechanische en hydrodynamische stress, alsook aan de aanwezigheid van verteringsenzymen 
en galzouten. Deze factoren kunnen de erosie van de gelkern van het matrix-in-cilinder 
systeem (en dus ook de geneesmiddelvrijstelling) beïnvloeden. Vandaar dat het effect van 
hydrodynamiek (dissolutie met verschillende ‘paddle’-snelheid) en mechanische stress 
(‘paddle-beads’ dissolutiemethode) en de invloed van verschillende ‘fysiologisch relevante’ 
dissolutiemedia op het in vitro vrijstellingsprofiel van de matrix-in-cilinder formulatie (met 
propranolol hydrochloride als het modelgeneesmiddel) werden onderzocht in Hoofdstuk 5. 
Uit deze dissolutietesten kon besloten worden dat de omhullende ethylcellulose cilinder een 
beschermend effect uitoefende op de HPMC-Gelucire® kern, waardoor zowel 
hydrodynamische als mechanische stress slechts in beperkte mate de geneesmiddelvrijgave 
beïnvloedden. Daarnaast bleek ook de samenstelling van het dissolutiemedium weinig invloed 
te hebben op het vrijstellingsprofiel. Deze waarnemingen deden veronderstellen dat 
geneesmiddelvrijstelling uit het matrix-in-cilinder systeem waarschijnlijk niet beïnvloed zal 
worden door de gastro-intestinale omstandigheden. 
De biologische beschikbaarheid van propranolol hydrochloride, geformuleerd als matrix-in-
cilinder systeem, werd eveneens behandeld in Hoofdstuk 5. Hierbij werd 80 mg propranolol 
hydrochloride toegediend aan 6 mannelijke honden in een ‘randomized cross-over’ studie. De 
matrix-in-cilinders bestonden uit 27 % propranolol HCl (equivalent met 80 mg), 23 % HPMC 
en 50 % Gelucire 44/14. De biologische beschikbaarheid van de experimentele formulatie 
werd vergeleken met het in vivo gedrag van een hoeveelheid (equivalent met 80 mg) van het 
kernmateriaal van het matrix-in-cilinder systeem, afgevuld in een harde gelatinecapsule (kern-
in-capsule formulatie) en met een commercieel beschikbaar preparaat (Inderal retard mitis, 
80 mg propranolol HCl). De propranololplasmaconcentraties werden bepaald via een 
gevalideerde HPLC-fluorescentie methode. 
Na toediening van het matrix-in-cilinder systeem werden gedurende de eerste 6 u 
plasmaspiegels van 8-10 ng/ml waargenomen, gevolgd door een lichte daling tot 5-6 ng/ml. 
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Cmax van de kern-in-capsule formulatie was niet significant verschillend van Cmax van het 
matrix-in-cilinder systeem, maar de kern-in-capsule formulatie vertoonde geen ‘sustained 
release’ effect wat aantoonde dat de omhullende ethylcellulose cilinder essentieel is om in 
vivo tot een vertraagd vrijstellingsprofiel te komen. De plasmaspiegels na toediening van 
Inderal waren heel wat lager dan die van het matrix-in-cilinder systeem. De gemiddelde 
AUC0-24h van de matrix-in-cilinder formulatie en van Inderal bedroegen respectievelijk 
146.0 en 35.8 ng ml-1 h-1, wat betekent dat de relatieve biologische beschikbaarheid van het 
matrix-in-cilinder systeem ten opzichte van Inderal ongeveer 400 % is. Uit de resultaten van 
deze in vivo studie kon besloten worden dat de matrix-in-cilinder formulatie de biologische 
beschikbaarheid van propranolol in honden doet toenemen in vergelijking met een 
commercieel beschikbaar ‘sustained release’ preparaat (Inderal). Omdat propranolol 
onderhevig is aan een sterk hepatisch eerste passage effect na orale inname, werd de 
verhoogde biologische beschikbaarheid toegeschreven aan een gedeeltelijke omzeiling van de 
hepatische klaring door middel van rectale absorptie van propranolol: ofwel via de 
hemorroïdale venen ofwel via de lymfevaten, aangezien beiden direct uitmonden in de 
systemische circulatie. 
 
Hoofdstuk 6 beschrijft de humane biologische beschikbaarheid van propranolol geformuleerd 
als matrix-in-cilinder. Hierbij werd 80 mg propranolol hydrochloride toegediend aan 10 
gezonde vrijwilligers in een ‘randomized cross-over’ studie. De matrix-in-cilinders bestonden 
uit 27 % propranolol HCl (equivalent met 80 mg), 23 % HPMC en 50 % Gelucire 44/14 en 
werden toegediend aan de proefpersonen in nuchtere toestand evenals in gevoede toestand 
(inname matrix-in-cilinder samen met een vet, hoog-calorisch ontbijt). Inderal retard mitis 
werd ook hier als referentie gebruikt. Toediening van het matrix-in-cilinder systeem 
resulteerde in gelijkaardige plasmaspiegels als het referentiepreparaat Inderal, tijdens de 
eerste 10 u na inname. Vanaf 10 u na de toediening van het matrix-in-cilinder systeem werd 
een toename van de propranololplasmaconcentraties vastgesteld. Deze toename was het 
grootst voor de experimentele formulatie ingenomen samen met voedsel. De relatieve 
biologische beschikbaarheid van het matrix-in-cilinder systeem bedroeg 156.0 % (nuchtere 
toestand) en 222.0 % (gevoede toestand) ten opzichte van de gecommercialiseerde formulatie 
Inderal. Om deze verhoogde biologische beschikbaarheid te kunnen verklaren, werden 
verschillende hypothesen onderzocht maar geen enkele ervan kon bevestigd worden. Om een 
correcte verklaring te vinden zal er dus nog verder onderzoek moeten verricht worden (zoals 
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de incorporatie van andere geneesmiddelen dan propranolol in het matrix-in-cilinder 
systeem). 
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RÉSUMÉ 
 
On fait souvent appel aux matrices monolithiques pour la libération orale ralentie de 
médicaments. Le désavantage principal d’une système matriciel est que le profil de 
libération est caractérisé par un phénomène appelé, ‘burst release’. Etant donné 
qu’une vitesse de libération constante est d’une importance primordiale pour les 
formulations à libération contrôlée, la recherche s’est surtout orientée vers de 
nouvelles formulations se caractérisant par un profil de libération d’ordre zéro. Le 
premier chapitre porte sur les stratégies - mentionnées dans la littérature - qui visent à 
restreindre le ‘burst release’ des matrices ou même de l’éliminer. L’analyse de la 
littérature a révélé que l’enrobage partiel d’une matrice constitue la méthode la plus 
efficace afin d’éviter l’effet de ‘burst release’ néanmoins la production de telles 
formulations s’avère compliquée, exigeant également beaucoup de temps. L’objectif 
de cette thèse de doctorat est le développement d’une matrice partiellement enrobée à 
l’aide d’une méthode de production simple, flexible et réalisable. Ceci a conduit à en 
un ‘système de matrice-en-cylindre’, qui consiste en une matrice, contenant un 
médicament, enveloppée d’un tube imperméable. Le Chapitre 2 nous esquisse un 
survol d’autres formulations qui font également appel à un tube ou à une fibre, afin de 
contrôler la libération de médicaments. 
 
Le Chapitre 3, décrit la formulation du système de matrice-en-cylindre. La première 
partie de cette étude s’est concentrée sur la production des tubes, qui s’emploient 
comme enrobage du noyau contenant le médicament. Lors de ce processus, 
l’éthylcellulose fut proposée pour la formulation des cylindres et l’extrusion à chaud 
comme méthode de production. L’influence des paramètres de formulation et de 
production sur les caractéristiques de l’extrusion, a été examinée. Dans une seconde 
phase de la recherche, celle-ci s’est orientée vers le matériel du noyau convenant pour 
le système de la matrice-en-cylindre, qui serait capable de libérer le médicament 
d’une manière ralentie et à une vitesse constante. Dans ce but, les tubes 
d’éthylcellulose (l = 18 mm, d = 5 mm) ont été remplis de triglycérides (Witepsol®, 
Ovucire®) et de glycérides polyglycolisés (Gélucire®), chacun avec des points de 
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fusion différents.  La théophylline monohydraté a été employée comme principe actif 
modèle. Les formulations ont été évaluées au moyen de tests de dissolution. Les 
résultats montraient que seul le système de la matrice-en-cylindre contenant le 
Gélucire® 44/14 comme matériel de base satisfaisait à l’objectif préétabli de libération 
prolongée de médicament selon un ordre zéro. Cependant, ceci était uniquement le cas 
pour une charge de médicament elevée du noyau (60 % de théophylline hydratée). 
Une charge de médicament du noyau plus basse a donné lieu à une libération de 
médicament accélérée. Ni l’incorporation du Gélucire® 50/02 (plus hydrophobe), ni 
celle des excipients dans Gélucire® 44/14, n’a entraîné en une libération de 
médicament ralentie et constante. 
 
Dans le Chapitre 4, il a été opté pour l’emploi d’un mélange d’hydroxypropyl 
méthycellulose (HPMC) et de Gélucire® 44/14, comme matériel de base pour le 
noyau, en supposant que les caractéristiques formant le gel de HPMC, pouvaient 
provoquer une libération ralentie du principe actif. La libération in vitro d’une 
matrice-en-cylindre, chargée de 5 % de théophylline monohydratée, 30 % de HPMC 
(degré de substitution et viscosité variables) et 65 % de Gélucire® 44/14, se déroulait 
de façon linéaire, mais trop lentement car pour la plupart des formulations (moins de 
50 % du médicament étaient libérés en 24 heures). Afin d’augmenter la vitesse de 
libération du médicament, tant la composition du noyau que les dimensions du 
cylindre, ont été modifiées. Ni la diminution de la concentration en HPMC, en 
suspension dans le Gélucire®, ni le remplacement d’une partie de l’HPMC par la 
méthylcellulose, n’a donné le profil de dissolution désiré. Dans une étape suivante, 
l’influence des dimensions du cilindre sur la libération de médicament a été étudiée, 
en ajustant leurs longueurs (12, 15, 18 mm) et leurs diamètres (3, 5, 7 mm). Nous 
avons pu observer que le raccourcissement de matrices-en-cylindres accélérait la 
libération du médicament, alors que le changement du diamètre n’influençait guère 
cette libération. Ceci signifiait que le profil de libération in vitro du système matrice-
en-cylindre pouvait être adapté, en variant la longueur des tubes. L’influence de la 
solubilité du médicament et celle de la charge du médicament sur les caractéristiques 
de la formulation matrice-en-cylindre (avec le noyau HPMC-Gélucire®) a également 
été examinée. L’effet de la solubilité du médicament sur la vitesse de libération était 
très limité. L’augmentation de la charge de médicament a induit une augmentation 
significative de la vitesse de libération. La stabilité des formulations matrices-en-
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cylindres a été démontrée durant 12 mois, lors d’une conservation à température 
ambiante et une humidité relative (HR) de 60 %, ainsi qu’à une température de 30°C 
et 75 % HR.   
 
Le Chapitre 4 nous a montré qu’un système de matrice-en-cylindre, se basant sur un 
cilindre d’éthylcellulose imperméable - ayant été extrudé - et rempli d’un noyau de 
HPMC-Gélucire® 44/14, peut être employé comme formulation ‘once-a-day’, 
conférant un profil de libération d’ordre zéro. Dans un milieu aqueux, le noyau 
HPMC-Gélucire® constitue une matrice gélifiée qui libère le principe actif 
principalement par érosion, à travers les extrémités ouvertes du cylindre. L’érosion du 
noyau constitue par conséquent le paramètre le plus critique pour l’obtention du profil 
de libération désiré et ainsi que pour les concentrations plasmatiques in vivo 
souhaitées. Dans le tractus gastro-intestinal, une formulation est exposée au stress 
mécanique et hydrodynamique, ainsi qu’à la présence des enzymes digestives et des 
sels biliaires.  Ces facteurs sont capables d’influencer l’érosion du noyau du système 
de matrice-en-cylindre. Afin de comprendre le rôle de ces facteurs, nous avons étudié 
l’influence des conditions hydrodynamiques (dissolution avec ‘paddles’ à différentes 
vitesses), du stress mécanique (dissolution selon la méthode ‘paddle-beads’) ainsi que 
de plusieurs compositions du milieu de dissolution sur les profils de libération in vitro 
(Chapitre 5). Ces tests de dissolution ont montré que le cylindre d’éthylcellulose 
exerçait un effet protecteur sur le noyau HPMC-Gélucire®, de sorte que les stress 
hydrodynamique et mécanique n’influençaient que modérément la libération de 
médicament. En outre, la composition du milieu de dissolution n’exerçait pas non plus 
beaucoup d’influence sur le profil de libération.   
La biodisponibilité du chlorhydrate de propranolol, formulé dans un système matrice-
en-cylindre, a également été abordée dans ce chapitre. Une dose de 80 mg de 
chlorhydrate de propranolol a été administrée à six chiens, dans une étude en 
‘randomized cross-over’. Les matrices-en-cylindres renfermaient de 27 % de 
propranolol HCl (équivalent à 80 mg), 23 % de HPMC et 50 % de Gélucire® 44/14.  
La biodisponibilité de la formulation expérimentale a été comparée à celle du noyau 
contenant la même dose mais introduit dans une gélule (formulation de noyau-en-
gélule) et à un  produit commercialement disponible (Inderal® retard mitis, 80 mg de 
propranolol HCl). Les concentrations de propranolol ont été déterminées au moyen 
d’une méthode de HPLC validée avec détection par fluorimétrie. Après 
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l’administration du système de matrice-en-cylindre, on a observé des concentrations 
plasmatiques de 8-10 ng/ml pendant les six premières heures, suivies d’une légère 
baisse jusqu’à 5-6 ng/ml. La concentration maximale (Cmax) de la formulation à 
noyau-en-gélule, n’était pas significativement différente de celle du système de 
matrice-en-cylindre, mais la formulation à noyau-en- gélule ne montrait pas d’effet 
retard prouvant que le cylindre d’éthylcellulose était essentiel pour arriver à un profil 
de libération à effet prolongé in vivo. Les concentrations plasmatiques, après 
l’administration d’Indéral®, étaient beaucoup plus basses que celles du système de 
matrice-en-cylindre. L’aire sous la courbe (AUC0-24h) de la formulation matrice-en-
cylindre et celle d’Indéral® étaient respectivement 146.0 et 35.8 ng ml-1 h-1, ce qui 
signifie que la biodisponibilité relative du système de matrice-en-cylindre, atteint 400 
% comparativement à l’Inderal®. Les résultats de cette étude in vivo nous ont permis 
de conclure que la formulation matrice-en-cylindre augmentait la biodisponibilité du 
propranolol chez le chien. Comme le propranolol subit un effet du premier passage 
hépatique prononcé, la biodisponibilité élevée fut attribuée à une diminution partielle 
métabolisme hépatique suite à une absorption rectale: soit par les veines 
hémorroïdales soit par les vaisseaux lymphatiques, tous deux débouchant dans la 
circulation systémique. 
 
Le Chapitre 6 traite de la biodisponibilité chez l’homme du propranolol, formulé dans 
une matrice-en-cylindre. Une dose de 80 mg de chlorhydrate de propranolol fut 
administrée à dix volontaires sains dans une étude ‘randomized cross-over’. Les 
matrices-en-cylindres contenaient 27 % de propranolol HCl (équivalent à 80 mg), 23 
% de HPMC, 50 % de Gélucire® 44/14, et étaient administrées aux volontaires à jeun 
et après prise d’un petit déjeuner à hautes calories. L’Inderal® retard mitis était ici 
également la référence. L’administration du système de matrice-en-cylindre a donné 
lieu à des concentrations plasmatiques semblables à celles après la prise de l’Inderal®, 
pendant les dix premières heures. Après, nous avons constaté une élévation des 
concentrations plasmatiques de propranolol après administration de la matrice-en-
cylindre. Cette augmentation était la plus élevée pour la formulation expérimentale, 
prise avec le déjeuner.  La biodisponibilité relative du système matrice-en-cylindre 
indiquait 156.0 % (à jeun) et 222.0 % (avec nourriture) vis-à-vis de la formulation 
Inderal®. Afin de pouvoir conclure à une augmentation de biodisponibilité, plusieurs 
hypothèses ont été examinées. Cependant aucune d’entre elles nous a permis de 
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proposer une réponse adéquate. De plus amples études devront être effectuées afin de 
trouver la cause réelle de l’augmentation de la biodisponibilité du propranolol formulé 
dans la matrice-en-cylindre (chez l’homme).   
